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Abstract 
 
Background & Aim: While the majority of myelodysplasia and acute myeloid leukaemia 
(MDS/AML) cases are sporadic, rare familial predisposition syndromes have been 
delineated and are regarded a separate disease entity in the 2016 WHO classification 
system. Germline mutations in 14 disease genes have been uncovered thus far, with GATA2 
representing one of the key transcriptional regulators commonly mutated in inherited 
leukaemias. The rarity of these familial cases opens the door to fundamental questions in 
biology, one of which is the phenomenon of reduced penetrance posing a clinical challenge 
particularly when identifying “silent” mutation carriers for genetic screening and exclusion 
as potential stem cell transplant donors. We have noted that this is indeed a feature within 
certain GATA2-mutated families, especially those carrying germline missense mutations 
such as (p.Thr354Met). In our example, two first-degree cousins developed MDS/AML with 
monosomy 7 while a third cousin presented with significant monocytopenia and 
neutropenia. This contrasted with the parental generation mutation carriers who all remain 
symptom free into their mid-late 60s. This thesis therefore sets out to investigate the 
molecular mechanisms underlying the reduced penetrance and clinical heterogeneity 
observed within a GATA2-mutated family with a view of identifying molecular features that 
distinguish between these two groups of mutation carriers.  
 
Results: Deep targeted sequencing of 33 genes frequently mutated in MDS/AML revealed 
acquisition of somatic ASXL1 mutation (p.Gly646TrpfsTer12) in all affected cousins with no 
mutations detected in asymptomatic family members. It was noteworthy that the variant 
allele frequency was lower (12%) in the third cousin symptomatic carrier and remained 
stable (range 12-6%) over a 6-year monitoring period. Total GATA2 expression was lower in 
the symptomatic compared with asymptomatic carriers as assessed by RT-qPCR and 
remarkably this was associated with monoallelic expression favouring the mutant GATA2 
allele with loss of the wild-type (WT) allele expression. Temporal analysis of the 
symptomatic carrier over a 6-year disease period demonstrated a reactivation of the WT 
allele expression 3 years later, coinciding with a persistent improvement in haematological 
parameters. We believe these allele-specific changes in GATA2 expression are driven by 
dynamic epigenetic reprogramming that include changes in DNA methylation and chromatin 
Abstract 
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mark deposition. Using a SNP (rs1806462 [C/A]) that generates/removes a CpG dinucleotide 
within GATA2 promoter region, we first assessed allele-specific differences in DNA 
methylation by bisulphite sequencing. This demonstrated a significant increase in promoter 
methylation in the WT allele that returned to normal levels at later time-points. We then 
assessed allele-specific deposition of H3K4me3 and H3K27me3 chromatin marks by 
chromatin immunoprecipitation (ChIP). Sanger sequencing revealed a significant 
enrichment in the deposition of H3K4me3 activating mark on the mutant allele at diagnosis 
that was reversed at later follow-up, correlating with reactivation of the WT allele 
expression.   
 
Conclusion: Reduced penetrance is a feature of many families with inherited forms of 
MDS/AML which may be governed by the acquisition of additional co-operating mutations 
(e.g. ASXL1). In this thesis, however, we show that changes in the WT:mutant GATA2 allele 
expression ratio as a result of local and allele-specific changes in DNA methylation and 
chromatin mark deposition may also influence the penetrance of the germline mutation, 
adding another layer of complexity to the (epi)genetic basis of familial MDS/AML.  
 
Keywords:  Familial MDS/AML, GATA2, reduced penetrance, epigenetics, gene expression. 
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1. Introduction 
 
               “I start with the premise that all human disease is genetic”  
– Paul Berg  
 
Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) are clinically diverse and 
genetically heterogeneous haematopoietic stem cell malignancies characterised by defective 
haematopoiesis and premature mortality in many patients (Grimwade et al., 2016). Whilst the 
majority of MDS/AML cases occur de-novo or secondary to chemo- or radio-therapy (sporadic 
MDS/AML), there are rare occurrences of familial cases (<5% in adults – 4-13% in paediatrics) 
where disease manifestations run in at least two members within the same family (familial 
MDS/AML) (Akpan et al., 2018). These cases represent a high-risk group of patients who require 
a high-index of clinical suspicion and unique follow-up for comprehensive management and care. 
The relative rarity of familial MDS/AML cases probably reflects that many patients in this group 
are not recognised by the current diagnostic algorithms. This is hindered by the lack of accessible 
family history and marked variations in disease latency, phenotype and outcome between and 
within families. This is also accompanied by a paucity of comprehensive diagnostic guidelines 
and certified genetic testing to meet the clinical need of this rare patient population, ultimately 
leading to deficiencies in patient care, particularly when considering unsuitable related donors 
for allogeneic haematopoietic stem cell transplantation (HSCT) with several reports describing 
donor-derived episodes of AML (Xiao et al., 2011, Berger et al., 2017, Galera et al., 2018). The 
overarching goal of the research community in this field therefore is to establish a multi-
disciplinary roadmap combining efforts from clinicians, genetic counsellors and scientists 
working together to improve diagnosis, screening and management of these patients. 
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Fortunately, we are making significant progress in delineating the germline mutational 
repertoire of these inherited leukaemias; thanks to advances in next generation sequencing 
(NGS) technologies, germline mutations in approximately a dozen genes, primarily in the myeloid 
transcription factors (RUNX1, CEBPA, GATA2 and ETV6) have been implicated thus far, 
corresponding to ~60% of familial cases (Nickels et al., 2013, Godley, 2014, Babushok et al., 2016, 
Drazer et al., 2016, Wlodarski and Niemeyer, 2017). These technologies are also offering an 
unprecedented opportunity to identify novel disease-causing alleles in cases with unknown 
aetiology and decipher the intra- and inter-familial disease heterogeneity and evolution. Despite 
these advances, however, assigning pathogenicity to new variants is further complicated by the 
scarcity of familial cases and the enormous genetic and phenotypic diversity and our knowledge 
of the functional impact of some of these newly-discovered variants is still very much in its 
infancy.  
 
Another challenge to contend with is the incomplete or reduced penetrance of disease 
mutations where for example in one family sharing a common germline mutation, several 
members display varying symptoms and ages of onset while others are protected from the 
disease entirely (Hahn et al., 2011, Bodor et al., 2012). What is the likelihood of developing overt 
disease or indeed providing a protection mechanism from disease in those “silent” germline 
mutation carriers? Thus far, we have only scratched the surface of the patterns and order of 
secondary genetic abnormalities that may contribute to such clinical variability and therefore 
the molecular basis of this phenomenon merits further investigation. 
 
Going forward, not only is understanding the biology and genetic complexity of these rare 
inherited syndromes important for the families themselves but it can also offer valuable insights 
into the molecular pathogenesis of sporadic disease. It is hoped that by raising clinical awareness 
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of the known disease symptoms and maximising research endeavors on a collaborative basis we 
can improve the way we identify, test and manage these patients and their families and realise 
their clinical needs towards better outcomes. And indeed, a familial MDS/AML programme 
initiative, led by my supervisor Jude Fitzgibbon in collaboration with Inderjeet Dokal and Tom 
Vulliamy, started in 2015 with an untapped treasure trove of unique familial cases and an 
ambition to tackle these key research questions and this is where my PhD project is embedded. 
 
In this thesis, recent advances in our understanding of the genetic basis of familial leukaemia 
and myelodysplasia will be discussed, including some of the challenges the field is facing in 
relation to defining novel germline mutations and optimal diagnostic practices for patients, 
before focusing on the molecular mechanisms underlying reduced penetrance of germline 
GATA2 mutations, one of the key transcriptional regulators frequently mutated in inherited 
leukaemias. However, to set the scene, an overview of MDS/AML: its evolving molecular 
landscape and clinic-pathological and prognostic features, is warranted. 
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1.1 Sporadic MDS/AML  
 
1.1.1 Incidence and Clinical Features  
 
AML represents one of the commonest forms of acute leukaemias in adults, accounting for ~32% 
of all leukaemias and affecting approximately 3100 new cases each year in the United Kingdom 
(UK) (Cancer Research UK (CRUK)). It is a clinically diverse and genetically heterogeneous stem 
cell clonal disorder characterised by an uncontrolled proliferation of malignant immature 
myeloid progenitor cells (myeloblasts) within the bone marrow (BM) and the inability of these 
cells to fully differentiate into mature myeloid cells (Figure 1.1) (Grimwade et al., 2016). It can 
arise as a separate disease entity or preceded by a precursor myeloid malignancy, such as 
myeloproliferative neoplasms (MPN) or MDS. The latter is defined by peripheral blood (PB) 
cytopenias and morphologic and cytogenetic abnormalities of the BM (Invernizzi et al., 2015). 
According to CRUK (https://www.cancerresearchuk.org/about-cancer/acute-myeloid-
leukaemia-aml), the incidence of MDS and AML increases with age, with median age of onset 
approximately 65 years old. Patients predominantly present with symptoms suggestive of BM 
failure and low blood counts; namely fatigue or breathlessness (due to anaemia), recurrent or 
severe infections (due to neutropenia) or a bleeding propensity (due to thrombocytopenia) 
(Grimwade, 2012).  
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A suspicion of AML is primarily made on the basis of an abnormal full blood count followed by 
examination of a blood film to assess for the presence and percentage of leukaemic blasts. The 
diagnosis is typically confirmed on a BM aspirate and/or a trephine biopsy looking at cell 
numbers, morphology and BM architecture. Furthermore, immunophenotyping 
(immunohistochemical and flow cytometric), cytogenetic and molecular genetic analyses are 
conducted in parallel, after which tests results are integrated and optimal treatment options are 
considered on a case-by-case basis as part of a multidisciplinary meeting. Samples are also taken 
to identify a leukaemia specific phenotype or a molecular marker for the assessment of minimal 
residual disease (MRD), which involves detecting the persistence of AML post-remission and 
represents an important prognostic marker for relapse (Grimwade and Freeman, 2014). 
 
Figure 1.1 Schema of normal haematopoiesis in the bone marrow, where all blood cells have 
an equilibrium between proliferation and differentiation. AML typically occurs when this 
equilibrium is disrupted (as depicted in the red box) as malignant immature common myeloid 
progenitor cells start to proliferate abnormally in the bone marrow and differentiation is blocked 
as a result. Figure reproduced from (Shaikh and Bhartiya, 2012). 
 
Chapter 1 - Introduction 
 28 
 
1.1.2 Molecular Classification, Prognostic Factors and Cytogenetic Risk Groups 
 
“Cancer was not disorganized chromosomal chaos. It was organized chromosomal chaos...”  
― Siddhartha Mukherjee, The Emperor of All Maladies  
 
Leukaemias are genetically simple and the relatively easy access to malignant cells has made it 
the forerunner of molecular-based discoveries. Forty years ago, the pioneering work of Janet 
Rowley and others uncovered the importance of somatic chromosomal abnormalities including 
balanced translocations (e.g. t(8;21), t(9;22) and t(15;17)) giving rise to in-frame chimeric fusion 
and target genes encoding haematopoietic transcription factors (e.g. RUNX1, RARA), epigenetic 
regulators (e.g. MLL (KMT2A)) and components of the nuclear pore complex (e.g. NUP98) 
(Rowley, 1980, Dohner et al., 2017, Rowley, 1973). 
 
These molecular discoveries paved the way towards the introduction of disease classification 
systems, the most widely known schema is the World Health Organization (WHO) classification, 
providing an important framework for diagnosis, patient risk stratification and therapy decision 
making. In 2001, WHO published the ‘Classification of Tumours of the Hematopoietic and 
Lymphoid Tissues’ which superseded its predecessors (e.g. the French-American-British (FAB) 
classification) by redefining the AML BM blast threshold to 20% (Jaffe et al., 2001). Further 
investigations of the molecular aberrations in AML prompted the revised WHO classification in 
2008 and its current incarnation in 2016 (Table 1.1) (Vardiman et al., 2009, Swerdlow, 2008, 
Arber et al., 2016). This integrated framework encompasses morphological, chromosomal and 
molecular findings and remains part and parcel of all multidisciplinary AML meetings today. 
Notably, the inclusion of familial myeloid malignancies as a separate disease entity in the 2016 
WHO classification represents an important step in the recognition and management of this 
group of patients (discussed in section 1.2).  
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Table 1.1 The 2016 WHO Classification of AML. Adapted from (Arber et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
1) AML and Related Neoplasms 
AML with 
Recurrent 
Genetic 
Abnormalities 
- AML with t(8;21)(q22;q22); RUNX1-RUNX1T1  
- AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
- APL with t(15;17)(q22;q12); PML-RARA 
- AML with t(9;11)(p22;q23); MLLT3-MLL 
- AML with t(6;9)(p23;924); DEK-NUP214 
- AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN-EVI1 
- AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
- Provisional entity: AML with BCR-ABL1 
- AML with mutated NPM1 
- AML with mutated CEBPA 
- Provisional entity: AML with mutated RUNX1 
AML with MDS-related Changes 
Therapy-related Myeloid Neoplasms 
AML, Not 
Otherwise 
Specified  
- AML with minimal differentiation 
- AML without maturation 
- AML with maturation 
- Acute myelomonocytic leukaemia 
- Acute monoblastic/monocytic leukaemia 
- Acute erythroid leukaemia i) Pure erythroid leukaemia  
   ii) Erythroleukaemia 
- Acute megakaryoblastic leukaemia 
- Acute basophilic leukaemia 
- Acute panmyelosis with myelofibrosis 
Myeloid Sarcoma 
Myeloid 
Proliferations 
Related to 
Down 
Syndrome 
- Transient abnormal myelopoiesis 
- Myeloid Leukaemia associated with Down Syndrome 
Blastic/Plasmacytoid Dendritic Cell Neoplasm 
                  2)  Myeloid Neoplasms with Germline Predisposition 
                         3)  Acute Leukaemias of Ambiguous Lineage 
- Acute undifferentiated leukaemia 
- Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 
- Mixed -phenotype acute leukemia with t(v;11q23.3); KMT2A rearranged  
- Mixed phenotype - acute leukemia, B/myeloid, NOS 
- Mixed phenotype acute leukemia, T/myeloid, NOS 
- Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma  
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1.1.2.1 Cytogenetic Risk Classification 
 
Recurrent chromosomal rearrangements remain the most established prognostic markers in 
AML, dividing patients into 3 outcome groups according to favourable, intermediate and poor 
risk cytogenetic abnormalities (Table 1.3) (Grimwade et al., 1998, Grimwade et al., 2010, 
Grimwade, 2012). The favourable risk group includes t(8;21) translocations, inv(16)/t(16;16) and 
the t(15;17) PML-RARA fusion gene, whilst the poor risk group represents ~17% of patients with 
AML and includes those with monosomies or deletions of chromosomes 5 and/or 7, 
chromosome 3q or 11q abnormalities or with complex karyotypes (≥4 unrelated abnormalities). 
The 10-year survival in this patient group is dismal (<10%) necessitating improvement on existing 
treatments and care (Dombret and Gardin, 2016). Indeed, this is an active research area in my 
host laboratory who are performing multi-omic profiling to capture the multi-faceted personality 
of this poor risk disease, with the hypothesis that improvement in patient care will not be 
achieved by focusing on a single deregulated pathway or an actionable mutation. Lastly, the 
intermediate risk category represents ~50% of AML cases, including all normal karyotype AML 
(NK-AML) and those not otherwise classified as favourable or poor risk. Clinical outcomes in 
intermediate risk patients are heterogeneous with long-term survival estimated at 35-40% in 
young adults (Rockova et al., 2011, Breems et al., 2005). This has prompted the quest for 
additional prognostic markers to further stratify the disease and offer a more accurate prognosis 
for patients in this group.  
Collectively, whilst cytogenetic risk group rarely influences the choice of induction therapy (as 
treatment usually begins before these results are available), it has proven powerful for informing 
optimal consolidation strategies, in particular, whether a patient should undergo allogeneic 
HSCT or not (Bullinger et al., 2017). The current degree of uncertainty around patients with 
intermediate cytogenetic risk means that a proportion of patients who would have been cured 
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from chemotherapy alone will go on to have a transplant with its associated morbidity, and 
improved prognostic scoring is therefore warranted in order to target this potentially toxic 
therapy for only those patients who really need it.   
AML that arises from a pre-leukaemic MDS has the worst prognosis. Indeed, chromosomal 
alterations are observed in more than 50% of MDS cases, including deletions of chromosomes 
5q, 7q and 20q, trisomy 8 and monosomy 7 (Cazzola et al., 2013a). The International Prognostic 
Scoring System (IPSS-R) is the most used tool for MDS classification (Table 1.2). The overall risk 
score is based on variables including patient’s age, BM blast percentage, karyotype and white-
cell counts, all of which can be used to predict overall survival (OS) and likelihood of AML 
transformation (Greenberg et al., 2012). 
 
     Table 1.2 IPSS-R classification criteria of MDS. Adapted from (Greenberg et al., 2012). 
 
 
 
 
 
 
 
 
 
Risk Category Cytogenetic Abnormality 
Very Good -Y, del(11q) 
Good 
Normal, del(5q), del(12p), del(20q), double including 
del(5q) 
Intermediate 
 
del(7q), +8, +19, i(17q), any other single or double 
independent clones 
 
Poor 
-7, inv(3)/t(3q)/del(3q), double clone including -7/del(7q), 
Complex: 3 abnormalities 
Very Poor Complex: >3 abnormalities 
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1.1.2.2 Identification of Molecular Markers with a Prognostic Impact  
 
Over the last twenty years, research efforts have focused on deciphering the molecular basis of 
AML (particularly NK-AML), leading to the discovery of recurrent mutations in three genes: FLT3, 
NPM1 and CEBPA, all of which are considered the earliest prognostic markers in AML that define 
survival outcomes (Schlenk et al., 2008, Vardiman et al., 2009) (Table 1.3). For example, while 
FLT3 mutations modify risk from intermediate to poor and lead to reduced OS, NPM1 and 
biallelic CEBPA mutations have been linked with favourable prognosis and long term OS 
approaching 60% (Dufour et al., 2010). These genes are now recognised as an essential 
component in the AML risk stratification system, leading to their incorporation into the revised 
WHO classification as confirmed disease entities and subsequently, into routine clinical testing 
(Arber et al., 2016, Dohner et al., 2017, Vardiman et al., 2009) . 
 
Table 1.3 The 2017 European Leukemia Net (ELN) prognostication of AML risk groups. 
Adapted from (Dohner et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk Category Cytogenetic/Molecular Genetic Abnormality 
Favourable 
t(8,21) (q22;q22); RUNX1-RUNX1T1 
inv(16) (p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
t(15;17)(q24;q21) PML-RARA 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Biallelic mutated CEBPA (normal karyotype) 
Intermediate 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wildtype NPM1 and FLT3-ITD (normal karyotype) 
Wildtype NPM1 without FLT3-ITD (normal karyotype) 
Normal karyotype not classified as favourable. 
t(9;11)(p22;q23); MLLT3-KMT2A 
Cytogenetic abnormalities not classified as favourable or poor 
Poor 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2);GATA2-MECOM (EVI1) 
t(6;9)(p23;q34);DEK-NUP214 
t(v;11)(v;q23); KMT2A rearranged 
t(9;22)(q34.1;q11.2); BCR-ABL1 
-5 or del(5q); -7; -17/abn(17p)  
Complex karyotype (>3), monosomal karyotype 
Wild type NPM1 and FLT3-ITD 
Mutated RUNX1 
Mutated ASXL1 
Mutated TP53 
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1.1.3 The Genetic Landscape of MDS and AML 
 
“The capacity to blunder is the real marvel of DNA.  
Without this special attribute, we would still be anaerobic bacteria and there 
 would be no music”  
 
 ― Lewis Thomas, The lives of a cell. Notes of a biology watcher 
 
 
Aside from the earliest three genes discovered, recent advancements in NGS technologies have 
pushed the boundaries of unbiased AML genomic discoveries even further by capturing the 
enormous genetic heterogeneity. This has led to the characterisation of a plethora of genes and 
pathways known to have a role in haematopoiesis with the potential to inform classification and 
selection of therapies. Notably, AML and MDS were shown to share molecular lesions occurring 
due to deregulation in pathways involving: RNA splicing machinery, transcriptional regulation, 
epigenetic modification, DNA repair, signal transduction and the cohesin complex (Bejar et al., 
2011, Marcucci et al., 2011, Grossmann et al., 2012, Cazzola et al., 2013b, Grimwade et al., 2016, 
Papaemmanuil et al., 2016). Indeed, there are now >100 genes known to be recurrently mutated 
in AML and MDS albeit many occur at low frequencies (<5%). Table 1.4 shows a list of the top 25 
mutated genes ranging in frequency from ~1-30%, and outlines the prognostic significance of 
these molecular lesions. 
 
Perhaps one of the key findings from these NGS studies was the identification of recurrent 
actionable mutations affecting components of the epigenetic machinery, resulting in the co-
ordinated disruption of transcriptional control and chromatin remodeling. Such mutations exert 
their effects via alterations in histone structure e.g. methylation, ubiquitination and 
phosphorylation which in turn lead to global alterations in gene expression. Prior to the 
introduction of NGS, MLL partial tandem duplications (PTDs) were the sole recurrent epigenetic 
lesions and cumulatively, additional epigenetic lesions have been identified. These are enriched 
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in genes encoding regulators of DNA methylation (DNMT3A, TET2, IDH1, IDH2) and post-
translational histone modifications (ASXL1, EZH2), majority of which are loss-of-function 
aberrations (Delhommeau et al., 2009, Ley et al., 2010, Ntziachristos et al., 2016)(Table 1.4). 
These findings challenge the theoretical “two-step” model of leukaemogenesis (Gilliland, 2002), 
whereby the pathogenesis of leukaemia is not merely driven by mutations that confer a 
proliferative and/or survival advantage (e.g. FLT3 and c-Kit) and a block in differentiation (NPM1, 
RUNX1 and CEBPA). Instead, they form part of a bigger picture, further demonstrating the beauty 
and complexity of the (epi)genetic make-up of these diseases. 
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Functional Category Gene 
Mutation 
Frequency in 
AML (%) 
Prognostic Impact  
Nuclear Regulators NPM1 28.3 
Favourable in NPM1-mutant 
without FLT3-ITD 
Cell Signalling 
FLT3 31 Adverse 
NRAS 12.5 conflicting information 
PTPN11 5.9 
Adverse in NPM1:DNMT3A 
mutant 
KRAS 4.6-10 conflicting information 
c-KIT 4.4 Adverse in CBF-AML 
Transcription Factors 
RUNX1 11.3 Adverse 
TP53 7.8 Adverse 
CEBPA 7.4 Double-mutant: favourable 
WT1 5.7 conflicting information 
GATA2 4 conflicting information 
Epigenetic 
modifiers 
DNA 
Methylation 
DNMT3A 23.4 Adverse 
TET2 9.4 Adverse 
IDH2 9.7 conflicting information 
IDH1 8.6 conflicting information 
Histone 
Modifications 
MLL 5.3 Adverse 
ASXL1 4 Adverse 
EZH2 2.3 Adverse in MDS 
BCOR 1.8 Adverse in MDS 
Cohesin Complex 
SMC3 4 conflicting information 
STAG2 3.8 conflicting information 
RAD21 2.7 conflicting information 
Spliceosome Complex 
SRFS2 3.2 Adverse in MDS 
U2AF1 2.8 Adverse in MDS 
SF3B1 1.6 Favourable in MDS 
Table 1.4 Key pathways and genetic lesions recurrently mutated in AML. Data 
derived from (Papaemmanuil et al., 2016) and (Cancer Genome Atlas Research, 2013). 
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1.1.3.1 Improved Genomic Classification  
 
Over the past few years, applications of NGS have led to further refinement of AML disease 
classification and prognostic stratification. Taking together findings from different sequencing 
studies, two new provisional entities: AML with mutated RUNX1 and AML with BCR-ABL1 have 
now been included in the current WHO classification (Table 1.1) and mutations in three genes 
(ASXL1, RUNX1 and TP53) have been incorporated into the risk stratification algorithm as new 
molecular markers that confer a poor prognosis (Arber et al., 2016) (Table 1.3). However, this is 
just the beginning; a recent study by Papaemmanuil et al. (2016) defined the driver genomic 
landscape further in more than 1,500 patients with AML. This comprehensive analysis revealed 
four new AML molecular subgroups including NPM1 emerging as a separate entity, rarely found 
in isolation and for which its prognostic impact is largely dependent on concurrent mutation(s). 
Remaining subgroups include AML with mutated chromatin or spliceosome genes, AML with 
TP53 mutations, chromosomal aneuploidy or both and AML with IDH2R172 mutations 
(Papaemmanuil et al., 2016). By implementing these classification schemes, patients with AML 
can be segregated into several distinct subgroups based on their underlying genetic 
abnormalities, allowing for more stratified approach to treatment and management.  
 
1.1.3.2 Patterns of Mutational Co-occurrence Modifying Clinical Outcomes  
 
It is worth noting that not all of these mutations occur independently and non-random molecular 
associations often take place and have the potential to shape prognosis (Papaemmanuil et al., 
2016, Cancer Genome Atlas Research, 2013). For example, extensive analyses from the cancer 
genome atlas (TCGA) consortium sequencing ~200 sporadic AML cases reported an average of 
13 coding mutations per genome, of which recurrent mutations in DNMT3A, IDH1/2, RUNX1 and 
CEBPA were found to be mutually exclusive with transcription factor fusion genes, suggesting 
the former were putative initiating lesions (Cancer Genome Atlas Research, 2013).  
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In contrast, molecular co-operation is frequently noted between FLT3-ITD and NPM1 mutations 
(Gale et al., 2008, Grimwade et al., 2016), CBF translocations and c-KIT mutations (Paschka et al., 
2006) and between TP53 mutations and chromosomal aneuploidies, predicting a very poor 
outcome (Metzeler et al., 2016). Several studies also reported somatic GATA2 mutations to co-
occur with biallelic CEBPA mutations in approximately 20-40% of CEBPA-mutated sporadic AML 
cases and were associated with a favourable prognosis (Greif et al., 2012, Fasan et al., 2013b, 
Green et al., 2013). These studies shed light on the notion of predestination (canalisation), where 
the sequential order of mutation acquisition is essential in governing tumour initiation and 
evolution (more examples of familial cases is provided in section 1.2.2).  
 
1.1.4 Clonal Evolution in AML 
 
 “Whilst this planet has gone cycling on according to the fixed law of 
gravity, from so simple a beginning endless forms most beautiful and 
most wonderful have been, and are being, evolved”.  
 
                                               – Charles Darwin, On the Origin of Species 
 
We now know that AML cell populations also undergo Darwinian evolution during their 
malignant transformation (Ferrando and Lopez-Otin, 2017). Indeed, an important revelation 
emerging in AML and cancer as a whole is that seldom does a biopsy represent a homogeneous 
population of tumour cells but rather, it is composed of a mosaic of multiple genomes, reflecting 
the expansion of subclones that confer a selective advantage and compete with progenitor 
clones for survival (Graubert and Mardis, 2011, Zhang et al., 2016). This concept was first 
introduced by Nowell in 1976 who postulated that cancer cells evolve and accumulate genetic 
and epigenetic alterations over a protracted period of time, some of which provide a survival 
advantage and subsequently lead to this “Darwinian” natural selection that promotes clonal 
Chapter 1 - Introduction 
 38 
expansion, tumour progression and resistance to cytotoxic therapies (Nowell, 1976, Yates and 
Campbell, 2012). 
 
Forty years later, and following the publication of the first AML genome by Ley et al. (2008), 
subsequent NGS studies have led to the development of novel computational algorithms with 
which to study AML clonal architecture and evolution by analysing the mutant allele fraction (or 
variant allele frequency (VAF)) of clonal cell populations (Welch et al., 2012). These studies 
revealed that mutational patterns seem to follow specific temporally ordered trajectories from 
which evolutionary phylogenetic trees can be inferred. For example, mutations in genes involved 
in epigenetic regulation such as ASXL1, DNMT3A, IDH1/2 and TET2 represent initiating clonal 
events (i.e. the trunk of the tree) with seemingly high VAFs. In contrast, mutations involving FLT3 
or NPM1 represent secondary genetic events that occur later in leukaemogenesis (i.e. the 
branches of the tree) and therefore are likely to have lower VAF values (Bullinger et al., 2017).   
 
These findings support the concept that stepwise acquisition of genetic events is required to 
fashion disease development. For example, initiating mutations (e.g. DNMT3A, TET2 or IDH1/2) 
can follow different routes of transformation depending on the secondary mutational event: 
NPM1 mutations would lead to AML, JAK2 mutations to myeloproliferative neoplasms and SF3B1 
mutations to MDS with ring sideroblasts (Papaemmanuil et al., 2016). Another example is an 
elegant study by Ding and colleagues who employed NGS to trace the clonal evolution of AML 
by comparing the mutational reservoir between paired diagnostic and relapse patient samples. 
They proposed two scenarios of disease relapse: a linear pattern, whereby relapse is driven by 
the evolution of the founding clone, or a branching evolution, where fitter subclones acquire 
additional mutations and expand leading to disease recurrence (Ding et al., 2012, Tawana et al., 
2013). 
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It has also become apparent that some of these somatic clones might not always lead to clonal 
expansion and overt disease development. Instead, they can remain dormant in a pre-leukaemic 
or a quiescent state, and the term Clonal Haematopoiesis of Indeterminate Potential (CHIP) has 
been proposed to describe the phenomenon where certain recurrent mutations (e.g. ASXL1, 
DNMT3A, TET2 and TP53) can be detected in the peripheral blood of elderly (>65 years), 
seemingly healthy individuals without prior diagnosis of a haematological malignancy (Becker, 
2016). This suggests that there is a period of latency that precedes AML during which monitoring 
individuals should be considered to detect signs of progression to overt malignancy when these 
dormant clones have reawakened and start to proliferate aberrantly (Desai et al., 2018). 
 
Nevertheless, a key challenge from these studies remains in discriminating driver from 
innocuous passenger or bystander mutations and further contextualise the prognostic impact of 
these molecular aberrations on disease pathogenesis. This is still a field very much in its infancy 
and work is now focusing on characterising tumour architecture and complexity in more detail, 
by using xenograft models of purified haematopoietic stem cells (HSC) and in-depth genetic 
profiling technologies such as single-cell sequencing with a view of dissecting the precise 
molecular lesions governing sensitivity vs. resistance to chemotherapy. Such findings will 
ultimately guide the future design and execution of targeted therapies to reduce the risk of 
relapse, the leading cause of death in AML (Tawana, 2015). 
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1.1.5 Current and New Treatment Strategies in MDS and AML  
 
“Cancer is an expansionist disease; it invades through tissues, sets up colonies in 
hostile landscapes, seeking “sanctuary” in one organ and then immigrating to 
another. It lives desperately, inventively, fiercely, territorially, cannily 
and defensively — at times, as if teaching us how to survive…” 
 
― Siddhartha Mukherjee, The Emperor of All Maladies  
 
The need to combat these leukaemias has never been more pressing. However, despite 
progressive improvement in our understanding of the molecular heterogeneity underlying these 
diseases, therapeutic strategies in AML have not significantly changed in over 40 years. 
Generally, the standard approach to treatment consists of two cycles of intensive induction 
chemotherapy to induce complete remission (CR), most commonly 7 days of cytarabine and 3 
days of daunorubicin (so-called 7+3 regimen) or a variation, followed by a consolidation regimen 
depending on the patient's prognostic factors (e.g. age, co-morbidities, disease status following 
induction and genetic risk) (Yates et al., 1973, Dohner and Paschka, 2014). For example, patients 
with favourable prognosis undergo additional cycles of chemotherapy whilst those at a high-risk 
of relapse or with complex karyotype may benefit from an allogeneic HSCT given the availability 
of a suitable stem cell donor. Current treatments for low-risk MDS entail growth factor support, 
mainly erythroid stimulating agents (ESA) such as granulocyte-colony stimulating factor (G-CSF) 
and disease modulating agents like lenalidomide (List et al., 2005).  In high-risk MDS, however, 
DNA hypomethylating agents such as azacitidine or decitabine have demonstrated clinical 
efficacy in patients who cannot tolerate allogeneic HSCT (Bejar and Steensma, 2014).  
In the UK, the majority of patients are enrolled in national clinical trials, which may include 
randomisation to receive investigational therapies considered to be of potential benefit from 
earlier phase I and II trials. Furthermore, advances in donor selection techniques (human 
leukocyte antigen (HLA) typing) combined with improvements in the management of graft vs. 
Chapter 1 - Introduction 
 41 
host disease (GvHD) and widespread adoption of reduced intensity conditioning protocols have 
led to reductions in transplant related mortality (TRM) (Horan et al., 2011). However, despite 
progress in therapeutics and supportive care, AML continues to pose a major clinical burden as 
many cases (especially elderly patients >60 years with 5-year survival estimated at 14%) 
experience short remission periods and ultimately relapse and develop resistance to standard 
chemotherapy, fully warranting the development of new therapeutic strategies (Buchner et al., 
2009). Moreover, elderly patients with significant co-morbidities are often not able to withstand 
standard intensive chemotherapy regimens due to high treatment related mortality, leaving 
them with a negligible chance of cure and effective treatment options with reduced toxicity are 
therefore urgently needed. This can only be afforded by improving the diagnostic and prognostic 
tools at our disposal and increasing our understanding of the biology underlying this disease, 
uncovering new pathways and investigating ways in which these pathways can be 
therapeutically exploited.   
Perhaps one of the most important implementations of NGS-based profiling directly relating to 
patient care is the identification of a specific pathway or mutation in AML that could define 
response (or a lack thereof) to targeted therapies. The most successful example has been the 
use of all-trans retinoic acid (ATRA) in PML-RARA positive cases, changing this disease from one 
with a dire prognosis to the highest cure rate of all AML subtypes and it is a key research aim to 
replicate the success of this agent in other types of AML (Castaigne et al., 1990, Kanamaru et al., 
1995).  
Indeed, giant strides are currently being made in unravelling the biological consequences of 
mutations discovered through large AML sequencing consortia, opening up new opportunities 
for therapeutic intervention. Recently approved targeted therapies include FLT3 tyrosine kinase 
inhibitors (e.g. midostaurin) in poor risk AML cases with FLT3-ITD mutations and IDH2 inhibitors 
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(e.g. Enasidenib or Idhifa) in IDH2-mutant AMLs (Stone et al., 2017, Garcia and Stone, 2017, Kim, 
2017, Stein et al., 2017). Other promising examples include drugs that influence epigenetic 
regulation of gene expression e.g. histone deacetylase (HDAC) inhibitors or hypomethylating 
agents (e.g. 5-azacytidine) in TET2/DNMT3A/ASXL1-mutant AMLs and DOT1L inhibitors in MLL-
rearranged leukaemias, demonstrating clinical utility in ongoing clinical trials (Dombret et al., 
2015, Cruijsen et al., 2014, Daigle et al., 2013, Stein and Tallman, 2015).  
Ultimately, it is hoped that the future clinical management of AML patients will move away from 
the classic “one size fits all” formula and towards a more stratified (patient and disease) targeted 
approach. This long-term mission might finally become a reality through initiatives such as the 
Beat AML® Master Trial, a collaborative effort led by the Leukemia & Lymphoma Society (LLS) 
where each AML patient enrolled on the trial can be screened for actionable mutations and then 
assigned to a targeted therapy based on his/her underlying genetic profile 
(http://www.lls.org/beat-aml) (Tyner et al., 2018). While these initiatives are by no means a final 
solution, they offer a substantive opportunity for precision medicine. 
1.1.6 Minimal Residual Disease (MRD) Detection  
 
Another emerging area of potential risk adapted therapy is the monitoring of persistent AML-
associated mutations after therapy (also known as MRD). The conventional definition of 
remission post therapy involves the achievement of specific haematological parameters 
(demonstrating restoration of normal haematopoiesis) and the identification of <5% BM blasts 
(Ossenkoppele and Schuurhuis, 2016). Assays for the detection of MRD at levels not otherwise 
identified by standard morphology include real-time quantitative polymerase chain reaction (RT-
qPCR) for the detection of fusion gene transcripts and molecular variants and secondly, 
multiparameter flow cytometry (MFC) for detecting leukaemia-associated immunophenotypes 
(LAIPs) (Ouyang et al., 2016). 
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Newer NGS advances such as single-cell sequencing offer the possibility of capturing disease 
heterogeneity at the single-cell level therefore allowing for more accurate assessment of MRD 
(Roloff et al., 2017, Ravandi et al., 2018).  
 
The clinical application of MRD analysis at present is largely restricted to acute promyelocytic 
leukaemia (APL) and monitoring of t(15;17) PML-RARA transcripts (Tawana et al., 2013). In AML, 
however, MRD positivity of molecular aberrations (e.g. NPM1) has been linked with adverse 
outcomes (Grimwade et al., 2010, Schnittger et al., 2009, Ivey et al., 2016), indicating its potential 
efficacy as a prognostic marker for relapse. Opinions are often divided concerning the use and 
implementation of MRD analysis but it seems likely that it will prove particularly useful for select 
patients who will benefit from more aggressive therapy (e.g. allogeneic HSCT) in the first 
remission (Grimwade and Freeman, 2014) and in the absence of less effective therapies to target 
this residual population of leukaemia initiating cells (LICs) (Tawana, 2015, Ommem, 2016). 
 
1.2 Familial MDS/AML  
 
“The blood of your parents is not lost in you”.  
 
– Menelaus, The Odyssey 
 
 
1.2.1 The Current Molecular Landscape of Familial Leukaemia 
 
While the majority of MDS/AML cases are indeed sporadic, less than 5% of cases are familial, 
where two or more individuals within the same family present with haematological malignancy 
(Godley, 2014). These rare cases are predominantly inherited in an autosomal dominant fashion, 
with median age of onset lower than sporadic disease and improving care and outcome in this 
high-risk group is essential, especially now that WHO listed hereditary myeloid malignancies as 
a separate disease entity in their 2016 revised classification system (Arber et al., 2016) 
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(Table 1.1). However, as alluded to already, the clinical recognition of inherited forms of these 
diseases is not an easy task; patients may be unaware of their predispositions, coupled with 
marked differences in disease latency and phenotype across mutation carriers and this is further 
complicated by a paucity of available family history and customised diagnostics guidelines and 
assays, leading to an under-representation of these familial cases (Rio-Machin et al., 2018b). 
Also, many mutation carriers remain asymptomatic into late adulthood due to incomplete or 
variable penetrance of mutations (discussed in section 1.3) rendering their investigation and 
follow-up all the more challenging.   
Such intra- and inter-familial disease heterogeneity highlights the high index of suspicion needed 
on behalf of the treating physician, to first recognise the symptoms and then perform 
appropriate testing to detect the underlying genetic predisposition. Notably, not only is studying 
familial leukaemias important for the individual families but it also offers insights into the 
management of sporadic disease. For example, lessons can be learned from familial leukaemia 
in relation to disease latency and penetrance, host genetics effects, the order by which 
mutations arise and novel disease mechanisms caused by genes only mutated in familial cases. 
Following the identification of germline RUNX1 mutations in 1999 by (Song et al.), advancements 
in NGS technologies have accelerated efforts to elucidate the genomic landscape of these 
inherited tumours. To date, leukaemia predisposition syndromes have been associated with 
germline mutations in ~14 discrete disease loci with variable mutation frequencies and clinical 
manifestations, illustrated in Figure 1.2. Our group at the Barts Cancer Institute have a 
longstanding clinical and research interest in this field and, together with other research groups 
worldwide, have made major contributions to the identification and discovery of families with 
germline mutations in these genes reported to date.  
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Unsurprisingly, some of these genes (e.g. CEBPA and RUNX1) are also recurrently mutated in 
sporadic leukaemia and are implicated in several key biological pathways and cellular processes 
including transcription, telomere maintenance and RNA processing, highlighting the 
considerable genetic heterogeneity. There is also clinical heterogeneity associated with each 
syndrome/genetic subgroup with a myriad of phenotypes varying from pre-existing platelet 
dysfunction to lymphoedema and BM failure (in addition to MDS and/or AML) (Figure 1.2) 
(Drazer et al., 2016, Akpan et al., 2018).  
 
 
 
 
The most well-recognised MDS/AML predisposition syndromes are: familial platelet disorder 
with propensity to develop AML (FPD/AML) due to mutations in RUNX1; pure familial AML with 
mutated CEBPA; GATA2 deficiency syndromes and the inherited bone marrow failure syndromes 
(IBMFS) caused by mutations in genes including key telomere regulators (TERC and TERT) (West 
et al., 2014a).  
Figure 01.2 The genetic landscape of familial MDS/AML. The order 
of the 14 germline mutations is shown based on their date of 
discovery. Mutations are broadly assigned to 3 groups according to 
clinical phenotype: myeloid malignancies presenting ‘purely’ 
without a pre-existing disease (blue), accompanying abnormal 
platelet number/function (yellow) or associated with other organs 
dysfunction (red). These genes can also be classified according to 
their protein functions including transcription (RUNX1, CEBPA, 
GATA2, ETV6, MECOM), telomere maintenance (ACD, TERT, TERC), 
RNA processing (DDX41), cell trafficking (SRP72), inflammation 
(SAMD9, SAMD9L), and other unknown functions (ANKRD26, 
ATG2B). The most frequently mutated genes are DDX41, GATA2 
RUNX1 and TERT. Germline DDX41, ETV6 and RUNX1 mutations 
predispose to both myeloid and lymphoid malignancies. Figure 
modified from (Tawana and Fitzgibbon, 2016). 
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These syndromes are briefly described in the ensuing section (1.2.2), concentrating on the 
unique features that distinguish them from one another, whilst GATA2, the focus of my thesis, 
is discussed in more detail in section (1.2.3). Lastly, an overview on how to identify, test and 
manage patients and families at risk for these inherited syndromes is provided in section (1.2.4), 
while also highlighting some questions arising in the field. 
 
1.2.2 Familial MDS/AML Genetic Predisposition Syndromes 
 
 
“Human beings are ultimately nothing but carriers – passageways – for genes.  
They ride us into the ground like racehorses from generation to generation”. 
 
– Haruki Murakami   
 
 
1.2.2.1 FPD/AML with RUNX1 Mutations  
 
Familial platelet disorders are rare autosomal dominant diseases characterised by 
thrombocytopenia, clinical bleeding due to platelet dysfunction and a propensity to develop 
MDS and/or AML (Owen et al., 2008). Since the initial discovery of RUNX1 germline mutations in 
6 FPD/AML families by Song and colleagues in (1999), more than 30 families have been reported 
in the literature so far. These cases harbour a spectrum of RUNX1 germline aberrations 
encompassing frameshift, missense or nonsense mutations localised to either of the two highly-
conserved domains as shown in Figure 1.3 (Liew and Owen, 2011, Nickels et al., 2013). 
RUNX1 (also known as CBFA2 or AML1) encodes an alpha sub-unit of the core binding factor 
(CBF) complex and is a key transcription factor important in haematopoietic regulation and 
myeloid differentiation (Owen et al., 2008). Germline mutations in RUNX1 typically cluster in the 
N-terminal RUNT homology domain (RHD), predicted to disrupt DNA binding and 
heterodimerisation with CBFβ subunit, rendering RUNX1 haploinsufficient in these cases (Song 
et al., 1999, Preudhomme et al., 2009).  
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Germline lesions in the C-terminal transactivation domain (TAD), however, are less frequent and 
are likely to impair interactions with downstream regulatory targets like PU.1. Such mutations 
exert a dominant-negative effect thereby antagonising WT RUNX1 function (Michaud et al., 
2002).  
 
There appears to be however no discernable differences in the clinical presentation between 
RUNX1 dominant-negative mutations or those predicted to cause haploinsufficiency, although a 
higher frequency of MDS/AML might be associated with the former (Liew and Owen, 2011). 
However, several reports showed that ~20% of FPD/AML patients exhibit loss of one RUNX1 
allele by deletion of chromosome 21, leaving the remaining allele intact, suggesting 
haploinsufficiency of RUNX1 is also sufficient to cause FPD/AML (Beri-Dexheimer et al., 2008, 
Sakurai et al., 2016, Preudhomme et al., 2009). Germline testing analysis for individuals with 
suspected thrombocytopenia or FPD/AML should therefore not only be restricted to RUNX1 
mutations but also include tests sensitive to detect whole or partial chromosomal deletions or 
copy number alterations (CNAs) that may go unnoticed by more conventional sequencing 
techniques. These tests include comparative genomic hybridisation (CGH) arrays or multiplex 
Figure 1.3 Schematic representation of the RUNX1 protein demonstrating the distribution of 
germline RUNX1 mutations in familial FPD/AML reported to date. RHD: Runt homology domain; 
TAD: transactivation domain. Figure adapted from (Nickels et al., 2013). 
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ligation-dependent probe amplification (MLPA) analyses (Jongmans et al., 2010). Indeed, a study 
by our group identified germline RUNX1 deletions (ranging from 311-666Kb and mainly 
encompassing exons 1 and 2) across four FPD/AML pedigrees using array CGH and were further 
validated by MLPA ((Tawana, 2015) unpublished observations). 
Moreover, a certain degree of heterogeneity in disease phenotypes exists within and between 
RUNX1-mutated families, rendering this syndrome difficult to recognise. Approximately 40% of 
RUNX1 mutation carriers develop full-blown malignancy whilst others present with mild to 
moderate thrombocytopenia and some even retain normal PB counts (Owen et al., 2008). This 
suggests that germline mutations alone are not always sufficient to initiate disease and may 
need synergy with other molecular events to initiate clonal expansion and proliferation. This is 
exemplified by a study which reported acquisition of CDC25C variants as a recurrent or 
secondary molecular event in germline RUNX1-mutated Japanese families (Yoshimi et al., 2014). 
In addition, previous work from our lab performed comprehensive genetic profiling across 
multiple siblings from a Hungarian RUNX1-mutated pedigree with AML and showed somatic 
acquisition of variants upregulating JAK-STAT signalling pathway, including JAK2 and SH2B3 (a 
negative regulator of JAK2) whilst also sharing the 46/1 haplotype linked with sporadic JAK2-
positive myeloproliferative neoplasms (MPNs). This study provided a notable example of intra-
familial convergent AML evolution, where inherited genetic factors may govern somatic 
mutation acquisition and leukaemic transformation (Tawana et al., 2017b).  
Other genetic lesions that confer thrombocytopenia and/or an inherited predisposition to 
haematological malignancy are ANKRD26 (Noris et al., 2013) and ETV6 (Zhang et al., 2015, 
Noetzli et al., 2015). The inter-relationship across different lesions is noteworthy, for example, 
ETV6 is recurrently translocated with RUNX1, t(12;21), in ~25% of paediatric B-cell acute 
lymphoblastic leukaemia (ALL) patients (Romana et al., 1995, Ford et al., 1998). 
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1.2.2.2 Pure Familial AML with Mutated CEBPA  
 
The transcription factor CCAAT/enhancer-binding protein alpha (CEBPA) represents another 
important loci predisposing to familial AML as its main presenting feature (without any precursor 
cytopenias or MDS). It is encoded on chromosome 19q13.1 and has an essential role in mediating 
granulocytic differentiation and cellular growth arrest (Nerlov, 2007). 
While heterozygous mutations in this intronless, single-exon gene were reported in 10-15% of 
sporadic NK-AML, Smith and colleagues from the Fitzgibbon lab were the first to report germline 
CEBPA mutations in two siblings and their father who presented to St. Bartholomew’s Hospital, 
London, two weeks apart with AML (Smith et al., 2004). All 3 family members harboured an 
identical N-terminal mutation (c.212delC:p.P23RfsX137). This frameshift lesion results in an 
increase in translation of the shorter p30 isoform, which lacks its first transactivation domain but 
nevertheless retains the leucine zipper region (bZIP) required for dimerisation with the p42 
protein, leading to a dominant-negative inhibition (Figure 1.4). Disease progression in these 
siblings was accompanied by the acquisition of additional somatic in-frame insertions in the C-
terminal section of the protein. Such mutations result in alteration of the structure of bZIP; 
dimerisation with WT CEBPA is therefore disrupted leading to a loss-of-function (LoF) (Smith et 
al., 2004, Pabst et al., 2008). 
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Since this discovery, a retrospective analysis of 25 patients from 11 CEBPA-mutated pedigrees 
revealed that AML with germline CEBPA mutation is associated with favourable long-term 
clinical outcomes, with the molecular and clinical features resembling that of sporadic NK-AML 
with double-mutated CEBPA and a 10-year OS approaching 65% (Tawana et al., 2015, Dufour et 
al., 2010). However, despite this favorable prognosis, AML patients with germline CEBPA 
mutations are prone to the development of future leukaemias, occurring as late events (27 
months). Indeed, a striking observation was made following deep sequencing of paired 
diagnostic and relapse samples from these patients revealing the occurrence of secondary 
somatic C-terminal CEBPA mutations at relapse that were absent at diagnosis. This suggests that 
not only were patients cured from their initial disease but rather the relapse was triggered by 
entirely new leukaemic episodes, supporting a new mode of disease recurrence and progression 
in familial AML. While these patients responded well to salvage therapies (i.e. are 
chemosensitive), allogeneic HSCT should be considered to alleviate the risk of AML recurrence, 
although the timing of HSCT (at the first or second remission period) has been controversial 
(Tawana et al., 2017a). 
Figure 1.4 Schematic representation of the CEBPA protein demonstrating the distribution of 
germline and acquired CEBPA mutations in familial AML. The majority of germline mutations are 
located in the N-terminal region (frameshift) while somatic acquired mutations typically cluster 
within the C-terminal, with a hotspot located at residue K313. TAD 1/2: transactivation domain 1/2; 
DBD: DNA-binding domain. KDa: kilodalton. Figure adapted from (Nickels et al., 2013, Tawana et al., 
2015). 
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To investigate additional molecular events accelerating the development of AML, whole exome 
sequencing (WES) data showed clustering of identical acquired somatic mutations within 2 of 
these CEBPA-mutated families (C-terminal CEBPA with GATA2 mutations and C-terminal CEBPA 
with WT1 mutations and 11p acquired uniparental disomy (aUPD)) providing another evidence 
for convergent evolution whereby the nature of secondary mutations (or lack thereof) is 
prescribed by an individual’s host genotype (Tawana et al., 2015). 
While germline CEBPA mutations are predominately localised to the N-terminal domain and are 
associated with a near-complete penetrance albeit with a variable latency period (range 2-46 
years), rare pedigrees with inherited C-terminal CEBPA mutations have recently been delineated 
and appear to demonstrate reduced penetrance, impeding clinical recognition and surveillance 
in those carriers (Pathak et al., 2016, Tawana, 2015) unpublished observations).  
1.2.2.3 Inherited Bone Marrow Failure Syndromes (IBMFS) and Telomeropathies  
 
 
IBMFS are a diverse group of disorders characterised by features indicative of BM failure with 
predisposition to hereditary MDS/AML. Although initially thought to be diseases of early 
childhood, these syndromes can also manifest in adulthood (West et al., 2014a) and range from 
Fanconi anaemia (FA) (caused by mutations in FANCA and FANCD1) to dyskeratosis congenital 
(DC) (mutations in DKC1), Shwachman-Diamond syndrome (SDS) and telomere biology disorders 
(TBD)(Bluteau et al., 2017). The latter is considered the most common IBMFS caused by 
heterozygous mutations in genes responsible for telomere maintenance: (TERT, encoding 
telomerase reverse transcriptase and TERC, encoding telomerase RNA component) so called the 
“telomeropathies” (Vulliamy et al., 2001, Yamaguchi et al., 2005, Townsley et al., 2014). The 
genetic and phenotypic complexity of telomeropathies has been further delineated by the 
discovery of mutations in other genes including NOP10 (Walne et al., 2007), TINF2 (Savage et al., 
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2008) and RTEL1 (Walne et al., 2013b, Cardoso et al., 2017). Such mutations lead to genomic 
instability, disruption of the DNA repair machinery and shorter telomeres (Kirwan et al., 2009, 
Dokal and Vulliamy, 2010). 
 
More interestingly and specifically, mutations in TERC and TERT have been associated with 
anticipation, whereby younger generations present with more severe disease phenotypes and 
shorter telomeres compared to their older counterparts (Vulliamy et al., 2004). Awareness of 
such phenomenon and appropriate screening is essential as a child inheriting a TERC or TERT 
mutation could present even before his/her parent carrying the same mutation (West and 
Churpek, 2017). Ultimately, IBMFS are inherited in an autosomal dominant fashion (except for 
FA where the mode of inheritance is autosomal recessive) with a myriad of clinical 
manifestations and incomplete penetrance, highlighting the importance of integrating TERT and 
TERC into the diagnostic algorithm of familial MDS/AML and conducting telomere length testing 
in patients with suspected diagnosis of IBMFS.  
 
 Recently Identified Disease Genes in Familial MDS/AML (2015-2018):  
1.2.2.4 The RNA Helicase DDX41  
 
 
Germline mutations in the RNA helicase DEAD/H-box polypeptide 41 (DDX41) have recently been 
associated with an inherited predisposition to MDS/AML and late age of disease onset (for 
certain mutations) similar to that of sporadic disease (mean 65.5 years). DDX41 is located on 
chromosome 5q35.3 and defects in this gene lead to loss of tumor suppressor function due to 
altered pre-mRNA splicing and RNA processing, representing a new genetic class in familial 
MDS/AML. Polprasert et al (2015) initially reported germline DDX41 mutations in seven 
MDS/AML families, five of which carried the recurrent frameshift (p.D140GfsX2) mutation and 
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subsequently, Lewinsohn and colleagues (2016) expanded this cohort even further by reporting 
nine additional MDS/AML families with novel germline heterozygous DDX41 mutations. Notably, 
50% of these affected members acquired somatic DDX41 mutations (p.R525H) in the other allele, 
akin to biallelic CEBPA-mutated cases (Smith et al., 2004, Tawana et al., 2015, Tawana and 
Fitzgibbon, 2016). In the same year, four more MDS/AML families with novel germline DDX41 
variants and a tendency to shortened telomeres were described by our sister lab at the Blizard 
institute (Cardoso et al., 2016). Of note, somatic DDX41 mutations are seldom seen without a 
germline DDX41 alteration and therefore, identification of any DDX41 mutation should raise a 
suspicion of a germline involvement (Brown et al., 2017). Notably, not only were DDX41 
mutations identified in families with MDS/AML but also with colorectal cancers and other 
haematological malignancies including non-Hodgkin’s lymphoma (NHL), Hodgkin disease (HD) 
and multiple myeloma (MM) (Lewinsohn et al., 2016, Cheah et al., 2017). 
The prolonged latency of MDS/AML associated with this genetic subtype may hinder the timely 
recognition of familial disease occurrence in older patients as well as appropriate donor selection 
when it comes to HSCT. This dilemma is demonstrated in two families (Figure 1.5) in which the 
index cases presented with NK-AML at age >40 years and both received HSCT from their 
respective, healthy HLA-matched brothers and subsequently relapsed with 99% donor 
chimericsm (Berger et al., 2017, Kobayashi et al., 2017). To find a genetic explanation for this 
disease recurrence, the authors from these two studies performed WES and showed the 
presence of germline heterozygous DDX41 mutations in all brothers (donors and recipients). 
Targeted deep sequencing was then performed to detect co-operating somatic mutations that 
could contribute to AML development and identified acquired mutations in DNMT3A, ASXL1 and 
even secondary somatic missense DDX41 mutations (p.R525H) shared between donor and 
recipient samples. Altogether, these rare incidences indicate that disease relapse was likely of 
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donor origin (donor-derived leukaemia) and underline the necessity for heightened clinical 
awareness and comprehensive family screening (even in older members) to detect these 
mutations prior to making any donor selection related decisions. 
 
Figure 1.5 Donor-derived leukaemia in germline DDX41-mutated families.    
 
1.2.2.5 SAMD9, SAMD9L and Making a Monosomy 7 
 
 
Two newly discovered genes recently joined the catalogue of germline variants predisposing to 
MDS/AML. The SAMD9L locus and its paralog SAMD9, residing head to tail on chromosome arm 
7q21, function to inhibit cell proliferation and are therefore regarded as tumor suppressor 
genes. Whilst SAMD9 mutations were associated with a syndrome of MDS, infection, restriction 
of growth, adrenal hypoplasia, genital phenotypes and enteropathy (known as the MIRAGE 
syndrome), germline heterozygous gain-of-function (GoF) SAMD9L mutations can cause a 
syndrome of cytopenia, immunodeficiency, MDS and neurological symptoms  
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(e.g. Ataxia-Pancytopenia) (Narumi et al., 2016, Chen et al., 2016, Tesi et al., 2017, Pastor et al., 
2018, Davidsson et al., 2018). 
 
Consistent with a GoF effect, Tesi et al showed that SAMD9L missense mutants can cause 
decreased cell proliferation compared to WT protein, leading to loss of SAMD9L-mutant allele 
and cytopenias (Tesi et al., 2017). The resultant haematopoietic crisis can therefore facilitate 
selection and expansion of monosomy 7 clones, foreshadowing the development of overt MDS. 
On the other hand, some SAMD9L GoF mutation carriers can experience milder clinical 
presentation and recovery from their cytopenias explained by haematopoietic revertant 
mosaicism derived from either UPD of 7q or additional somatic SAMD9L LoF truncating 
mutations in cis, disguising carriers of SAMD9L germline mutations. Further studies are therefore 
needed to determine the likelihood of developing overt disease in those carriers. Overall, these 
studies highlight a novel mechanism in familial MDS/AML involving monosomy 7 driven by the 
selective loss of germline SAMD9L mutation. However, it seems likely that SAMD9/SAMD9L are 
yet another gene entity that behave differently in adults and children; germline LoF SAMD9 and 
SAMD9L mutations have recently been identified in adult MDS and convey different 
pathophysiologic effects than their GoF counterparts (Nagata et al., 2018, Pastor et al., 2017). 
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1.2.3 Focusing on GATA2 – the Stemness Gene  
 
 
Transcription factors (TFs) are considered master regulators of haematopoiesis through their 
roles in orchestrating cellular proliferation and differentiation, and so it comes as no surprise 
that disruption of such control, through mutations or altered gene expression in these TFs, can 
trigger the development of overt malignancy in a Domino like fashion. Take GATA2, one of six 
GATA binding protein factors and key players in this ensemble, essential for the development 
and differentiation of haematopoietic and lymphatic vascular systems. It is expressed in early 
myeloid progenitors and plays a key role in cell fate determination and target gene regulation, 
joining the ranks of other TFs, namely RUNX1 and CEBPA (Kazenwadel et al., 2012, Vicente et al., 
2012, Collin et al., 2015).  
1.2.3.1 Gene Structure, Role in Haematopoiesis and Transcriptional Regulation  
 
 
The GATA2 gene is mapped to chromosome 3q21.3, composed of six coding exons (the first exon 
is untranslated (UTR)) and encodes two highly conserved zinc-finger domains (ZF1 and ZF2) 
(Figure 1.7). Its name was derived owing to the ability of these domains to bind the consensus 
DNA sequence site (A/T)GATA(A/G) in promoter regions of target genes to enable accessible 
transcription. GATA2 is a 480 amino acids long (50.5kDa) and is predominantly expressed in early 
haematopoietic stem cells in the BM, hence it has been called the haematopoietic “stemness” 
gene (Scott et al., 2010). It is also expressed in mature megakaryocytes, monocytes and mast 
cells as shown in Figure 1.6 (Hahn et al., 2011, Rodrigues et al., 2012, Vicente et al., 2012).  
The function of GATA2 in normal haematopoiesis has been widely studied in vivo. For example, 
Tsai and colleagues showed that Gata2 -/- mice succumb to anaemia at day 10 of gestation due 
to failure of definitive haematopoiesis, whereas mice heterozygously deficient for Gata2-/+ 
exhibit dramatically reduced numbers of BM progenitor cells associated with increased 
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apoptosis and cellular quiescence, demonstrating its importance in the proliferation and survival 
of early stages of blood development (Tsai et al., 1994, Tsai and Orkin, 1997, Rodrigues et al., 
2005). Precisely, GATA2 controls the transition from endothelium to haematopoietic stem cells 
(HSC). During HSC differentiation, GATA2 plays a critical role in controlling downstream cell fate 
decisions, working in concert with TFs CEBPA, GATA1 and SPI1 (PU.1). For example, GATA2 is 
displaced from chromatin by GATA1 (a process known as the GATA switch) which drives HSC 
towards erythroid and megakaryocytic differentiation (Figure 1.6) (Vicente et al., 2012, Collin et 
al., 2015, Wlodarski et al., 2017).  
 
 
 
 
 
 
 
 
In addition to its role in haematopoietic differentiation, GATA2 is involved in lineage-specific 
transcriptional regulation. Indeed, GATA2 collaborates with six other TFs (ERG, FLI1, LMO2, LYL1, 
RUNX1 and TAL1) forming a core heptad regulatory unit to direct early lineage development 
(Figure 1.6) (Vicente et al., 2012).  
 
Figure 1.6 The role of GATA2 in haematopoietic development and differentiation. 
A model of key interactions of GATA2 with other major lineage-specifying TFs. 
Figure reproduced from (Collin et al., 2015). 
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Interestingly, using chromatin immunoprecipitation (ChIP), it was demonstrated that not only is 
GATA2 expression regulated by a cloud of proteins including BMP4, CEBPA, ETS1, EVI1, HOXA9 
and NOTCH1 but also it regulates its own transcription by binding to its own promoter (Cortes-
Lavaud et al., 2015, Vicente et al., 2012). Several reports showed that GATA2 modulates the 
expression of other target genes downstream such as GATA1, LMO2, PU.1, RUNX1, SCL and TAL1 
(Gao et al., 2015, Katsumura et al., 2017). Altogether, these findings highlight the importance of 
complex interactions and crosstalk between lineage-specific TFs in regulating haematopoiesis 
and how mutations in either of these genes can perturb the network and contribute to overt 
haematopoietic disease, including leukaemia. 
1.2.3.2 Clinical Syndromes Associated with Germline GATA2 Mutations – GATA2 Deficiency   
 
 
While GATA2 is mutated in ~4-7% of sporadic MDS/AML, especially in 20-40% of biallelic CEBPA-
mutated cases and typically cluster in the first zinc-finger (ZF1) domain (Greif et al., 2012, Fasan 
et al., 2013b, Green et al., 2013), the first report depicting the role of germline GATA2 mutations 
in familial disease was in 2011. It started when Hahn and colleagues identified germline GATA2 
lesions in four families presenting with pure “out of the blue” leukaemia inherited in an 
autosomal dominant manner. All affected individuals harboured heterozygous GATA2 mutations 
within the second zinc-finger (ZF2) domain. The missense mutation (p.Thr354Met) was identified 
in three families whilst a 3bp deletion (p.Thr355del) was described in the fourth family, all of 
which are regarded as LoF aberrations and predicted to impair DNA binding (Hahn et al., 2011). 
Shortly thereafter, more than 30 GATA2-mutated families were reported as outlined in Table 
1.5. 
Remarkably, not only were germline GATA2 mutations associated with pure familial MDS/AML 
in those families but rather with a wide spectrum of overlapping clinical manifestations 
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encompassing immunodeficiency, vulnerability to mycobacterial, viral or fungal infections, 
warts, autoimmunity and cytopenias (Hyde and Liu, 2011, Hsu et al., 2013, Dickinson et al., 2011, 
Ostergaard et al., 2011). These fall under the umbrella of “GATA2 deficiency” syndromes and 
include: Emberger syndrome (primary lymphoedema with predisposition to MDS/AML), 
MonoMAC syndrome (monocytopenia and mycobacterium infection) and DCML (dendritic cell, 
monocyte, B- and natural killer-lymphoid) deficiency, reinforcing the general notion that “Every 
gene is pleiotropic, it influences multiple traits to varying degrees. Every trait is multigenic, 
multiple genes contribute to the expression of every phenotypic detail” – Myers. 
Year of 
Study 
Reference 
(et al) 
Clinical Phenotype 
No. of 
GATA2 
-mutated 
cases 
No. of cases 
with myeloid 
malignancy 
Age at 
diagnosis; range 
(median) years 
2011 Hahn Familial MDS/AML 21 15 10-53 (20.5) 
2011 Ostergaard Emberger Syndrome 14 8 9-53 (12) 
2012 Bödör Familial MDS/AML 6 3 18-31 (24.5) 
2012 Kazenwadel Familial MDS/AML 
Lymphoedema 
10 9 10-33 (16) 
2012 Holme Familial MDS/AML 
Lymphoedema 
4 4 12-48 (20) 
2013 Pasquet Chronic Neutropenia 14 10 6-35 (15) 
2013 Hsu MonoMAC 32 20 3-78 (21.5) 
2014 Spinner GATA2 Deficiency 57 42 0.4-78 (19) 
2014 West GATA2 Deficiency 48 42 12-78 (35.5) 
2014 Dickinson DCML 30 11 4-40 (25) 
2015 Mir Familial MDS/AML 5 3 7-38 (22.5) 
2015 Ganapathi GATA2 Deficiency 28 28 14-60 (30) 
2015 Churpek Familial MDS/AML 7 6 13-68 (16.5) 
Table 1.5 Prevalence of inherited GATA2-mutated myeloid malignancies since its initial description in 
2011. Adapted from (Wlodarski et al., 2017). 
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2015 Wang Paediatric MDS 6 5 Not Available 
2015 Zhang Paediatric MDS 5 5 12-22 (16) 
2016 Wlodarski Paediatric MDS 60 57 3-19 (12) 
2016 Novakova Paediatric MDS 12 10 4.4-17 (14.5) 
2017 Schlums GATA2 Deficiency 13 5 7-60 (18) 
2018 Galera Familial MDS/AML 
(Donor-derived AML) 
6 5 13-64 (34) 
Total 378 288 (76%) 12-35.5 (19.7)  
 
It is worth noting here however that not all GATA2-deficient individuals exhibit all (or even any) 
of these features and their timing and sequence of manifestation are not fully understood 
(Horwitz, 2014). The spectrum of GATA2-related disease extends even further to include 
thrombosis, congenital neutropenia, deafness, pulmonary complications and bone marrow 
failure (Pasquet et al., 2013, Spinner et al., 2014). GATA2 deficiency also appears to be key in the 
aetiology of paediatric MDS. Indeed, Wlodarski et al screened >600 cases of children and young 
adults with de novo MDS and showed that 7-15% of these cases carried germline GATA2 
mutations complicated by systemic infections and a high risk of developing MDS/AML (Wlodarski 
et al., 2016, Hirabayashi et al., 2017). 
1.2.3.3 Landscape and Functional Consequences of Germline GATA2 Mutations  
 
 
The mutations identified in these aforementioned GATA2 deficiency syndromes are scattered 
throughout the gene, which may explain the observed clinical heterogeneity, and include 
protein-truncating frameshifts, missense mutations and in-frame insertions or deletions (Figure 
1.7) (Holme et al., 2012, Ostergaard et al., 2011). In particular, GATA2 germline mutations in 
familial MDS/AML are predominantly missense and appear to cluster mainly within ZF2 domain, 
acting as a mutational hotspot which mediates interactions with other proteins and TFs such as 
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PU.1 and FOG-1 (Hahn et al., 2011). Several lines of evidence suggest that these GATA2 
mutations impair its transcription and promoter activation leading to a LoF, implying that the 
underlying mechanism is that of haploinsufficiency (Cortes-Lavaud et al., 2015, Kazenwadel et 
al., 2012). Indeed, using several in vitro techniques such as electrophoretic mobility shift (EMSA) 
and luciferase reporter assays, Hahn and colleagues showed that p.Thr354Met and p.Thr355del 
mutations reduce DNA binding affinity and transactivation abilities with potential dominant 
negative activities (Hahn et al., 2011, Chong et al., 2017). 
 
Although the majority of GATA2 germline mutations reside within the coding region, non-coding 
mutations in the conserved +9.5kb intron 5 enhancer element have been reported in patients 
with MonoMAC syndrome and in 10% of paediatric MDS patients, leading to decreased GATA2 
transcript levels and haploinsufficiency (Hsu et al., 2013). Also more recently, GATA2 silent 
(synonymous) exonic mutations have been identified in patients with GATA2 deficiency and 
were predicted to introduce splice sites defects leading to loss of mutant allele expression and 
premature RNA degradation (Kozyra et al., 2017, Wehr et al., 2018).  
Figure 1.7 We “GATA” focus on GATA! Schematic representation of the GATA2 protein 
demonstrating the distribution of germline GATA2 mutations in familial MDS/AML. Missense 
mutations (e.g. T354M) and deletions (e.g. T355del) in ZF2 are more associated with familial 
MDS/AML while nonsense and frameshift mutations in ZF1 are more associated with Emberger 
and MonoMAC syndromes. ZF1: zinc-finger 1; ZF2: zinc-finger 2. Figure adapted from (Nickels 
et al., 2013, Hyde and Liu, 2011). 
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Such mutations constitute a new disease-causing mutational class in GATA2 deficiency and 
necessitate further mechanistic studies in order to elucidate the functional impact of these 
germline non-coding variants.  
1.2.3.4 Acquired Genetic Abnormalities Associated with GATA2 Mutations  
 
The mechanisms of clonal evolution in a GATA2-deficient background is not well understood. 
However, what became evident from the various studies so far was the high prevalence of 
trisomy 8 (15%) and monosomy 7 (40%) as recurrent cytogenetic aberrations linked with adverse 
outcomes (Bodor et al., 2012, Spinner et al., 2014, West et al., 2014b, Hirabayashi et al., 2017). 
In particular, Wlodarski and colleagues reported that ~72% of children and adolescents with MDS 
and monosomy 7 harbour germline GATA2 mutations (Wlodarski et al., 2016). GATA2 germline 
mutation screening should therefore be included in the work-up of all children and young adults 
with primary de novo MDS regardless of karyotype, family history or features of GATA2 
deficiency (Fisher et al., 2017). In addition, acquired mutations in the epigenetic regulator ASXL1 
have been demonstrated as an important second-hit in ~30% of germline GATA2-mutated 
patients and confer a poor prognosis (Bodor et al., 2012, West et al., 2014b, Micol and Abdel-
Wahab, 2014, Wang et al., 2015). These acquired mutations in ASXL1 are often accompanied by 
the presence of monosomy 7 acting as a diagnostic red flag although the order of these 
molecular events has not been elucidated. 
 
Other secondary mutations encountered in GATA2-related disease are EZH2, GATA1 and 
HECW2, reported in a de novo MDS patient with germline GATA2 mutation (p.R330X) that was 
subjected to nonsense-mediated decay (NMD) (Fujiwara et al., 2014). Recurrent mutations in 
STAG2 and SETBP1 were also noted in a small subset of GATA2-deficient patients and are 
regarded as oncogenic drivers (Makishima et al., 2013, Inoue et al., 2015, Ding et al., 2017). 
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Altogether, these studies serve as another reminder for close monitoring of GATA2-mutated 
individuals for secondary cytogenetic or molecular genetic aberrations in order to trace the 
genetic evolution and progression of disease and identify patients in need for timely HSCT, 
considered to be the ideal choice of treatment modality for GATA2-mutated patients, with 4-
year OS approaching 54% (Cuellar-Rodriguez et al., 2011, Spinner et al., 2014, Saida et al., 2016, 
Wlodarski et al., 2017). 
 
Collectively, GATA2 deficiency predisposes its carriers to familial MDS/AML and protean 
manifestations with cytopenia as its prominent clinical feature, highlighting the pleiotropic 
nature of this TF. A question remains in what determines the variable clinical presentation seen 
in some GATA2-mutated families despite carrying the same germline mutation. Thus far, there 
is no evidence of revertant somatic mosaicism in GATA2 deficiency such as that encountered in 
SAMD9L-mutant AMLs and so the molecular mechanisms underpinning this enigmatic feature 
merits further investigation (Al Seraihi et al., 2018). I talk about that in more detail in section 1.3. 
 
1.2.4 How to Diagnose, Test and Manage Patients with Familial MDS/AML 
 
 
Taken together, these germline predisposition syndromes are heterogeneous with regards to 
their causative genetic mutations, clinical manifestations and progression to overt MDS/AML. 
However, as a group, they all share the unique requirement for a high index of clinical suspicion 
to recognise the symptoms and perform appropriate genetic counseling, testing and mutation-
specific clinical management (West et al., 2014a). These inherited forms of MDS/AML are more 
common than generally appreciated and the assumption that they are solely disorders of 
childhood no longer holds true, especially with the identification of germline DDX41 mutations 
in patients aged over 62 years, making the recognition of these cases all the more difficult. 
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Therefore, accurate diagnosis and clinical management of affected individuals as well as 
asymptomatic carriers is of utmost importance and requires full knowledge and an in-depth 
understanding of the implications of inherited mutations, especially when considering suitable 
donors for allogeneic stem cell transplantation (Godley, 2014). Thankfully, we have come a long 
way since the discovery of germline RUNX1 mutations in families with FPD/AML (Song et al., 
1999) and are making significant progress in understanding the molecular pathogenesis of these 
series of diseases, where genetic testing is becoming more feasible in routine clinical practice 
and the candidacy of new genes is emerging from basic research and requiring functional 
validation.  
 
1.2.4.1 Panel-based Molecular Testing and Germline Tissue Selection 
 
 
Recently, genomic technologies have advanced to adopt multi-gene targeted resequencing 
panels for quick and reliable assessment of multiple genes in multiple samples simultaneously 
(with a coverage of ~1000x). This greater sequencing depth improves analytical sensitivity for 
VAF detection as low as 1% thus superseding traditional Sanger Sequencing with VAF cut-off of 
~20% (Kadri et al., 2017). 
The current diagnostic work-up in sporadic AML includes screening for mutations in CEBPA, FLT3, 
NPM1, and RUNX1 however the compendium of genes is likely to expand following the 
identification of new mutations with prognostic and therapeutic impact or a role in familial 
disease (Dohner et al., 2017, Greenberg et al., 2017). In light of these findings, 12 out of the 14 
familial MDS/AML disease loci (ACD, ANKRD26, CEBPA, DDX41, ERCC6L2, ETV6, GATA2, MECOM, 
RUNX1, SRP72, TERC and TERT) have been integrated into accredited diagnostic screening 
panels. In the UK, this is located at the West Midlands Regional Genetics Labs in Birmingham that 
the familial MDS/AML programme developed in collaboration with Dr Susanna Akiki 
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(https://ukgtn.nhs.uk). In the USA, a similar gene panel is available at the University of Chicago 
led by Dr Lucy Godley (https://dnatesting.uchicago.edu) while screening panels developed by 
other institutions can be found at GeneTests (www.genetests.org) and there is a global effort at 
present to increase access to genetic testing worldwide to help delineate population similarities 
and differences in mutational spectrum, prevalence and phenotype (Brown et al., 2017). Indeed, 
my ambition is to see a familial MDS/AML gene panel come into fruition in my home country or 
help establish one, soon.  
Nevertheless, the aim of these initiatives is to ensure that every index case and their family 
members with suspected diagnosis of hereditary leukaemias can be genetically tested for 
mutations in these known genes and to capture the underlying genetic predisposition. Testing 
parental samples, if possible, might also be needed to confirm variant segregation with disease 
in the family (i.e. whether the germline variant is inherited or de novo). And clinicians are 
encouraged to integrate timely germline data into anticipatory patient care as not only does this 
information aid in diagnosis but it also has the potential to guide treatment decisions e.g. 
chemotherapy dosing and/or HSCT timing and donor selection (Guidugli et al., 2017). 
 
As many of the genes that confer familial inheritance can also be mutated as acquired secondary 
events or in sporadic MDS/AML (e.g. RUNX1 and CEBPA), the use of germline DNA is absolutely 
essential to distinguish whether a mutation detected is of a somatic or germline origin. Obtaining 
germline material is however challenging since easily accessible samples such as PB, BM, saliva 
or buccal swabs are potentially contaminated with tumour DNA which can lead to false-positive 
results (Obrochta and Godley, 2018). The “gold standard” is constitutional DNA derived from 
cultured skin fibroblasts however it takes several weeks (4-6) to grow a sufficient number of cells 
and so this approach presents a time constraint that could complicate patient management 
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particularly when allogeneic HSCT is being considered (Bannon and DiNardo, 2016, Drazer et al., 
2016). Therefore, in the absence of a matched germline sample, VAF assessment (e.g. if a 
mutation is present at heterozygous allelic frequency with VAF of >40%) and publically available 
datasets (e.g. the Exome Aggregation Consortium (ExAC) and TCGA) may provide valuable clues 
in support of a germline origin (Drazer et al., 2018). Also, follow-up testing of a remission DNA 
sample (where germline mutations would typically persist) or the presence of an unchanged VAF 
at multiple treatment time points may further support a germline origin of a variant (DiNardo et 
al., 2018). Where possible, it is advised to move towards an upfront paired tumour/remission 
testing (or tumour/germline testing at diagnosis) to maximise germline variant detection and 
identify acquired somatic mutations associated with disease progression. In fact, discussions are 
currently ongoing to see if this approach can become a standard diagnostic practice for every 
MDS/AML patient (Akpan et al., 2018, Tawana et al., 2018). 
It is important to note however that these NGS-based gene panels will not tell the whole story 
as they are not equipped to detect large structural gene deletions, duplications or CNAs like the 
case of germline RUNX1 deletions (Jongmans et al., 2010) nor non-coding germline mutations 
residing outside of the transcribed exons such as GATA2 intronic variants (Hsu et al., 2013). This 
may lead to false-negative results and warrant referral for a more comprehensive research-
based testing (e.g. by MLPA, CGH array or whole genome sequencing (WGS)), especially when 
the familial presentation is well established clinically.  While non-coding variants may predispose 
to leukaemia, the interpretation of this data is less clear at the present time and may require 
functional validation. Moreover, it is not just testing for mutations as other phenotypic assays 
such as telomere length measurement can be employed for the diagnosis of patients with IBMFS 
by means of flow-fluorescence in situ hybridisation (FISH) (Walne et al., 2013a). 
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1.2.4.2 New Gene Discovery and Variant Assessment  
 
“As we know, there are known knowns; these are things we know we know. 
We also know there are known unknowns; that is to say we know there are 
some things we do not know. But there are also unknown unknowns – the 
things we don't know we don't know….it is the latter category that tend to 
be the difficult one.” 
                – Donald Rumsfeld - US Secretary of Defence  
 
Remarkably, germline mutations in the aforementioned genes represent merely 60% of familial 
cases investigated to date and so approximately 40% of families remain without an underlying 
genetic aetiology, where variants in the known genes were not identified, at least from 
interrogation of the coding genome. Therefore, ongoing investigations currently being carried 
out in my host laboratory and others are focused on identifying novel inherited disease lesions 
in candidate genes and expanding the current germline mutational repertoire (Rio-Machin et al., 
2018a). Briefly, this is done by integration of WES data from these uncharacterised families 
(where two or more members are diagnosed with a haematological malignancy (AML, MDS or 
BM failure) including at least one member with MDS and/or AML in each family) and filtering 
genes based on stringent criteria (see box - next page). This is then followed by variant 
confirmation by Sanger sequencing and functional validation of select candidates in vitro or in 
vivo (e.g. by shRNA gene knockdown or CRISPR-Cas9 genome editing) to determine if these 
putative candidates are bona fide disease-causing in familial MDS/AML. This is exemplified by 
the recent discovery of novel germline variants in CHEK1, MECOM, SAMD9 and SAMD9L 
segregating in families with MDS/AML and/or other accessory phenotypes (e.g. MIRAGE 
syndrome) (Wartiovaara-Kautto et al., 2018, Ripperger et al., 2018, Narumi et al., 2016, Chen et 
al., 2016).  
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Given the increasing use of NGS technologies both in research and clinical setting, not only do 
these tour de force tools offer an exceptional opportunity for comprehensive and unbiased gene 
hunting but also an immense challenge as to how one can systematically interpret the data and 
assign true pathogenicity when over 500 non-synonymous variants are detected per sample. 
Therefore, using the features of known germline disease-causing variants (known knowns) as a 
guide, our laboratory has established the following criteria of filtering WES data to narrow down 
the search and exclude non-pathogenic variants or frequent single nucleotide polymorphisms 
(SNPs) taking into account:  
1) Whether a variant has been previously reported in the literature or mutated 
in sporadic disease and assessing variant frequency in healthy populations using 
publicly available databases such as (ExAC, HAPMAP, dbSNP, ClinVar or gnomAD) 
where for example ExAC variant frequency of <0.0001 is considered novel; 
2) Variant type (missense or protein-truncating etc.) and predicting the 
biochemical function of variants by virtue of in-silico tools such as (PolyPhen2, 
MutationTaster, SIFT, Provean, GERP, cBioPortal, OMIM or CADD) where for 
example variants with PolyPhen2 scores >0.850 are predicted to be damaging 
and most importantly;  
3) Pedigree information and whether the variant is present in at least two or 
more families (with at least two members analysed per family) can be a useful 
source to determine if there is a segregation of the variant with disease (this is 
not often the case unfortunately as in some families, only the index case is 
analysed, owing to limited sample availability). 
 
Based on these population, computational and segregation data, variants can be classified into 
different categories varying from benign to pathogenic (or actionable) and variants of uncertain 
significance (VUS) (Richards et al., 2015, Baudhuin et al., 2016). However, despite the availability 
of these in silico prediction tools, interpreting with certainty the pathogenicity and functional 
consequences of the detected variants can still be very difficult especially when the variant 
corresponds to the latter category. Additional evidence (e.g. clinical phenotype and/or family 
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history) would therefore be needed to support variants’ association with disease (Richards et al., 
2015). For example, a family member presenting with lymphoedema, MDS and a novel GATA2 
VUS (known unknown) would raise a suspicion of a GATA2 deficiency syndrome and prompt 
variant re-classification to likely pathogenic (Brown et al., 2017). The difficulty arises when a 
novel VUS is identified in a family without a clear candidate gene (unknown unknown). 
Therefore, knowing the function of the encoded protein, its impact on leukaemogenesis (if any) 
and fine-tuning the filtering criteria (e.g. by increasing the number of families analysed or 
tweaking ExAC frequency cutoffs) would help shortlist credible candidates and shine light on 
these needles lurking in the genomic haystack.  
Given the rarity of families with MDS/AML at present and the marked genetic and clinical 
heterogeneity, these investigations require a network of collaboration to consolidate these 
findings, which our group and several others around the world (e.g. Hamish Scott’s group from 
Adelaide, Australia, Marcin Wlodarski’s group from Freiburg, Germany and Lucy Godley’s group 
from Chicago, the United States) have begun to establish over the past few years.  
1.2.4.3 Considerations for Clinical Management and Genetic Counselling  
 
 
The identification of individuals with germline predisposition to myeloid malignancies for 
referral for genetic counselling and testing remains challenging for several reasons: there is a 
lack of awareness regarding the existence of these predisposition syndromes, difficulty in 
obtaining germline material coupled with lack of widespread availability of testing and 
incomplete family/personal history (DiNardo et al., 2018). Clinical vigilance of disease symptoms 
underpins the detection of these cases. Fortunately, since the start of my PhD in 2015, several 
disease genes have been identified including DDX41 (Polprasert et al., 2015), SAMD9 (Narumi et 
al., 2016) and SAMD9L (Chen et al., 2016, Tesi et al., 2017) and current screening assays should 
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incorporate these new findings. While these discoveries brought a momentum to the field of 
familial leukaemia research, it is likely that they merely represent ‘the tip of the iceberg’ and so 
routine testing of germline or remission DNA is essential to identify more familial cases.  
 
Currently, there is little practical information or guidelines on how diagnostic evaluation should 
be performed in these cases, particularly in the context of clinical trials, and recommendations 
for surveillance often depend on the nature of the predisposing syndrome and are emerging 
from several research groups in the field. Figure 1.8 depicts an algorithm adapted from expert 
opinion for diagnostic work-up and to identify appropriate patients for referral to the clinic 
(Churpek et al., 2013, Drazer et al., 2016, Akpan et al., 2018). Generally, it is recommended to 
refer patients who have a family history (2 or more members within at least 2 generations) of 
haematological malignancies or a personal history of multiple cancers or any features suggestive 
of a haematological malignancy such as unexplained cytopenias, severe anaemia or bleeding. 
The occurrence of MDS in a younger patient should also raise suspicion of a germline syndrome 
(e.g. GATA2 deficiency) (Brown et al., 2017). Close clinical follow-up and monitoring of affected 
as well as asymptomatic carriers, where possible, is critical as they are advised to undergo a 
baseline bone marrow biopsy and cytogenetic analysis to asses for occult malignancy in addition 
to twice annual physical examination and complete blood count (CBC) (Drazer et al., 2018). 
 
Patients under consideration for allogeneic HSCT with an HLA-matched first-degree relative 
donor warrant expedited germline genetic testing to rule out a familial MDS/AML syndrome and 
exclude asymptomatic mutation carriers, who may have normal CBCs, from the transplant 
scenario (Nickels et al., 2013). Indeed, reports on engraftment failure and donor-derived 
leukaemia (DDL) act as an important reminder of the potential consequences when germline 
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mutations are not considered and tested first hand. Examples of DDL cases include those 
harbouring mutations in CEBPA (Xiao et al., 2011), DDX41 (Berger et al., 2017, Kobayashi et al., 
2017) and GATA2 (Galera et al., 2018). However, in the absence of a known germline mutation 
but a strong family medical history, the use of a matched unrelated donor is advisable (Niemeyer 
and Mecucci, 2017). 
 
Finally, prompt genetic counselling remains an integral component for the optimal care of these 
patients and their families, to help them better understand the principles of human genetics as 
well as overcome the impact of these inherited disorders on their emotional well-being. Genetic 
counsellors also help patients and family members become aware of the benefits and potential 
risks of genetic testing, possible test outcomes and implications for treatment and donor 
Figure 1.8 An algorithm for work-up of patients with familial predisposition of myeloid 
malignancies. Figure adapted from (Drazer et al., 2016).  
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selection and above all, respect their choice, privacy and autonomy. This information forms the 
basis of the informed consent process for testing and disclosure of results (Nickels et al., 2013). 
Affected couples may seek reproductive counseling for prenatal testing options including in vitro 
fertilisation (IVF) and preimplantation genetic diagnosis (PGD) to determine disease risk in their 
offspring and/or select embryos lacking the germline defect (Niemeyer and Mecucci, 2017). 
Patients are also encouraged to participate in research to allow for the discovery of new variants 
and susceptibility syndromes (Brown et al., 2017). Indeed, patients and their families feel 
empowered knowing their contributions and stories can have a major impact on the research 
and medical field by helping other families going through similar experiences they have been 
through. 
1.2.4.4 Unanswered Questions in Familial Leukaemia Research 
 
 
The field of familial leukaemia research is evolving rapidly. Much remains to be learned 
considering the rarity of these familial cases and as with all good studies, there are more 
questions than answers. For example, what is the true prevalence of familial MDS/AML 
syndromes in adult populations (currently amounts to <5% of all MDS/AML cases) now that more 
susceptibility genes are likely to be identified? Does the scientific community need a uniform 
and accessible algorithm for research-based gene discovery and variant triage? Secondly, should 
all patients with MDS/AML undergo germline testing at the time of diagnosis and irrespective of 
family history, or be included in a tumour/germline panel-based testing pipeline as part of a 
standard procedure in routine clinical practice? And thirdly (and somewhat controversial), 
considering that germline mutations in familial leukaemia can display reduced penetrance, 
should prophylactic allogeneic HSCT be offered to asymptomatic mutation carriers or indeed to 
those presenting with symptomatic manifestations but have not yet developed full-blown 
malignancy? And how can we identify these unaffected carriers in the first place? 
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 (Drazer et al., 2016, Akpan et al., 2018, Rio-Machin et al., 2018b, Tawana et al., 2018). 
Addressing these questions and more as they develop over the coming years will likely require 
the collaborative efforts of an international clinical and research community who can provide 
consensus and practical guidelines. All this information will hopefully lay a strong enough 
foundation for optimal management and care of this unique patient population, with novel 
molecular insights that may ultimately lead to the implementation of new diagnostic measures 
and mechanism-based therapeutic interventions for both familial and sporadic forms of the 
disease. 
1.3 Penetrance of Germline Mutations 
 
 
“They f*** you up, mum and dad.                          
They may not mean to, but they do. 
They fill you with the faults they had 
And add some extra, just for you”  
 
– Phillip Larkin, This Be The Verse 
 
 
 
 
 
One of the conundrums in familial cancers in general and leukaemias in particular is the notion 
that not every individual carrying a particular variant (or genotype) will eventually exhibit clinical 
symptoms (or phenotypes) associated with the disease in question – a phenomenon known as 
“incomplete or reduced penetrance” (Cooper et al., 2013). Throughout this thesis, the term 
“reduced penetrance” is used to describe both penetrance (proportion of mutation carriers 
showing a phenotype – not always 100%) and variable expressivity (severity of phenotype) 
although I personally like to call it “mutation shyness” as the same bona fida disease-causing 
mutation may not be expressed equally in all individuals who carry it.  
“They tuck you up, mum and dad. 
They read you Peter Rabbit, too. 
They give you all the treats they had 
And add some extra, just for you” 
 
– Adrian Mitchell, This Be The Worst 
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This inter-individual variability poses a great challenge for understanding how genetic variants 
manifest in disease (or why certain carriers do or do not manifest it) and a caveat for the 
prognosis of patients’ disease outcomes based solely on their genetic information (Castel et al., 
2018).  
 
Reduced penetrance is more evident in autosomal dominant disorders when simple rules of 
Mendelian genetics are not followed. These include muscular dystrophy (caused by LMNA 
mutations), retinoblastoma (RB1 mutations), Huntington’s disease (HTT mutations) and breast 
and ovarian cancers (BRCA1 and BRCA2 mutations) (Vytopil et al., 2002, Lefevre et al., 2002, 
McNeil et al., 1997, Chen and Parmigiani, 2007). However, the precise molecular explanation of 
such occurrence is not well understood. 
 
1.3.1 Reduced Penetrance in Inherited GATA2-mutated MDS/AML  
 
 
Scientific investigations of familial leukaemia have not addressed the question of reduced 
penetrance in earnest which could have important connotations for the counselling and 
management of patients and their families. Germline mutations that display low penetrance 
tend to be associated with a higher frequency of asymptomatic “silent” carriers such that the 
clinical manifestation may not be evident in one generation but can still be transmitted, through 
unaffected parents, to the next generation where it can once again manifest itself – so-called 
generation skipping (Cooper et al., 2013). We have noted that this is indeed a feature within 
certain GATA2-mutated families, particularly those carrying germline missense LoF mutations 
and seems less likely in other types of GATA2 mutations, suggesting that penetrance is 
potentially a mutation-dependent occurrence. It is pertinent to note that penetrance may vary 
not only with mutation type, but also with the location of the mutation in the protein. An 
example is germline CEBPA mutations in the C-terminal domain being more apt to exhibit 
Chapter 1 - Introduction 
 75 
reduced penetrance as opposed to N-terminal mutations where penetrance is almost near 
complete (Tawana et al., 2015, Pathak et al., 2016).  
 
In the initial study reported by Hahn and colleagues from Australia describing three GATA2-
mutated MDS/AML pedigrees spanning multiple generations, all affected members who were 
tested in those families (13/19) carried the heterozygous missense mutation (p.Thr354Met). 
However, not all family members (6/19) harbouring this germline mutation developed 
symptoms of haematological malignancy (e.g. cytopenia or neutropenia), remaining symptom-
free well into their 50’s or 60’s (Figure 1.9 – pedigrees 1, 2 and 3) (Hahn et al., 2011). Since this 
observation, few additional families where disease penetrance varied from 50 to 70% came to 
light concomitantly (Table 1.5), including a five-generation GATA2-mutated MDS/AML family 
published by our group carrying p.Thr354Met and monosomy 7 (Bodor et al., 2012) (Figure 1.9 
– pedigree 4) (discussed in detail in Chapter 3). 
Figure 1.9 GATA2 (p.T354M)-mutated MDS/AML families with reduced penetrance.                       
Pedigrees re-drawn from (Hahn et al., 2011) and (Bodor et al., 2012). Asymptomatic carriers are 
circled in red.  M: family member carrying the p.T354M mutation. 
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Why do we care about a phenomenon that is a rare exception to the norm? True estimates of 
reduced penetrance are masked by limited genetic and phenotypic screening of extended family 
members and absence of comprehensive family medical histories, suggesting it may be more 
common than previously considered (Shawky, 2014). Measuring penetrance quantitatively, 
however, has been a subject of controversy as what constitutes a “symptomatic”, 
“asymptomatic”, “affected” or “obligate” carrier may vary from one institution to another and 
therefore, a consensus definition of these nomenclature, at least within the realm of familial 
AML, is needed. Ultimately, reduced penetrance represents an added complication for clinicians 
and genetic counsellors alike, particularly when predicting disease risk in future generations 
(Drazer et al., 2016). Reduced penetrance is also likely to present an impediment to the 
interpretation of NGS data (e.g. based on ExAC allele frequencies) and so it must be taken into 
account when classifying the pathological significance of variants (Plon et al., 2008, Richards et 
al., 2015). Therefore, careful family clinical evaluation and identification of asymptomatic ‘silent’ 
mutation carriers, to include them on surveillance and genetic testing but critically to exclude 
them as potential stem cell transplant donors, is of great importance. It is hoped that deciphering 
the molecular mechanisms governing this enigmatic feature of human inherited disease and 
uncovering potential genotype-phenotype correlations will help improve our understanding of 
leukaemia pathogenesis and aid in genetic counselling of at-risk germline mutation carriers. 
 
Aside from familial studies, estimates of penetrance can also be obtained through population-
based linkage analyses and genome wide association studies (GWAS) using large disease cohort 
datasets. For example, several studies showed that certain common variants in cis have the 
potential to modify the penetrance of BRCA1- and BRCA2-associated breast cancers (Gaudet et 
al., 2010, Couch et al., 2013). 
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Another example is a recent study by Tuuli Lappalainen’s lab who used population-scale 
functional genomics to assess how cis-regulatory modifiers of penetrance affect disease risk in 
individuals with cancer and autism spectrum disorder (ASD) (Castel et al., 2018). 
 
 
1.3.2 Molecular Factors Associated with Reduced Penetrance  
 
What accounts for the clinical variability between symptomatic carriers sharing an identical 
germline mutation or determines progression to overt malignancy in asymptomatic ones 
remains unclear. It is difficult to pinpoint a single mechanism or answer but it is likely to be down 
to a combination of complex genetic and environmental factors. These include: mutation type, 
differential gene or allelic expression, cis- or trans-regulatory allelic variations, epigenetic 
modifications, copy number alterations, age or simply, luck.  
The premise is that genotype is not the sole determinant of phenotype but rather the 
intersection of genetic variants, environment, chance and other genetic modifier effects 
(Mukherjee, 2016). Identification of such molecular events can blur the boundaries between 
simple monogenic and complex genetic diseases, challenging the traditional dogma that a 
human disease can be caused by a “single” mutated gene (Badano and Katsanis, 2002). 
Concurring with these views and in the context of familial leukaemia, one would argue that 
germline mutations with reduced penetrance (as is the case for GATA2) may contribute to 
disease pathogenesis but are perhaps insufficient on their own to trigger the development of 
overt malignancy and in so doing, require the presence of additional co-operating events. Whilst 
each of these factors may influence disease penetrance in their own right in some fashion, 
different combinations are likely to exert different effects on the severity of symptoms and so 
for the purpose of this thesis, the involvement of these molecular factors in disease penetrance 
shall be tested. 
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1.4 Aims & Objectives 
 
“Find out the cause of this effect, 
Or rather say, the cause of this defect, 
For this effect defective comes by cause.” 
  – William Shakespeare, Hamlet 
Over the past two decades, many research studies have provided examples of inherited forms 
of myeloid malignancies and a glimpse of their genetic and phenotypic complexities, with 
germline mutations reported in ~14 disease genes so far, leading to their incorporation as a 
separate diagnostic entity into the 2016 WHO classification system. However, a number of 
questions are yet to be answered in this emerging field, including disease penetrance and what 
accounts for the clinical heterogeneity seen within a given family sharing the same germline 
mutation. Therefore, in light of these observations in GATA2 p.Thr354Met MDS/AML pedigrees 
and the availability of sequential samples and NGS/molecular tools at one’s disposal, the primary 
aim of the study addressed in my thesis was to:  
 
Investigate the molecular mechanisms underlying reduced penetrance of germline 
GATA2 mutations. In particular, this work aimed to understand the molecular basis of 
disease initiation and identify molecular features that distinguish symptomatic from that 
of asymptomatic family members by:  
 Employing in-depth molecular profiling – with the hypothesis that penetrance might reflect on the 
acquisition of secondary somatic mutations (or second hits) that differentiates between these two groups 
of mutation carriers and; 
 Investigating GATA2 expression levels – with the hypothesis that penetrance may be modulated by 
changes in GATA2 expression (and all its elements: global, regulatory and allelic dosage) defining 
symptomatic and asymptomatic carriers and potentially paving the mutational path towards malignancy. 
 Elucidating the molecular mechanisms by which GATA2 is regulated in these GATA2-mutated patients.   
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2. Materials and Methods 
 
“Progress in science depends on new techniques, new 
discoveries and new ideas, probably in that order.” 
– Sydney Brenner  
 
2.1 Familial MDS/AML patient sample collection and study approval 
 
Bone marrow (BM), peripheral blood (PB) or salivary material were obtained from select 
members of the GATA2-mutated MDS/AML family investigated in this thesis (described in detail 
in Chapter 3 with a summary of the clinical history in section 3.2). These include: asymptomatic 
mutation carriers (III.5 and III.7), wild-type individuals (IV.8 and IV.9) and multiple time-points 
from the symptomatic patient (IV.10: y.1, 3, 4 and 6) obtained through routine clinical follow-up. 
Tumour DNA samples were extracted from BMs of (IV.1 and IV.6) deceased MDS/AML cousins at 
diagnosis while constitutional or germline DNA was sampled from (IV.6) during disease remission. 
Samples were collected via referrals from clinicians managing these patients at St. 
Bartholomew’s hospital, London. Informed, written consent was obtained for use of samples for 
research with ethical approval (06/Q0401/31) received in accordance with the Declaration of 
Helsinki.  
2.2 DNA mutational profiling and sequencing 
 
PCR amplification followed by Sanger sequencing of regions encompassing variants of interest 
was performed. Briefly, primers designed to anneal specific sequences surrounding a particular 
variant were used for target DNA amplification (see Table 2.1 for primer sequences and annealing 
temperatures (TA)). PCR amplicons were run on an agarose gel and cleaned to remove excess 
reagents and primer dimers. Purified PCR amplicons were then sequenced on forward and 
reverse directions via fluorescent cycle sequencing. Sanger sequencing products were analysed 
on the Life Technology 3730xl DNA Analyzer and trace chromatograms visualised on the BioEdit 
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software and compared against a reference human genome. 
 
2.2.1 Genomic DNA extraction and quantification 
 
Genomic DNA was extracted from patient PB or BM aspirates using the DNeasy Blood & Tissue 
Kit (Qiagen) following standard procedures. For samples recovered from the liquid nitrogen, cells 
were thawed at 37oC water bath and transferred to a fresh medium. Approximately 5 million 
cells were centrifuged (300g for 5 minutes at 18oC) and resuspended in 200μl Dulbecco’s 
Phosphate-Buffered Saline (PBS) to remove any dimethyl sulfoxide (DMSO) residues. 20μl of 
Proteinase K and 200μl of lysis buffer (AL) were next added to the cells and the mixture vortexed 
prior to incubation at 56oC for 10 minutes. The later addition of 200μl of 100% ethanol allowed 
DNA to precipitate which was then transferred onto silica-based membranes in DNeasy Mini spin 
columns and centrifuged at 6000g for 1 minute. DNA bound to the membrane columns then 
underwent sequential washes using ethanol-containing buffers: 500μl of buffer AW1 (6000g for 
1 minute) followed by 500μL of buffer AW2 (20,000g for 3 minutes). Finally, purified DNA 
samples were eluted in 100μl of elution buffer (EB) or nuclease-free water prior to long-term 
storage at -20oC.  
 
Nucleic acid concentration and quality were measured (in ng/μl) following extraction using the 
NanoDropTM ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, MA) to establish the 
260nm/280nm and 260nm/230nm absorbance ratios, where ratios between 1.8 and 2.0 were 
regarded as “pure” DNA and/or RNA. Any ratios significantly lower than these values potentially 
indicate sample contamination (e.g. by residual phenols or proteins). Alternatively, a flurometric-
based approach (Qubit® 3.0) and the dsDNA Broad Range Assay Kit (Life Technologies) was used 
for DNA quantification due to its higher sensitivity and specificity compared to its absorbance-
based counterpart. 
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2.2.2 Direct polymerase chain reaction (PCR)  
 
Direct PCR was used to amplify precise regions of the DNA. PCR reactions were performed using 
the 2x ReddyMixTM PCR Master Mix (Life Technologies) that contains a Thermoprime Taq DNA 
Polymerase and a Taq buffer with a red loading dye to aid in visualisation of PCR products. 
Primers sequences encompassing variants of interest (coding or non-coding regulatory regions) 
were designed using the IDT PrimerQuest tool: 
(http://www.idtdna.com/primerquest/home/index) and sequences are listed in Table 2.1. Each 
10μl reaction contained 4μl of ReddyMix, 4μl of water, 0.5μl of forward and reverse primers 
(10μM concentration per primer) and 1μl of DNA (or cDNA) template (~50ng/μl). A non-template 
control (NTC) (1μl of water) was also added in each experiment to detect possible reagent 
contamination and/or non-specific amplification. 
The PCR cycling conditions consisted of an initial denaturation step (at 95°C for 10 minutes), 
followed by 35 cycles of DNA denaturation (at 95°C for 30 seconds), primer annealing (at 50-65°C 
for 30 seconds) and extension (at 72°C for 60 seconds) followed by a final extension step (at 72°C 
for 10 minutes). The optimal annealing temperature (TA) for each primer pair/PCR reaction (Table 
2.1) depends on multiple variables (e.g. primer nucleotide length (20-30) and GC content (40-
60%)) and is ideally 5°C below the lowest primer’s melting temperature (Tm) (New England 
BioLabs (NEB)). 
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Table 2.1 Primer sequences used in this study together with their annealing temperatures. These primers 
were designed using different programs including: Primer3plus, Primer-BLAST, IDT PrimerQuest Tool and 
MethPrimer. The vector M13 insert primer sequence was obtained from the TA-cloning protocol 
(Invitrogen). 
Gene Forward Primer Reverse Primer 
Annealing 
Temperature 
(TA) 
                                           Intronic PCR primers for Genomic DNA amplification 
GATA2 Exon 4 GACTCCCTCCCGAGAACTTG GCGTCTGCATTTGAAGGAGT 58°C 
GATA2 Exon 5 TTAGCCCTCCTTGACTGAGC AGCCAAGCTGGATATTGTGG 58°C 
GATA2 Exon 6 GTTGCTGGAGGAAGGAACTG AACTGTCCATGCAGGAAACC 58°C 
ASXL1 GGTTAAAGGTCAGCCCACTTA CAGTAGTTGTGTTCGCTGTAGA 56°C 
                                             Exonic RT-qPCR primers for cDNA amplification 
GATA2 Exon 5 ACTCATCAAGCCCAAGCGAA CTTCATGGTCAGTGGCCTGT 60°C 
GAPDH    CCATCACCATCTTCCAGGAG GAGATGATGACCCTTTTGGC 56°C 
Overlapping PCR primer sets covering GATA2 regulatory regions 
Promoter 1 (1) GGAAGGTGGAAGTGGAAGAAA GCTGCTCAAGTCTGTCTATT 54°C 
Promoter 1 (2) GGCAGGCAATAGACAGACTT GGGCGTCTGTGTACCATTAT 57°C 
Promoter 1 (3) AGCTTGGGACACGTCTTTAC GACTCCCACACTCACTTTCT 57°C 
Promoter 2 (1) CGCCAGATACACATACTGATCTC GCTGGCTTGGGCTTCTTA 57°C 
Promoter 2 (2) GACTCCTGCACAGACATGAA GGGCAGTTGGTGGTTAGTTA 57°C 
Promoter 2 (3) TCCGCAATTCCCGAACC GGGCAGTTGGTGGTTAGTTA 57°C 
Promoter 2 (4) GGCCTCCCTAGCAGTAACTAA AGGTGACTTAGAAGACGGAGAC 58°C 
Enhancer 1 TTTGCAGAGTGGAGGGTATTAG ATGGAGTCACCTATACTGTGTATTT 54°C 
Enhancer 2 (1) CCTCCCAAAGTGCTGAGATTAC CTGGGAGTTGGAAGTTGTAGTG 58°C 
Enhancer 2 (2) CTCCTAGGTTCATGCCATTCTC TGGTAAGGCTATGAGGGATACA 57°C 
Enhancer 2 (3) CCCAGGTTCAAGCGATTCT GGCTGAGGGTATCAACAAGAG 58°C 
Enhancer 2 (4) TTTCTCAGGCCTCCTGATTTC CCTGCTGACCATGAGTGATT 57°C 
Enhancer 2 (5) GCCTAAGAGCGTCTTGCTAAA CTCGTGAGAGTGGTCTGAATTG 57°C 
                                                Methylation-specific PCR (MSP) GATA2 primers 
Promoter 1 
(Methylated) 
CGGGTATTTTTTTGTTTTTTGC TAACCTCGCTACCTTCCTAACG 51°C 
Promoter 1 
(Unmethylated) 
TTTTGGGTATTTTTTTGTTTTTTGT CTAACCTCACTACCTTCCTAACACT 50°C 
Promoter 2 
(Methylated) 
TTCGTTTTATGTTTGTGTAGGAGTC AACTAAAAATAAAATACGCCTCGAC 52°C 
Promoter 2 
(Unmethylated) 
TGTTTTATGTTTGTGTAGGAGTTGG AACTAAAAATAAAATACACCTCAAC 50°C 
        Allele-specific bisulphite-specific PCR (BSP) GATA2 primers encompassing P2 SNP [C/A] 
Promoter 2 
(Methylated) 
GGTTTTTGAGAGTGAAGGAGTTTC CTATACAAAAATCGACAACTAACGC 53°C 
Promoter 2 
(Unmethylated) 
GGTTTTTGAGAGTGAAGGAGTTTT TATACAAAAATCAACAACTAACACC 50°C 
TA Vector M13 GTAAAACGACGGCCAGT CAGGAAACAGCTATGAC 50°C 
   Allele-specific ChIP GATA2 primers (shorter amplicon sizes  for ChIP-enriched DNA) 
Promoter 2 
(141bp) 
AACCCCAAACTTACACACGC CAGCTCCTACCCTGTAAGCC 59°C 
Promoter 2 
(95bp) 
GAGAGTGAAGGAGTTCCGGC CCCCAGCTCCTACCCTGTAA 61°C 
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2.2.3 Agarose gel electrophoresis and purification of PCR products 
 
Agarose gel electrophoresis was used to confirm the size and presence of the amplified PCR 
products. 1.5% (w/v) agarose gels were prepared using 2.25g of agarose with 150mL of 1x Tris-
Borate-EDTA (TBE) buffer (10x TBE contains: 108.9g Tris base, 55.7g boric acid and 7.4g EDTA in 
1 litre of H2O). The agarose was melted by heating for approximately 4 minutes in a microwave 
and once partly cooled down, 7.5μl of 1x GelGreenTM (Biotium, Hayward, CA) was added. The gel 
was then poured into a cassette with fitted combs and allowed to set. PCR products along with a 
5μl of 1kB DNA ladder (exACTGene™, Fisher Scientific) were loaded into separate wells and gel 
electrophoresis was performed at 100V (for ~60 minutes) in a 1xTBE running buffer and 
subsequently visualised under ultra violet (UV) light to confirm the size and presence of PCR 
products.  
The correct-sized PCR bands were then excised from the agarose gel and purified using the 
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s protocol. Alternatively, PCR 
products were enzymatically cleaned from superfluous primers or unincorporated dNTPs using 
Exonuclease I (Exo I) and shrimp alkaline phosphatase (SAP) (USB, Cleveland, Ohio, U.S.A). The 
Exo-SAP stock solution constituted of 1μL exonuclease, 20μL SAP and 179μL water. 4μL of Exo-
SAP was added to 5μL of PCR products and the mixture underwent thermal cycling at 37oC for 15 
minutes, 80oC for 15 minutes and 10oC for 10 minutes before proceeding to the sequencing 
reaction.  
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2.2.4 Sanger Sequencing  
 
“Of the three main activities involved in scientific research, thinking, 
talking and doing, I much prefer the last and am probably best at it…” 
                                                                                                    – Frederick Sanger  
 
Purified PCR products were sequenced in both forward and reverse directions using the BigDye™ 
Terminator Cycle Sequencing kit version 3.1 (Applied Biosystems). Briefly, the 10μl sequencing 
reaction consisted of 0.25μl Big Dye Terminator mix™, 1.875μl of 5x sequencing buffer, 0.5μl of 
forward or reverse primers (final concentration is 10μM per primer) (please see Table 2.1 for 
primer sequences used in this study), 1μl of the purified PCR product and 6.375μl of RNase-free 
water. The hybridisation reaction entailed an initial denaturation step at 96o C for 1 minute 
followed by 26 cycles of denaturation at 96oC for 30 seconds, primer annealing at 50oC for 15 
seconds and extension at 60oC for 4 minutes. Purified PCR products/primer mixture were then 
diluted accordingly and shipped to GATC Biotech Sanger sequencing services (Eurofins) in 
Germany for clean-up and DNA size separation via bidirectional capillary electrophoresis using 
the ABI PRISM 3730xl Genetic Analyser (Applied Biosystems, CA).  
 
2.2.5 Identification and validation of mutations   
 
Sanger sequencing trace chromatograms were visualised and interpreted using the BioEdit 
software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) and compared against a human 
reference genome sequence obtained from the Ensembl genome browser 
(https://www.ensembl.org/index.html) to validate the sequenced variants. All variants were 
confirmed by at least three independent PCR and sequencing experiments.  
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2.2.6 TA-cloning of PCR products  
 
To define the allelic ratios of mutations or quantify mutant vs. WT alleles, PCR products were 
cloned into TA-plasmid vectors which were then transformed into chemically competent E. coli 
cells and subsequently sequenced to obtain individual clones (each clone corresponding to one 
allele). This was achieved using the TA cloningTM kit (Invitrogen). 
 
Briefly, PCR products were generated using ReddiyMix master mix, as described in section 2.2.2. 
The single 3’(A)-overhangs on PCR amplicons can attach to 3’(T)-overhangs on the linearised 
pCR2.1® vector, thereby facilitating the ligation. The 10μl ligation reaction consisted of: 2μl of 
pCR2.1® vector (50ng), 1μl of ExpressLink T4 DNA ligase, 1μl of ligation buffer (10x), 5μl of 
nuclease-free water and 1μl of the PCR product (~10ng insert DNA). This reaction mixture was 
then incubated for at least 1 hour at room temperature.  
 
The cloned PCR products were then transformed into chemically competent E. coli (One ShotTM 
TOP10 cells, Invitrogen). Approximately 2μl of ligation mixture was added to each thawed vial of 
E. coli cells (50μl) and the mixture was left on ice for 30 minutes. Cells were then heat-shocked 
for 30 seconds at 42oC, to enable vectors to enter the bacterial cells, before transferring them 
back on ice for further 2 minutes. 250μl of SOC medium (2% tryptone, 0.5% yeast extract, 10mM 
NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4, 20mM glucose) was next added to each vial of 
transformed cells and left incubated at 37oC for 1 hour on an incubator shaker at 225rpm. Later, 
approximately 100-150μl of the transformed bacterial cells/vials were spread onto Luria Bertani 
(LB) agar plates containing an antibiotic e.g. ampicillin (100μg/ml) and layered with 40μl of X-Gal 
solution (Bioline) (40mg/ml) diluted in dimethylformamide (DMF), to facilitate blue/white 
selection of colonies.  
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Lastly, agar plates were incubated overnight at 37oC to allow for colony formation and were 
transferred the next day to 4oC for 2-3 hours to allow for proper colour development. 
 
Following overnight incubation, in the bacterial colonies with no insert DNA, the empty vector 
promotes the production of β-galactosidase, encoded by the LacZ gene, which is hydrolysed by 
X-Gal thereby producing a blue colour (these were discarded). The selection of white colonies, 
however, implies that the vector and insert are both intact within the bacterial clones, therefore 
the formation of an active β-galactosidase is disrupted (Figure 2.1). Following an overnight 
incubation at 37oC and shaking of ~25 white colonies (per plate) seeded separately into LB broth 
containing ampicillin, plasmid DNA purification was performed using the QIAprep Spin Miniprep 
Kit (Qiagen) as per the manufacturer’s instructions followed by Sanger sequencing of single 
clones using the vector M13 primer pair (Table 2.1).  
Figure 2.1 An overview of the TA-cloning procedure and blue/white screening of colonies by way of β- 
galactosidase activity. Figure taken from Thermo-Fisher Scientific: 
https://www.thermofisher.com/uk/en/home/life-science/cloning.html 
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2.3 Targeted deep sequencing and bioinformatics data analysis  
 
A targeted myeloid panel of 33 genes frequently mutated in MDS/AML (Table 2.2) was employed 
to determine the secondary mutational repertoire across the sequential samples from the 
symptomatic patient (IV.10) compared with asymptomatic (III.7), WT (IV.9) and deceased 
MDS/AML (IV.6) family members (results in Chapter 3.3 and Appendix 2. Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Exons Targeted 
ASXL1 12 
BCOR all 
CALR 9 
CBL 7+8+9 
CEBPA all 
CSF3R 14-17 
DNMT3A all 
ETV6 all 
EZH2 all 
FLT3 14+15+20 
GATA2 all 
GNAS 8+9 
IDH1 4 
IDH2 4 
IKZF1 all 
JAK2 12+14 
KIT 2, 8-11, 13 +17 
KRAS 2+3 
MPL 10 
NPM1 12 
NRAS 2+3 
PDGFRA 12,14,18 
PHF6 all 
PTPN11 3+13 
RUNX1 all 
SETBP1 4 
SF3B1 12-16 
SRSF2 1 
TET2 all 
TP53 all 
U2AF1 2+6 
WT1 7+9 
ZRSR2 all 
Table 2.2 List of 33 genes included in the targeted myeloid gene panel together with the regions sequenced.  
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Bioinformatics analysis was performed by Dr Steven Best at King’s College London. Target 
enrichment was achieved using an in-house TruSeq® Custom Amplicon (TSCA) design (Illumina, 
San Diego, USA). The targeted region consisted of a total of 71Kb represented by 295 amplicons. 
Pooled library targets were sequenced in batches of 24 samples on the MiSeq sequencing 
platform, using version 3.0 MiSeq sequencing reagents (Illumina, San Diego, USA). Minimum read 
depth threshold was 150 reads; lower limit of sensitivity was 5-10% variant allele frequency 
(VAF). All variants of unknown significance were eliminated (Tobiasson et al., 2016).  
2.4 Gene expression analysis 
 
Quantitative real-time PCR (RT-qPCR) analysis was performed to investigate global GATA2 mRNA 
transcript levels across GATA2-mutated family members (results in Chapter 3.4). This generally 
involves: 1. conversion of RNA to a more stable complementary DNA (cDNA) template via reverse 
transcription; 2. PCR amplification of the cDNA and 3. quantification of PCR products in real time 
using SYBR Green fluorescence. 
 
2.4.1 RNA extraction and quantification 
 
Total RNA was extracted from patient BM aspirates using the RNeasy Kit (Qiagen), as per the 
manufacturer’s instructions. Approximately five million cells were collected from patient BM vials 
by centrifugation at 300g for 5 minutes. Cell pellets were then lysed in 350μL of Buffer (RLT) 
accompanied with 10μL/mL β-mercaptoethanol to denature RNAases. Cell lysates were then 
centrifuged at full-speed for 2 minutes using QIAshredder spin columns. 350μL of 70% ethanol 
was subsequently added to lysates to enable effective binding of RNA to the silica membrane. 
Samples were centrifuged at 8000g for 15 seconds using RNeasy Mini spin columns and were 
then washed with 350μL buffer RW1 at 8000g for 15 seconds.  
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An on-column DNase digestion step (80μL DNase I incubation mix containing 10μL of DNase and 
70μL of RDD buffer) was performed and further incubated for 15 minutes at room temperature, 
to remove any remaining genomic DNA. After the DNase digestion step, the columns were 
washed with 350μL of buffer RW1 and with 500μL of buffer RPE followed by a final centrifugation 
step at full-speed for 2 minutes to remove any residual ethanol. Finally, the purified RNA was 
eluted intp 30μL of RNase-free water and stored at -80oC. RNA concentrations were next 
determined using Qubit® 3.0 Fluorometer and the Quant-iT™ RNA Assay Broad Range Kit 
(Thermo Fisher Scientific, Waltham, USA) which is considered more sensitive in detecting dsDNA 
than Nanodrop.  
 
2.4.2 cDNA synthesis 
 
DNase-treated RNA was then reverse transcribed to single-stranded cDNA using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). In brief, 20μl of the reverse 
transcription (RT) reaction was prepared as described in Table 2.3. 10μl of the RT master mix was 
added to 10μl of RNA (~500ng) and the reverse transcription was carried out using the following 
thermal cycling conditions: (25°C for 10 minutes, 37°C for 2 hours and 85°C for 5 minutes).  
cDNA samples were diluted in 480μL of RNase-free water (to reach a concentration of 
approximately 20ng/μl) which was then used as templates for the RT-qPCR reaction.  
 
 
 
 
 
 
 
Component  Volume (μl) 
10X RT Buffer 2 
10X RT random primers 2 
MultiScribe Reverse Transcriptase 1 
25X dNTP mix (100 mM) 0.8 
Rnase free water 4 
Rnase inhibitor 0.2 
Total RNA (~500ng) 10 
Final volume 20 
Table 2.3 Reagents used for cDNA synthesis. 
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2.4.3 Quantitative real-time PCR (RT-qPCR) using SYBR Green assay 
 
Quantitative real-time PCR was performed on the synthesised cDNA using the SsoAdvanced 
Universal SYBR® Green assay (Bio-Rad) to measure GATA2 expression levels (exonic RT-qPCR 
primers are listed in Table 2.1) relative to the expression of the housekeeping gene (GAPDH). 
Briefly, RT-qPCR reactions were run in triplicates and in a final volume of 10μl per reaction, 
consisting of: (4.6μl of cDNA template (20ng, prepared as described in 2.4.2), 5μl of the SYBR 
Green PCR master mix and 0.2μl of forward and reverse GATA2 exon-exon boundary primers 
(10μM concentration each). The universal SYBR Green comprises of all ingredients required for 
RT-qPCR reaction: (Taq Polymerase, dNTP mix with dUTP rather than dTTP, SYBR Green I DNA-
binding dye and MgCl2) to minimise pipetting errors and contamination risk. 
 
These amplification reactions were performed in sealed 384-well plates on the CFX384 Touch™ 
Real-Time PCR Detection System (Bio-Rad). The cycling conditions include an initial polymerase 
activation and cDNA denaturation step at 95°C for 10 minutes followed by 40 cycles of cDNA 
denaturation to a single-stranded template at 95°C for 15 seconds, primer annealing at 60°C for 
1 minute and cDNA final extension at 72°C for 30 seconds. Finally, a melting curve analysis was 
performed to check for the specificity of these amplifications. 
 
2.4.4 RT-qPCR relative quantification and data analysis 
 
Quantification and data analysis in RT-qPCR relies on the basic idea that the more copies of a 
particular gene are present in a particular sample, the fewer the amplification cycles needed to 
generate a fluorescent signal above threshold. The Ct (threshold cycle) therefore signifies the 
number of cycles required for a fluorescent signal to become detectable above a background 
sample and was used here to calculate the relative quantification. In order to control for 
differences in amplification efficiencies between samples, however, the expression levels of 
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target genes were normalised to the expression levels of a housekeeping gene (e.g. GAPDH) 
whose expression is considered constant regardless of cell type and experimental condition 
(Barber et al., 2005). 
 
The ΔΔCt method was employed to determine GATA2 expression levels relative to GAPDH and 
using a healthy BM as a positive control sample (Livak and Schmittgen, 2001). First, the ΔCt 
between GATA2 and GAPDH was calculated for each sample (ΔCt = CtGATA2 – CtGAPDH) and averaged 
across the three replicates. The average ΔCt of each sample was then normalised to the ΔCt of a 
positive control sample to give ΔΔCt as follows: (ΔΔCt = ΔCtsample – ΔCtpositive control). Finally, the 
normalised expression ratio (2-ΔΔCt) gives the fold increase or decrease of GATA2 expression 
between the samples and relative to the positive control sample. 
 
2.5 RNA-sequencing and bioinformatics data analysis 
 
High-throughput RNA-sequencing was performed to compare transcript profiles between GATA2 
monoallelic (IV.10-yr.1 and yr.3) vs. biallelic (IV.10-yr.4 and III.7) groups (results in Chapter 3.5). 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and quantified using Qubit® 3.0 as 
previously mentioned and the integrity measured using the RNA 6000 nano assay kit on a 2100 
BioAnalyzer (Agilent technologies, California, USA), where RNA integrity number (RIN) >7.0 was 
considered good quality RNA suitable for sequencing (Table 2.4 and Figure 2.2). cDNA libraries 
were prepared using Poly-A selection and the TruSeq stranded mRNA library preparation kit 
(Illumina) according to the manufacturers’ instructions and then sequenced to a minimum depth 
of 30 million (2x100bp) paired-end reads per sample (300 cycles of sequencing) on the Illumina 
HiSeq 4000, carried out at Oxford Genomics (Wellcome Trust Centre for Human Genetics, Oxford, 
UK). 
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Bioinformatics data analysis was then completed by Dr Jun (Alex) Wang at the Barts Cancer 
Institute. Briefly, after FASTQ data quality check, raw reads were aligned to the reference genome 
(GRCh37) using STAMPY (Lunter and Goodson, 2011).The number of reads uniquely aligned 
(quality score q > 10) to the exonic region of each gene was counted using HTSeq based on the 
Ensembl annotation (Anders et al., 2015). Only genes that achieved at least one count per million 
Samples BioAnalyzer 
RIN 
Qubit 3.0 RNA concentration 
(ng/ul) 
IV.10_yr.1 7.70 234 
IV.10_yr.3 8.90 484 
IV.10_yr.4 8.50 314 
III.7_Asymptomatic 6.80 113 
Healthy BM Control 7.50 280 
Figure 2.2 Example electropherograms produced using the Agilent 2100 BioAnalyzer.                     
Good quality RNA displays a low threshold baseline (at the ladder) and a 28S rRNA peak twice as 
high as the 18S rRNA peak. Whereas a higher threshold baseline and a smaller 28S:18S ratio might 
indicate RNA degradation.  
Table 2.4 BioAnalyzer RNA quality control sample measurement. Table contains RNA 
concentrations by Qubit and RIN numbers by BioAnalyzer for each sample analysed. 
IV.10_yr.3 III.7_Asymtomatic 
RIN: 8.90  RIN: 6.80  
Ladder 18S 28S 
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(CPM) reads in at least 2 samples (the number of samples analysed in each group) were included, 
leading to 17,555 filtered genes in total. Read counts were further normalised using the 
conditional quantile normalisation (CQN) method, accounting for gene length and GC content 
(Hansen et al., 2012). Differential expression (DE) analyses between GATA2 biallelic vs. 
monoallelic groups were performed using the edgeR R package, employing the generalised linear 
model (GLM) approach (Robinson et al., 2010). The significantly DE genes were selected based 
on the false discovery rate (FDR) q-value of < 0.05 and the absolute log2 fold change value of > 1 
(Appendix 3. Table 2). Gene set enrichment analysis (GSEA) was performed using the GSEA tool 
to identify canonical pathways, motifs and signature gene sets acquired from the Molecular 
Signatures Database (MSigDB-C2 v.5.0) (Subramanian et al., 2005). Top significantly enriched 
gene sets were selected based on FDR q-value of <0.05. The normalised enrichment score (NES) 
from each gene set was also shown. RNA-seq data have been deposited into Gene Expression 
Omnibus (GEO) under the accession number GSE104570.  
2.6 Plasmid construct cloning, transfection and luciferase reporter assay 
Luciferase reporter assay was employed to measure allele-specific differences in GATA2 
promoter transcriptional activity in our GATA2 mutation carriers. First, luciferase reporter 
constructs were generated following subcloning of GATA2 promoter 1 and 2 SNP alleles (4 
plasmid clones) from the symptomatic patient (IV.10) and separately into the pGL2-Basic Vector 
(Promega) upstream of the firefly Luciferase gene (Luc) (Figure 2.3-A). The primers containing 
restriction enzyme (Xhol) used to amplify these promoter regions are listed in Table 2.5. DNA 
Plasmids were purified using the QIAprep Miniprep Kit (Qiagen) and insert identities and 
sequence orientation were verified by Sanger sequencing prior to transfection (Figure 2.3-B). 
 
Chapter 2 – Materials & Methods 
 
 95 
 
 
1μg of DNA firefly luciferase vector containing either one of the four alleles from GATA2 promoter 
1 and 2 SNPs were transiently co-transfected into HeLa cells (1.25 x 105 per well in a 6-well plate) 
together with 0.5μg of DNA Renilla luciferase control vector pRL-CMV (Promega) using the 
LipofectamineTM 2000 transfection protocol (Invitrogen). 1μg of empty vector was transfected as 
well to act as a control. Cells were lysed 48 hours after transfection in accordance with the Dual-
Luciferase® Reporter Assay System (Promega) as previously described (Sherf et al., 1996). 
 
 
 
Primer Forward Reverse 
Promoter 1_Luc_XhoI      CACCTCGAGGTGGCTCCGAGAAATGGGAA     TTCCTCGAGCGCTGACTGGTTGAATCCCT 
Promoter 2_Luc_XhoI  CACCTCGAGCACACTTGGCGCCAGATACA       TTCCTCGAGCCGATCTCCGGGCTAGAAGT 
Vector GL primer 
          TGTATCTTATGGTACTGTAACTG           CTTTATGTTTTTGGCGTCTTCCA 
Table 2.5 GATA2 promoter 1 and 2 PCR primers for luciferase assay – contacting restriction site Xhol. 
      
    TA vector  
 
     TA vector  
 
Figure 2.3 Luciferase reporter assay. A. Map showing the promotorless firefly luciferase vector (pGL2-Basic 
- Promega) used in this study and the region where GATA2 promoter fragments were inserted into Xhol 
restriction site (highlighted in red) in the multiple cloning site upstream of the Luc gene. B. PCR gels showing 
separated TA vector (upper lane) and DNA inserts (promoter 1 and promoter 2) (lower lane) on 0.8% agarose 
gel after digestion with Xhol. Bands corresponding to promoter 1 clones [C/T] (1318bp) and promoter 2 
clones [C/A] (1350bp) were excised for DNA purification prior to cloning into the luciferase vector. 
A. 
 
B. 
 
 1318 bp-- 
 
 1350 bp-- 
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The activities of Firefly and Renilla luciferases were measured sequentially from a single sample; 
the Firefly luciferase reporter was measured first by adding Luciferase Assay Reagent II (LAR II) 
to generate a stabilised luminescent signal. The reaction was then quenched subsequently after 
addition of Stop & Glo® reagent to activate the Renilla luciferase reaction (Figure 2.4). This is 
achieved using the luminescence function on the FluoStar Optima plate reader (BMG Labtech, 
Germany). 
 
 
 
 
 
 
 
 
 
 
The luciferase reporter assays were performed in triplicates (5 independent experiments) and 
the final results were expressed as a percentage relative luciferase activity calculated by 
normalising the ratio of Firefly luciferase to Renilla luciferase luminescence and a further 
normalisation to an empty vector control. 
 
 
 
Figure 2.4 Bioluminescent reactions catalysed by Firefly (Photinus pyralis) and Renilla (Renilla 
reniformis) luciferases. For Firefly luciferase, light emission is achieved by oxidation of Beetle Luciferin 
in a reaction that requires ATP, Mg2+ and O2 whereas the luminescent reaction catalysed by Renilla 
luciferase utilises O2 and Coelenterazine. Figure reproduced from the Promega dual-luciferase reporter 
assay system protocol and technical manual.  
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2.7 DNA methylation analysis 
 
2.7.1 Bisulphite DNA modification 
 
Genomic DNA of GATA2-mutated family members was bisulphite-converted to quantifiably 
measure DNA methylation at a single CpG level. Essentially, bisulphite conversion involves the 
deamination of cytosine residues by sodium bisulphite, thereby converting non-methylated 
cytosines into uracil (which is then PCR amplified into thymines) whilst keeping the methylated 
cytosines intact and thus protected from deamination (Frommer et al., 1992) (Figure 2.5). The 
ratio of methylated cytosines compared to the total number of cytosines and/or thymines in a 
given converted sequence can therefore give an indication of the level of DNA methylation at 
that particular locus. 
 
 
Figure 2.5 Schematic of bisulphite DNA conversion reaction of non-methylated cytosine into uracil.  
The first two steps (sulfonation and deamination) are performed at low pH while the final step 
(desulfonation) is performed under high pH conditions.  
 
 
Using the Bisulphite Conversion Kit (Active Motif), genomic DNA (~500ng) was first treated with 
Proteinase K (20mg/ml), to improve the efficiency of the conversion reaction, and incubated at 
50°C for 30 minutes. Following incubation, samples were then rapidly heat-denatured upon 
addition of the bisulphite conversion buffer (120μl) and hydroquinone (7μl) (protects DNA from 
strand breakage caused by depurination) using the following cycling conditions: 95°C for 30 
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seconds, 58°C for 20 minutes and 3 cycles of (95°C for 10 seconds and 58°C for 20 minutes). 
Following this 1.5-hour DNA conversion reaction, DNA samples together with 500μl of DNA 
binding buffer were added onto DNA purification columns and undergone several washes and 
centrifugation using ethanol-containing wash buffers. Next, 200μl of desulfonation buffer was 
added and the mixture was incubated for 20 minutes at room temperature. DNA is then washed 
and eluted from the columns by addition of 30μl of elution buffer. To check for the efficiency of 
the conversion, DNA samples were amplified using positive control conversion-specific PCR 
primer set (Active Motif) and run on a 1.5% agarose gel. Samples were considered to be 
successfully bisulfite-converted if they showed a PCR product. 
 
2.7.2 Methylation-specific PCR (MSP) 
 
Bisulphite-treated DNA was then PCR amplified using specific methylated (M) or unmethylated 
(UN) primer pairs covering GATA2 promoter 1 and 2 regions (Table 2.1) and the PCR products 
were visualised using 1.5% agarose gel electrophoreses (as detailed in section 2.2.3) to assess for 
global DNA methylation patterns between symptomatic and asymptomatic carriers.  
 
2.7.3 Bisulphite-specific PCR (BSP), cloning and sequencing 
 
Bisulphite-treated DNA was PCR amplified using primers encompassing a 200-bp region of GATA2 
second promoter and overlapping a CpG island (containing ~20 CpGs) (Table 2.1). The PCR 
products were then cloned into pCR2.1® vectors using the Original TA-cloning Kit (Invitrogen) and 
white colonies (approximately 25-30 clones per sample) were selected and DNA purified as 
mentioned previously in section 2.2.6 and sequenced using the vector M13 primers (Table 2.1) 
to measure allelic-specific differences in GATA2 promoter methylation between mutant and WT 
alleles across the symptomatic patient’s (IV.10) different time-points. 
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2.8 Chromatin immunoprecipitation (ChIP) assay  
 
ChIP was performed using the ChIP-IT High Sensitivity Kit (Active Motif) and following the 
manufacturer’s instructions, to assess allele-specific differences in the deposition of chromatin 
marks (H3K4me3 and H3K27me3) in our patient samples (Figure 2.6). Briefly, the symptomatic 
patient (IV.10) fresh BM samples (~7 million cells) across three different time-points (y.1, yr.3 and 
yr.4) were each subject to 5 minutes of formaldehyde fixation to cross-link and maintain 
protein/DNA interactions. Fixed chromatin was then sonicated for ~15 cycles to an average 
length of 200bp using the UCD-300 Bioruptor plus sonication system (Diagenode, Belgium). 2μg 
of H3K4me3 or 1μg of H3K27me3 antibodies (Diagenode) were added separately to sheared 
chromatin and reactions were incubated on a rotator overnight at 4°C. Chromatin bound to either 
of these antibodies was then immunoprecipitated using Protein G Agarose beads (Active Motif). 
ChIP reactions were next subject to several washes by gravity filtration after which proteins were 
removed and ChIP-enriched DNA was purified (in a process called reversal cross-linking) using 
proteinase K treatment and DNA purification columns. H3K4me3 or H3K27me3 ChIP-enriched 
DNA fragments were analysed by direct PCR and Sanger sequencing within GATA2 promoter 
regions using primer pairs with smaller amplicon sizes (See Table 2.1 for primer sequences).  
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2.9 Statistical analysis 
 
Statistical significance for relative levels of gene expression in RT-qPCR, luciferase reporter 
experiments, proportions of methylated CpGs in bisulphite cloning experiments and sequencing 
peak heights in ChIP experiments was determined at p≤0.05 (*), p≤0.01(**) and p≤0.001(***), 
calculated using t-test with Bonferroni correction. Data are expressed as mean ± standard error 
of the mean (SEM) of 3 to 5 independent experiments performed in triplicates and plotted using 
the GraphPad Prism version 8.0 software (GraphPad Software Inc., La Jolla, CA, USA). 
 
 
 
 
 
 
 
 
Figure 2.6 Schematic workflow of chromatin immunoprecipitation (ChIP).               
Figure obtained from Active Motif instruction manual (https://www.activemotif.com). 
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Investigating the Molecular Mechanisms Underlying 
Reduced Penetrance of Germline GATA2 Mutations 
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“Illness is the night-side of life, a more onerous citizenship. Everyone who is born holds dual 
citizenship, in the kingdom of the well and in the kingdom of the sick. Although we all prefer 
to use only the good passport, sooner or later each of us is obliged, at least 
for a spell, to identify ourselves as citizens of that other place.” 
– Susan Sontag 
 
3.1 Background and Rationale  
 
As introduced in Chapter 1, GATA2 is a master regulator of haematopoiesis, expressed in early 
BM progenitors and plays a key role in their differentiation and survival (Collin et al., 2015). While 
GATA2 is mutated at low frequencies (~4-7%) in sporadic leukaemia, germline mutations in 
GATA2 are commonly identified in autosomal dominant familial MDS/AML, particularly in de 
novo paediatric MDS (7-15%) (Wlodarski et al., 2016) and predispose its carriers to protean and 
overlapping clinical manifestations (including Emberger, MonoMAC and DCML deficiency) 
highlighting the pleiotropic nature of this transcription factor.  
 
Following the initial report of germline GATA2 mutations in four MDS/AML families by Hahn and 
colleagues in 2011, more than 30 pedigrees have been reported worldwide so far (Table 1.5). 
We have noticed that in a proportion of these families, especially those carrying germline 
missense mutations, there is a striking evidence of reduced penetrance (50-70%) where multi-
generation mutation carriers are split between symptomatic and asymptomatic family 
members. The molecular basis of such occurrence however has not been thoroughly explored. 
We hypothesised that these germline GATA2 mutations are unable to initiate disease solo but 
rather act synergistically with subsequent molecular events in order to facilitate clonal 
proliferation and expansion.  
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 The findings reported in this chapter and the following one (3 and 4) were published in and 
figures reproduced from (Al Seraihi et al., 2018) in Leukemia – Springer Nature (manuscript 
provided in Appendix 1.). 
 
3.2 Clinical profile of a GATA2-mutated MDS/AML pedigree with reduced penetrance 
 
Analysis of MDS/AML families harboring (p.Thr354Met (p.T354M), c.1061C>T) GATA2 mutations 
displayed significant intra- and inter-familial variations in disease latency, clinical phenotype, and 
penetrance. These observations suggest that individuals require additional co-operating 
aberrations for the development of overt malignancy within the context of a shared germline 
mutation. 
 
To investigate this hypothesis further, we examined a five-generation MDS/AML family who 
presented to St. Bartholomew’s hospital in London with varying symptom manifestations and 
ages of disease onset and where germline heterozygous p.T354M GATA2 mutations were 
detected in six individuals spanning two generations (III.1, III.5, III.7, IV.1, IV.6 and IV.10) (Bodor 
et al., 2012)(Figure 3.1-A).  
 
As illustrated in the clinical timeline (Figure 3.1-B), the family came into our attention when two 
first-degree cousins (IV.1 and IV.6) presented within one week from each other with high-grade 
MDS transforming to AML aged 18 and 23 years, respectively. IV.1 presented with multiple 
plantar warts and 7% myeloblasts in his diagnostic BM consistent with refractory anaemia with 
excess blasts-1 (RAEB-1). He had an absolute monocytopenia [0.0 x 109/L] at the time of 
presentation and underwent a 1-antigen mismatched unrelated donor HSCT but unfortunately 
passed away two years later due to transplant-related complications and relapsed disease.  
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The second cousin’s (IV.6) diagnostic BM displayed trilineage dysplasia with 17% myeloblasts 
(RAEB-2) albeit his monocyte count was within normal range [0.3 x 109/L]. He underwent 
intensive chemotherapy and obtained complete remission but with persistent dysplastic 
features in the BM. A second cycle of chemotherapy was further complicated by long-lasting 
anaemia and thrombocytopenia; he relapsed seven months following presentation and received 
re-induction chemotherapy and a haplo-identical HSCT from his mother (III.6) but developed 
GvHD, severe infections and died of pneumonic sepsis four months following allogeneic HSCT. 
Cytogenetic analysis confirmed monosomy 7 in both cousins and the GATA2 mutation was 
identified in the diagnostic tumour DNA samples from IV.1 and IV.6 as well as in a remission DNA 
sample from IV.6, supporting a germline origin (Bodor et al., 2012). The first part of this project 
therefore involved validating these mutations by Sanger sequencing, as part of the initial genetic 
profiling performed in this family (Figure 3.1-C). 
 
Ten years after the cousins’ (IV.1 and IV.6) presentation, their first cousin (IV.10) presented at 
31 years old with recurrent minor infections and severe leukopenia (monocytopenia [0.1x109/L] 
and neutropenia [0.8x109/L]) with mild macrocytosis and normal karyotype, haemoglobin and 
platelet counts. These clinical parameters subsequently stabilised (normal monocyte count, 
neutrophils [>1x109/L]) three years (yrs.) after presentation (Figure 3.2). It is worth mentioning 
here that IV.10 has not undergone any intensive chemotherapy regimen during this time period 
and continues to remain under close surveillance where her disease progression and blood 
counts are routinely monitored. Fortunately, all four of her children (V.1-4) have inherited her 
wildtype (WT) GATA2 allele. Similarly, healthy family members from the fourth generation (IV.7, 
IV.8, and IV.9) were screened for the mutation and all have a WT GATA2 configuration. 
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The paternal grandmother (II.2) of IV.10 as well as her paternal great-uncle (II.3) and great-
grandmother (I.2) all were reported to have succumbed to leukaemia (ages of disease onset 
were 53, 24, and 53 years old, respectively) although it is not known whether they were too 
carriers of the GATA2 mutation (genomic DNA material was not available).  
 
However quite remarkably, not only did the presence of germline GATA2 mutations correlate 
with early age of disease onset in the fourth generation (IV.1_18yr., IV.6_23yr. and IV.10_31yr.), 
but the parental third generation GATA2 mutation carriers (III.1, III.5, and III.7) remain 
haematologically normal and symptom-free, with no history of recurrent infections despite 
being in their mid-late 60s. This occurrence therefore spurred us to investigate what is protecting 
those asymptomatic carriers and indeed what is driving the onset of overt disease in the 
symptomatic ones.  
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Figure 3.1 A. Genogram of the GATA2-mutated MDS/AML pedigree with reduced penetrance. 
Squares denote males and circles denote females. A strikethrough line indicates a deceased 
family member (pedigree redrawn from Bodor et al., 2012). B. Clinical timeline of disease events 
in GATA2-mutated family members showing deceased cousins (IV.1 and IV.6) harbouring 
secondary aberrations (monosomy 7) whilst the third cousin (IV.10) remains under routine clinical 
follow-up. Third generation mutation carriers (III.1, III.5 and III.7) remain asymptomatic well into 
their 60s. Yellow squares represent BM cells available for this study. C. Sanger sequencing 
chromatograms demonstrating heterozygous germline GATA2 mutations (c.1061C>T, p.T354M) 
validated in five family members from the third and fourth generations with variable disease 
latency and phenotype. No DNA was available from the symptomatic individuals (I.2, II.2 and II.3) 
nor from other family members who were not mentioned. 
C. 
 
B. 
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3.3 Acquisition of somatic ASXL1 mutations in symptomatic vs. asymptomatic carriers  
 
Our initial assumption was that disease penetrance was governed by the acquisition of additional 
secondary mutations, akin to the group’s previous work on familial CEBPA, where the onset of 
overt leukaemia accompanied the acquisition of secondary C-terminal mutations (Smith et al., 
2004, Tawana et al., 2015). In order therefore to define the pattern of secondary genetic events 
across GATA2-mutation carriers that may account for the clinical heterogeneity and the reduced 
penetrance observed in this family, targeted deep sequencing using a myeloid panel of 33 genes 
frequently mutated in MDS/AML (e.g. DNMT3A, RUNX1, TET2 and WT1) was performed in select 
members of the family with a minimum depth coverage of ~1500x (see Chapter 2.3 – Table 2.2 
for a list of these 33 genes). Precisely, BM DNA samples from four family members were tested: 
one asymptomatic parent (III.7), one deceased MDS/AML cousin (IV.6), one healthy WT sibling 
(IV.9) and across three time-points (yr. 1, 4, and 6) from the symptomatic patient (IV.10), where 
sequential BM material became available through routine clinical follow-up (Figure 3.2 and 3.3-
A).  
 
Figure 3.2 Clinical timeline of IV.10 symptomatic patient showing the changes in clinical 
parameters over the course of disease presentation. Photographs of PB smears from IV.10 
(yr. 1, 3, 4 and 6) stained with May-Grünwald Giemsa staining. Magnification: x20.  
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As illustrated in Figure 3.3-B, the high VAFs of GATA2 p.T354M (range 46–51%) across mutation 
carriers reflect the germline origin of the mutation. Notably, while no acquired somatic 
mutations were detected in asymptomatic family members, all affected cousins analysed 
acquired an identical frameshift ASXL1 lesion (p.Gly646TrpfsTer12, c.1934dupG) (Figure 3.3-B). 
Indeed, ASXL1 mutations have been linked as a secondary genetic event in germline GATA2-
mutated pedigrees (West et al., 2014b, Wang et al., 2015), however, it was noteworthy that 
ASXL1 mutation was not clonal in IV.10 but critically remained stable (VAF range 12–6%) over a 
6-year monitoring period and was therefore not considered a primary driver for the 
development of overt MDS/AML.  
 
Apart from the ASXL1 mutation, no other somatic mutations were detected in the 33-myeloid 
genes assessed in the symptomatic cousins (except for few shared non-pathogenic SNPs (e.g. in 
TET2 and TP53), listed in Appendix 2. Table 1). Moreover, and as expected, ASXL1 mutation was 
not identified in the remission sample of the cousin with MDS/AML (IV.6), confirming that it 
represents an acquired secondary mutation.  
 
While the molecular co-occurrence of ASXL1 and GATA2 mutations has been proposed as one 
mechanism for driving the onset and severity of disease symptoms (West et al., 2014b), the low 
VAF of ASXL1 mutation and the steady improvement in haematopoiesis at IV.10 later follow-up 
(yrs. 4 and 6) (Figure 3.2) suggested that a combination of GATA2 and ASXL1 mutation is perhaps 
still not sufficient on its own to promote clonal expansion and leukaemic transformation. This 
indicates that other molecular events, possibly preceding the acquisition of ASXL1 mutation, 
might trigger the patient’s initial symptoms.     
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Figure 3.3 Identification of secondary ASXL1 somatic mutations in GATA2-mutated familial MDS/AML. 
A. Genogram of the GATA2-mutated family highlighting samples included in the targeted deep 
sequencing myeloid gene panel. B. Bar chart illustrating germline GATA2 (p.T354M) and acquired ASXL1 
(p.G646WfsX12) mutations identified in each sample together with their VAF levels. It is worth 
mentioning here that the MDS/AML cousin (IV.1) also acquired ASXL1 mutations (verified by Sanger 
sequencing) but was not included in the myeloid gene panel. 
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3.4 Monoallelic GATA2 expression differentiates between symptomatic and asymptomatic 
carriers and correlates with clinical parameters  
 
We next focused our attention on the GATA2 locus and investigated whether disease symptoms 
are influenced by endogenous levels of GATA2. GATA2 mRNA levels were first compared 
amongst family members using quantitative RT-PCR of BM material which showed total GATA2 
expression to be significantly lower in the symptomatic (IV.10_yr.1) compared with 
asymptomatic carriers (III.5 and III.7) (Figure 3.4-A and methods Chapter 2.4). We then 
wondered whether this global reduction in expression was accompanied by differences in the 
WT vs. mutant allelic expression; indeed, Sanger sequencing of GATA2 BM cDNA template 
revealed striking allele-specific expression (ASE) favouring the mutant allele (T) with an absence 
(or silencing) of the WT allele (C) expression in the symptomatic patient (IV.10), which contrasted 
with biallelic expression in asymptomatic family members (III.5 and III.7) (Figure 3.4-B). The 
observation of differential allelic-specific expression, favouring the mutant allele and leading to 
silencing of the WT allele, provided a rationale for explaining the differences between 
symptomatic and asymptomatic carriers in this family and suggests that the protection effect 
seen in the asymptomatic family members might reflect on the maintenance of the WT allele 
expression. 
 
As this suggested that changes in mutant:WT GATA2 allelic expression ratio may account for the 
reduced penetrance observed in this family, we had the opportunity to sequentially monitor 
GATA2 expression in IV.10 over a 6-year disease period where we collected BM material at 4 
different intervals (yr.1, 3, 4 and 6), as part of the patient’s routine clinical management. When 
we compared global GATA2 expression over this 6-year monitoring period (depicted in Figure 
3.4-C), we noticed that later time-points of IV.10 (yr.4 and 6) demonstrated increased global 
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GATA2 expression than earlier periods (yr.1 and 3), as assessed by RT-qPCR (described in 
methods Chapter 2.4). Remarkably, this upward shift coincided with reactivation of the WT allele 
(C) expression, demonstrated by the presence of a double cDNA sequencing peak (corresponding 
to both mutant (T) and WT (C) alleles) and a persistent improvement in haematological 
parameters (increase in neutrophil counts to >1x109/L), noted 3 years after presentation (yr. 4 
and 6) and in the absence of any treatment intervention (Figure 3.4-D).  
 
These monoallelic vs. biallelic GATA2 expression findings (based on qualitative Sanger 
sequencing trace chromatograms) were further validated by cDNA cloning of a 175bp fragment 
of GATA2 exon 5 region encompassing the p.T354M germline heterozygous mutation from IV.10 
(symptomatic), III.7 (asymptomatic) and IV.9 (WT) BM samples into pCR®2.1 vectors and 
subsequent Sanger sequencing of individual clones (an average of 25 clones were analysed per 
sample) to quantitatively measure the proportion of mutant (T) to WT (C) alleles expressed in 
each sample analysed (see methods Chapter 2.2.6). In particular, this demonstrated an allelic 
GATA2 mutant:WT clone ratio of 80.4:19.6% in IV.10 earlier time-points (yr. 1 and 3) compared 
with an allelic ratio of 50.2:49.8% in later periods (yr. 4 and 6) (Figure 3.5-A and B) confirming 
our cDNA Sanger sequencing results. 
 
Altogether, even though RNA material was not available to test GATA2 allelic expression at early 
time points of disease development in the two deceased cousins (IV.1 and IV.6), we believe that 
the silencing of the WT GATA2 allele and ASE of the mutant allele, leading to an almost complete 
depletion of GATA2 function, might indeed be one of the initial steps required to induce 
symptom manifestations (e.g. cytopenia) at the very early stages of the symptomatic patient’s 
disease development. 
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Figure 3.4 Investigating GATA2 mRNA expression. A. GATA2 global expression measured by RT-qPCR of BM samples and 
normalised to healthy BM control. Bar chart demonstrating downregulation in IV.10_yr.1 GATA2 expression compared with 
III.5 and III.7 asymptomatic carriers. No RNA material was available from the deceased MDS/AML cousins (IV.1 and IV.6) nor 
from the asymptomatic carrier (III.1). An average of 3 independent experiments is shown. Statistical significance was 
determined at *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 using a t-test with Bonferroni correction. Error bars represent standard 
error of the mean (SEM). B. Allele-specific expression of the GATA2 mutant allele (T) in the symptomatic (IV.10_yr.1) vs. 
asymptomatic (III.5 and III.7) carriers, as measured by cDNA Sanger sequencing of BM samples. C. Bar chart demonstrating 
a downregulation in IV.10_yr.1-3 global GATA2 expression compared with IV.10_yr.4-6 as measured by RT-qPCR. An average 
of 5 independent experiments is shown. Statistical significance was determined at *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 
using a t-test with Bonferroni correction. Error bars represent SEM. D. Correlation of monoallelic GATA2 expression with 
disease state across the 4 time-points studied in IV.10, with reactivation of the WT allele (C) expression noted 3 years after 
presentation (yr.4 and 6), concurrent with improvements in clinical parameters.  
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Figure 3.5 cDNA cloning to quantitatively measure GATA2 mRNA allelic expression. A. Bar chart 
showing the percentage of mutant and WT allele clones across the 4 time-points of IV.10 (yr.1, 3, 4 
and 6) and in III.7 (asymptomatic carrier) and IV.9 (WT sibling) based on cDNA cloning of GATA2 and 
Sanger sequencing of individual clones (an average of 25 clones were analysed per sample).  
B. A representative example of mutant (T) and WT (C) allele clones together with their corresponding 
Sanger trace chromatograms. Sequences in blue represent GATA2 exon 5 where the germline 
mutation (c.1061C>T, p.T354M) resides. Sequences highlighted in yellow represent the primer pair 
used to amplify this region prior to cloning the cDNA PCR products into pCR®2.1 TA-vectors (see 
Chapter 2.2.6 for a detailed method description). 
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3.5 GATA2 monoallelic samples display unique transcript profiles compared to their biallelic 
counterparts  
 
Based on the aforementioned results, we now have two entities: GATA2 monoallelic and GATA2 
biallelic expressing samples. The next question we asked was how similar or different are those 
two biological entities and whether GATA2 mutant ASE has an impact on the transcriptome 
driving the onset of disease symptoms. To this end, we performed RNA-seq analysis with a view 
of examining downstream biological features distinctive of each of these two groups. We tested 
five RNA samples derived from patients’ BMs: two GATA2 monoallelic (IV.10_yr.1 and 3), two 
GATA2 biallelic (IV.10_yr.4 and III.7) and one healthy BM control with WT GATA2. Following an 
in-house sample quality control (see Chapter 2.5), cDNA libraries were prepared using Poly-A 
selection and then sequenced to a minimum depth of 30 million (2x100bp) paired-end reads per 
sample, carried out at Oxford Genomics. Bioinformatics analysis was then completed by Dr Jun 
(Alex) Wang at the Barts Cancer Institute.  
 
While it is important to acknowledge that the number of samples available is few, as shown in 
Figure 3.6-A, an unsupervised principal component analysis (PCA) revealed a clear separation 
between GATA2 monoallelic and biallelic samples. Notably, the biallelic group (green) appears 
to cluster together even though it includes samples from two different individuals (IV.10_yr.4 
and III.7). Moreover, a supervised gene expression signature analysis identified more than 2000 
significantly differentially expressed (DE) genes (the large number of genes is likely a reflection 
of the small number of cases analysed) between these two groups, each driving a unique 
signature pattern (Figure 3.6-B and Appendix 3. Table 2). The significant DE genes were selected 
based on a stringent false discovery rate (FDR) filter of <0.05 and an absolute log2 fold change 
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(FC) value of >1. Precisely, 1,148 of these DE genes were downregulated and 1,284 were 
upregulated in GATA2 biallelic compared to the monoallelic group (Figure 3.6-C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 RNA-seq analysis. A. PCA plot showing a good separation between GATA2 biallelic (green), 
monoallelic (blue) and BM control (orange) groups, based on all 17,555 filtered genes. B. Heat-
map indicating 2,432 significantly DE genes between GATA2 biallelic (green) and monoallelic (blue) 
samples, selected based on FDR value of <0.05 and an absolute log2FC value of >1 (select DE genes are 
listed in Appendix 3. Table 2). C. Volcano plot indicating differential gene expression between these two 
groups and highlighting in red some of the most significantly DE genes, all of which are upregulated in 
GATA2 biallelic vs. monoallelic samples.  
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3.5.1 GSEA of differentially expressed genes  
 
Gene set enrichment analysis (GSEA) of RNA-seq data was next performed providing an 
opportunity to gain an appreciation of these DE genes and to explore significantly altered 
pathways (Subramanian et al., 2005). It was noteworthy that certain canonical pathways and 
oncogenic signature gene sets related to leukaemogenesis (e.g. cell cycle, DNA replication and 
HOXA9 signatures) were significantly downregulated (FDR <0.05) in GATA2 biallelic compared to 
monoallelic samples as determined by their decreased normalised enrichment scores (NES), 
possibly explaining the oncogenic events and symptom manifestations observed in GATA2 
monoallelic samples (Figure 3.7-A). At the same time, a number of other pathways and gene sets 
implicated in regulating gene transcription, immune modulation and cell signaling including 
“RNA Pol 1 promoter opening”, “Innate immune system” and “KRAS signatures” were found to 
be significantly upregulated (FDR <0.05) in GATA2 biallelic vs. monoallelic samples, potentially 
reflecting improvements in clinical parameters and symptom recovery in GATA2 biallelic samples 
which require further validation (Figure 3.7-A). 
 
Furthermore, genes with E2F1 (cell cycle regulator) and GATA1 (which replaces GATA2 in 
erythroid and megakaryocytic differentiation) binding motifs in their regulatory regions were 
each shown to be significantly downregulated in GATA2 biallelic vs. monoallelic groups whereas 
an enrichment of genes with CEBPA (GATA2 regulator) motifs was noted (although significance 
was not reached) (Figure 3.7-B). Of perhaps a greater significance, we observed that genes 
enriched for GATA2 co-factor PU.1 motifs in their regulatory regions were significantly 
overexpressed in GATA2 biallelic vs. monoallelic samples (NES = 2.06) (Figure 3.7-B). This is in 
line with a recent finding by (Chong et al., 2017) who showed that p.T354M mutants bind to 
PU.1 with more affinity than WT GATA2 protein, thus resulting in sequestration of PU.1 from its 
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normal cellular functions (e.g. HSC survival and differentiation) and blocking its activity. As a 
result, the transcriptional activation brought about by PU.1 will likely be diminished in our GATA2 
monoallelic samples, where only the mutant allele is being expressed.  
 
Taken together, these transcript profiles highlight the impact of losing expression of the WT 
allele (whilst still maintaining expression of the mutant allele) on GATA2 activity and that of other 
haematopoietic genes downstream and how this allelic imbalance can lead to overt disease 
symptoms. 
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Figure 3.7 GSEA analysis of DE genes. Heat-maps indicating normalised enrichment scores (NES) from GSEA 
pathway analysis of RNA-seq data for A. reactome pathways and oncogenic signature gene sets and B. TF binding 
motifs (select GSEA plots are shown). A negative NES (blue) indicates a downregulation in GATA2 biallelic vs. 
monoallelic samples whereas an opposite is the case for a positive NES (red). Statistical significance based on FDR 
q-values was determined at *p≤0.05, **p≤0.01 and ***p≤0.001. 
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3.6 Discussion 
 
 
While most MDS/AML cases occur sporadically, there are rare occurrences of familial cases 
representing a high risk group of patients who require tailored management and optimal care. 
These rare patient populations are characterised by wide variations in the age of onset, disease 
latency and outcome, with many mutation carriers remain asymptomatic into late adulthood, 
making their identification, follow-up and management all the more challenging. The increased 
frequency of asymptomatic carriers due to reduced penetrance appears to be a feature of 
germline GATA2 mutations, particularly in families segregating missense mutations such as 
p.Thr354Met. We believe that this observation opens an important question on leukaemia 
predisposition and how disease symptoms are initiated and potentially reversed. Since no 
published studies to date have addressed these questions in familial leukaemia, this study 
therefore sets out to uncover the molecular mechanisms governing the reduced penetrance and 
clinical heterogeneity in GATA2 deficiency syndromes. Elucidating these mechanisms would 
have important clinical implications for counselling and management of this group of at-risk 
individuals.  
 
The advent of NGS targeted gene panels has enabled us to decipher the pattern of secondary 
mutation acquisition at a greater depth sufficient to reveal haematopoietic subclones. Given that 
overt leukaemia typically in many cases reflects the acquisition of additional secondary 
mutations, targeted deep sequencing was employed across the symptomatic and asymptomatic 
family members in this study with a view of explaining the observed clinical heterogeneity that 
accompanies disease evolution from identical lesions. Our sequencing results suggest that the 
presence of somatic ASXL1 mutations (p.Gly646TrpfsTer12) in the symptomatic patient and not 
in asymptomatic family members correlated with disease symptoms, corroborating a pathogenic 
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link between GATA2 and ASXL1. This interpretation is in line with a report by West and colleagues 
(2014b) who noted molecular co-occurrence between germline GATA2 and acquired ASXL1 
mutations in 14/48 (29%) of GATA2-deficient patients, with p.Gly646TrpfsTer12 ASXL1 mutation 
(the one present in our family) being the most frequent by a significant margin (5/14). 
 
ASXL1 is an epigenetic regulator involved in PRC2-mediated gene repression (Abdel-Wahab et 
al., 2012). LoF ASXL1 aberrations were identified in sporadic AML and MDS cases (10% and 20% 
respectively), with a higher frequency in MDS/MPN cases such as chronic myelomonocytic 
leukaemia (CMML) (50%) and are associated with an adverse prognostic outcome (Boultwood 
et al., 2010, Asada and Kitamura, 2018). In addition, ASXL1 mutations are recurrently found in 
healthy individuals with clonal haematopoiesis with indeterminate potential (CHIP) along with 
DNMT3A and TET2 mutations (Genovese et al., 2014). Other examples where co-operating 
lesions ensue include 2nd biallelic CEBPA mutations in germline CEBPA-mutated cases (Tawana 
et al., 2015) and somatic JAK2 or CDC25C mutations in germline RUNX1-mutated families 
(Yoshimi et al., 2014, Tawana et al., 2017b). Overall, these observations indicate that progression 
to overt malignancy requires the involvement of second “hits” to exert phenotypic effects, 
although in our symptomatic patient example (IV.10), ASXL1 mutation VAF levels were low and 
maintained at (6-12%) over a 6-year monitoring period where spontaneous symptom recovery 
was noted at later time-points, suggesting that while these secondary mutations are important 
and in contrast to the assertion by West and colleagues, they are not sufficient alone to give rise 
to overt MDS or indeed determine when treatment is indicated. 
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Given that disease origin in GATA2-mutated patients is typically associated with haematopoietic 
stem cell exhaustion, recurrent infections and a resultant cytopenia, we would not discount the 
importance of monosomy 7, which was detected in the two cousins (IV.1 and IV.6) who 
developed MDS/AML, as a key secondary chromosomal anomaly. The aetiology for the selective 
loss of chromosome 7 in these patients remains unclear although the co-occurrence of 
monosomy 7 and LoF somatic ASXL1 mutations in a GATA2-deficient background has been 
described in several reports (see Table 3.1 below) but the order of these events has not been 
elucidated, reflecting perhaps the absence of longitudinal samples for analysis. However, on the 
basis of our observations and in agreement with previous studies (Wang et al., 2015, Pastor et 
al., 2017), it seems that monosomy 7 in IV.1 and IV.6 appears later than ASXL1 mutations, 
therefore contributing to the malignancy but not initiating the cytopenia.  
 
The second key observation from this study was the reduced total GATA2 expression levels in 
our symptomatic carrier (IV.10) accompanied by monoallelic expression favouring the mutant 
allele. In contrast, the higher GATA2 expression in the asymptomatic carriers (III.5 and III.7) 
provided a protective buffer which substitutes function of the faulty gene. Remarkably, this 
allelic GATA2 expression is dynamic and correlated with disease state in the symptomatic 
patient: (monoallelic expression – monocytopenia) in yr.1-3 and (biallelic expression – normal 
monocyte counts) in yr.4-6, providing a reasonable evidence of genotype-phenotype 
Family 
Germline GATA2 
mutation 
Acquired ASXL1 
mutation 
Cytogenetic  
alteration 
Reference 
1 p.Asn371Lys p.Leu817fs Monosomy 7  West et al., 2014 
2 p.Arg337X p.Glu635fs Monosomy 7 West et al., 2014 
3 c.1018-2A>G, splice site p.G646WfsX12 Monosomy 7 Wang et al., 2015 
4 p.Gly200ValfsX18 p.G646WfsX12 Monosomy 7 Pastor et al., 2017 
5 p.Ser447Arg p.Thr655AsnfsX3 Monosomy 7 Pastor et al., 2017 
Table 3.1 The co-occurrence between ASXL1 mutations and Monosomy 7 in germline GATA2-mutated families. 
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correlations. This skewed GATA2 expression is echoed further by a study in which MonoMAC 
patients exhibited reduced or absent expression of one GATA2 allele due to mutations in an 
intronic 5 enhancer element, leading to decreased GATA2 transcript levels and 
haploinsufficiency (Hsu et al., 2013). Monoallelic expression is therefore a phenomenon not only 
restricted to disease but also classical examples include imprinting of autosomal genes, where 
either the maternal or paternal allele is silenced, and the random inactivation of X-chromosomes 
in females (Reinius and Sandberg, 2015). Our data, however, provides the first example of 
reduced penetrance of germline coding mutations arising due to inter- and intra-individual 
variations in allelic expression and provides another plausible explanation for the variability in 
clinical presentations observed in a family with identical predisposing germline mutations.  
 
Intriguingly and to our knowledge, when we assembled information from all GATA2-mutated 
MDS/AML pedigrees with reduced penetrance, we noted that the reduced penetrance 
phenotype was most prominent (if not exclusive) to germline missense LoF mutations such as 
p.Thr354Met (other examples are shown in Table 3.2). Indeed, as previously suggested by 
Kazenwadel et al. (2012), GATA2 missense mutations might retain partial or residual activity, 
either in relation with DNA binding or interaction with partner proteins, rendering them less 
disruptive to protein function than GATA2 truncating or frameshift mutations. Therefore, we 
believe our findings are most likely to have a similar impact in families with missense GATA2 
mutations other than p.Thr354Met, as it seems that the silencing of the WT allele expression 
would lead to an almost complete depletion of protein activity, constituting the initial step 
needed for symptoms to develop.  
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For completeness, it is worth mentioning here that while genetic anticipation, the phenomenon 
whereby younger generations present with more severe disease phenotypes than their older 
counterparts, has been well-documented in RUNX1, TERC and TERT-mutated families, GATA2 
has not been associated with this phenomenon and we do not believe this to be the case in our 
family. Ages of disease onset for the deceased MDS/AML patients in the first and second 
generations (I.2, II.2 and II.3) were 53, 53 and 24 years old respectively, whereas third generation 
asymptomatic carriers (III.1, III.5 and III.7) are now in their mid-late 60s. 
 
We would be the first to recognise that mutant GATA2 monoallelic expression observed in the 
symptomatic vs. asymptomatic p.T354M carriers in this family would be strengthened further if 
a similar mechanism could be demonstrated in any of the other pedigrees mentioned. Indeed, 
our inability to access material for analysis across multiple pedigrees highlights one of the 
challenges in familial leukaemia research where available samples are limited, studies are 
primarily performed on retrospective material and consequently, DNA material is gathered 
rather than RNA and cells for subsequent studies.  
Family 
Germline GATA2 
mutation 
Asymptomatic 
carriers 
Haematological 
malignancy 
Reference 
1 p.Thr354Met 2 MDS/AML Hahn et al., 2011 
2 p.Thr354Met 1 MDS/AML Hahn et al., 2011 
3 p.Thr354Met 1 MDS/AML Hahn et al., 2011 
4 p.Thr354Met 3 MDS/AML Bödör et al., 2012 
5 p.Arg398Trp 1 MDS/AML Dickinson et al., 2014 
6 p.Arg398Gln 3 MDS/AML Dickinson et al., 2014 
7 p. Ser447Arg 2 MDS/AML Mir et al., 2015 
8 c.10171+572 (C>T), intronic 1 MDS/AML Churpek et al., 2015 
9 p.Thr354Met 1 - Unpublished (German family) 
10 c.1017+582(G>T), intronic 3 - Unpublished (German family) 
11 p.Cys349Ser 1 - Unpublished (German family) 
Table 3.2 Examples of germline GATA2-mutated families with reduced penetrance. 
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In our experiments, even with ongoing collaborations with other groups including Hamish Scott’s 
in Australia and Marcin Wlodarski’s in Germany, we were unable to obtain matched DNA-RNA 
material from these p.T354M GATA2-mutated pedigrees, especially from earlier disease time 
points where GATA2 monoallelic expression is most likely to be observed. We see ourselves as 
being rather fortunate therefore to have the case example (IV.10) where we have acquired 
multiple sequential RNA samples through routine clinical follow-up which allowed us to capture 
disease evolution and GATA2 expression at the very early stages of the symptomatic patient’s 
disease development. In a full-blown MDS/AML case scenario however, as in the two deceased 
cousins (IV.1 and IV.6), the ASE imbalance may not be so critical to the maintenance of 
malignancy and as such may go unnoticed.  
Altogether, reduced penetrance indicates that germline GATA2 p.T354M mutations may not be 
enough to lead to overt malignancy and while both monosomy 7 and ASXL1 mutations are critical 
and important secondary events (Figure 3.8), the work presented in this chapter suggests that 
silencing of the wild-type GATA2 allele observed in our symptomatic patient, leading to an 
almost complete abrogation of GATA2 function, is perhaps a more critical initiating event and a 
required step at the very early phases of disease in order to drive a patient’s initial symptoms 
and the acquisition of secondary genomic lesions. In the next section (Chapter 4), we will 
examine the molecular mechanisms underpinning GATA2 ASE and this loss of the WT allele 
expression.  
Figure 3.8 Model of clonal evolution of MDS/AML in a GATA2-deficient background. 
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“To study cancer, is to also study its opposite. Before a cancer cell becomes corrupted 
by malignant genes, there is a code of normalcy. What does the normal (epi)genome 
do and how does it function? How does it ensure the astonishing diversity we have as 
humans and also the astonishing commonality?” 
 
– Siddhartha Mukherjee 
 
4.1 Background and Rationale 
 
The experimental data in Chapter 3 prompted us to explore the molecular mechanisms impacting 
on monoallelic GATA2 expression. Reflecting for the most part the finite amount of primary 
material available to us, we focused our attention on non-coding genomic variants within GATA2 
regulatory regions and transient epigenetic mechanisms that could be responsible for the allele-
specific changes in GATA2 expression that accompany the p.T354M germline mutation in our 
symptomatic vs. asymptomatic carriers in the GATA2-mutated family. For the purpose of this 
thesis, the nitty-gritties of epigenetics and the mechanisms regulating gene expression are briefly 
reviewed in the following section. 
4.2 Epigenetic Regulation of Gene Expression 
 
In contrast with the focus on genetics in this thesis thus far, the term “epigenetics”, first 
introduced by Conrad Waddington in the early 1940’s, has evolved from the all-encompassing 
definition of “non-genetic heritable variations in phenotype” to now representing “the regulatory 
mechanisms that govern the expression of genetic information” (Waddington, 1942, Berger et 
al., 2009). Indeed, these mechanisms regulate gene expression through complex, dynamic, 
reversible and cell-specific post-translational modifications (PTMs) without changes in the DNA 
sequence itself (Holliday, 1987). Whilst many forms of epigenetic mechanisms do exist, two of 
the most frequently described (and briefly summarised in this section) are chemical alterations 
of the DNA (DNA methylation) and changes in DNA packaging via DNA binding proteins (histone 
modifications). These epigenetic marks decorate the DNA and its protein scaffold and, like music, 
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act as chemical notations, instructing the cells which genes to express and which ones to keep 
silent (Willyard, 2017).  
 
4.2.1 DNA Methylation 
 
DNA methylation involves the covalent addition of a methyl group to the 5’carbon of cytosine 
bases within CpG (Cytosine-phosphate-Guanine) dinucleotides (Bhalla, 2005). In cancer cells, this 
mainly takes place within CpG rich regions (~200 bases with GC content >50%) such as CpG islands 
located within promoter regions upstream of transcriptional start sites (TSSs) and typically 
constitutes a gene silencing mechanism by preventing the recruitment of TF machinery to 
facilitate gene transcription (Hashimshony et al., 2003). In somatic cells, however, these CpG 
islands are normally unmethylated (hypomethylated), whereas CpG sites outside of those regions 
are generally methylated (hypermethylated) (Weber et al., 2007) (Figure 4.1). 
 
Deposition of DNA methylation is catalysed by the DNA methyltransferase (DNMT) family of 
enzymes, which include DNMT1, DNMT3A and DNMT3B, all of which are essential for embryonic 
development (Okano et al., 1999, Holliday and Pugh, 1975). The removal of methyl groups from 
CpGs, however, is mediated by demethylase enzymes, namely TET1 and TET2, which oxidise 5-
methylcytosine (5mC) to generate 5-hydroxymethylcytosine (5hmC) (Cortellino et al., 2011, He 
et al., 2011). Indeed, knockdown of Tet1 and Tet2 in mouse embryonic stem (ES) cells was shown 
Figure 4.1 DNA methylation patterns in normal and malignant cells. Figure obtained from (Kandimalla 
et al., 2013). 
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to downregulate genes associated with pluripotency and increase methylation at their promoters 
(Ficz et al., 2011). Of note, somatic DNMT3A and TET2 are recurrently mutated in 10-20% of 
sporadic AML patients and confer an adverse impact on outcome (Delhommeau et al., 2009, 
Figueroa et al., 2010, Ley et al., 2010). 
 
The role of DNA methylation in transcriptional regulation has been extensively studied. For 
example, it has been linked with X-chromosome inactivation in females, embryonic patterning, 
genomic imprinting and tissue-specific gene repression (Feinberg et al., 2002, Illingworth et al., 
2008). In MDS/AML, promoter hypermethylation has been reported in RUNX1 (Webber et al., 
2013), CEBPA (Wouters et al., 2007, Lin et al., 2011) and GATA2 (Shih et al., 2015, Celton et al., 
2014). In particular, Celton and colleagues demonstrated a loss of GATA2 expression in NK-AMLs 
and attributed this to aberrant DNA hypermethylation. Given that these PTMs are reversible, the 
use of demethylating agents such as 5-Azacytidine or 5-Aza-2-deoxycytidine has been shown to 
inhibit DNMTs and re-activate the expression of silenced genes (Leone et al., 2003).  
 
More recently in relation to familial leukaemia, germline mutations in the DNA glycosylase 
(MBD4), which protects against methylation damage, were shown to predispose to inherited 
forms of MDS/AML, constituting a new candidate gene in familial disease (Sanders et al., 2018). 
DNA methylation also modulates disease penetrance; a study in monozygotic twins discordant 
for childhood leukaemia revealed that they displayed differential BRCA1 methylation status 
(Galetzka et al., 2012). 
 
Several techniques have been utilised for the analysis of DNA methylation including bisulphite 
sequencing. Sodium bisulphite treatment is considered the gold standard as it measures 
methylation at a single base resolution, converting unmethylated cytosines (C) into thymines (T) 
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whilst keeping methylated cytosines intact (Figure 4.2) (Frommer et al., 1992). This is then 
followed by either cloning for allele-specific quantitative approach (see methods Chapter 2.7) or 
deep sequencing of bisulphite-converted DNA for a more genome-wide analysis of DNA 
methylation (Lister et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
4.2.2 Chromatin Structure  
 
In human cells, DNA is typically wrapped around octamers containing four histone proteins (H2A, 
H2B, H3 and H4) forming nucleosomes (Luger et al., 1997, Strahl and Allis, 2000). These 
nucleosomes are tightly packed into chromatins, akin to “beads-on-a-string”, which are further 
coiled into chromatin fibers and then packaged into chromosomes (Figure 4.3). Each one of these 
highly conserved core histones has an N-terminal amino acid tail that protrudes outwardly, 
making it accessible for histone modifying enzymes to add specific PTMs to different amino acid 
residues (Kouzarides, 2007, Bannister and Kouzarides, 2011). These histone modifications 
orchestrate gene transcription, thereby facilitating the alternation of chromatin structure 
between two states; tightly compacted heterochromatin (state 1) which renders the DNA 
unattainable to TF machinery, whereas the opposite is the case for loosely packaged euchromatin 
(state 2), associated with transcriptionally active genomic regions (Henikoff, 2000, Bhalla, 2005). 
Figure 4.2 The effect of bisulphite DNA conversion on DNA sequence. Unmethylated 
cytosines are bisulphite-converted into uracils and upon PCR amplification, into 
thymines. Methylated cytosines remain unchanged following bisulphite conversion.   
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Figure 4.3 The structure and organisation of DNA packaging from the cell nucleus to the DNA 
double helix. Artwork obtained with permission from Sandra Black Culliton®.  
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4.2.3 Histone Modifications  
 
Core histones have been shown to be enzymatically modified through methylation, acetylation, 
phosphorylation, ubiquitination, SUMOylation, ADP-ribosylation and arginine deamination, 
among others (Bannister and Kouzarides, 2011). Intriguingly, specific types of modifications only 
take place on particular amino acid residues. For instance, methylation is only found on arginine 
and lysine residues, the latter of which is the focus in this chapter (Zhang and Reinberg, 2001, 
Black et al., 2012, Dawson and Kouzarides, 2012). 
 
These histone modifications collaborate together as part of a complex and dynamic “histone 
code”, which regulates chromatin structure and thereby patterns of gene expression. Whilst 
deciphering the intricacies within this “histone code” is not an easy task, recent technological 
advances such as chromatin immunoprecipitation (ChIP) have helped immensely; it employs 
antibodies that specifically identify the histone modification of interest (Gade and Kalvakolanu, 
2012). The ChIP-purified DNA can then be subjected to PCR and Sanger sequencing for an allelic-
specific approach, utilising heterozygous variants at regulatory (promoter and/or enhancer) 
regions to distinguish between alleles, or deep sequencing (ChIP-Seq) for a more global analysis 
of TF binding sites (Dawson and Kouzarides, 2012, Barski et al., 2007). 
 
4.2.3.1 Lysine Methylation 
 
The majority of lysine methylation takes place on core histone 3 (H3). Frequently methylated 
residues include K4, K9, K27 and K36 among others, where they can be mono-(me1), di-(me2) or 
tri-(me3) methylated. Lysine methylation is a reversible process regulated by the opposing 
actions of lysine methyltransferases (KMTs) and lysine demethylases (KDMs) which respectively 
add and remove these methyl groups (Tian et al., 2013). 
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Lysine methylation can be linked with both transcriptional activation such as H3K4, H3K36 and 
H3K79 methylations, and repression such as H3K9 and H3K27 methylations, in a context-
dependent fashion (Black et al., 2012). Herein, we focused on H3K4me3 and H3K27me3 to see if 
the enrichment of these chromatin marks can play a role in the ASE of GATA2 in our patient 
samples.  
 
Briefly, H3K4me3 is associated with transcriptionally active promoters and TSSs of transcribed 
genes and is mediated by the mixed-lineage leukaemia (MLL2) complex (Barski et al., 2007). 
Additionally, H3K4me3 was found to be inversely correlated with DNA methylation at CpG-rich 
promoters (Rose and Klose, 2014). H3K27me3, on the other hand, is catalysed by the polycomb 
repressive complex 2 (PRC2) including the histone methyltransferase EZH2 and is found at the 
promoters of repressed genes (Hock, 2012). Remarkably, while H3K27me3 and H3K4me3 
seemingly exert opposite effects on chromatin activity, they can co-exist together as “bivalent 
chromatin marks” in promoters of TFs regulating lineage commitment in pluripotent stem cells, 
keeping them in a poised state for later activation during differentiation (Bernstein et al., 2006) 
(Figure 4.4). 
 
 
 
 
 
 
 
Figure 4.4 H3K4me3 (sail) and H3K27me3 (anchor) bivalent chromatin marks – an analogy. 
Figure obtained from (Harikumar and Meshorer, 2015). 
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Results 
4.3 Variants within GATA2 promoter regions were identified in the symptomatic but not in 
asymptomatic family members 
 
There are many different potential mechanisms to explain ASE. In the following sections we 
investigate several of these in turn. First, to determine whether cis-regulatory variants within the 
GATA2 locus could affect the binding affinity of TFs and therefore be implicated in the observed 
ASE, select members (III.5, III.7, IV.9 and IV.10) of the GATA2 p.T354M-mutated family (described 
in Chapter 3.2) were screened for variants across key GATA2 regulatory regions as defined by 
Ensembl and University of California Santa Cruz (UCSC) genome browsers and described in 
published literature e.g. (Pan et al., 2000, Hsu et al., 2013). We called these regions promoter 1 
(GRCh38:3:128492893:128493893 – 1090bp), promoter 2 (GRCh38:3:128487621:128488621 – 
1272bp) which also includes the 5’-UTR of GATA2, enhancer 1 (GRCh38: 3:128481374-128482164 
– 217bp) located within an intronic region +9.5kb downstream of the TSS, and enhancer 2 
(GRCh38:3:128601086:128603086 – 1655bp) which corresponds to -77kb region upstream of the 
TSS (Figure 4.5-A), representing 4234bp in total.  
 
While Sanger sequencing detected no mutations in either of these 4 regions, two SNPs 
(rs9851497 [T/C] and rs1806462 [C/A]) located within GATA2 promoters 1 and 2, respectively, 
were identified in the symptomatic (IV.10) but not in asymptomatic (III.5 and III.7) nor in WT 
(IV.9) family members, defining a distinct genotype between these two groups of mutation 
carriers (Figure 4.5-B).  
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Figure 4.5 GATA2 regulatory variant screening. A. A schematic representation of the GATA2 locus (located 
on chromosome 3 – canonical transcript ENST00000341105.6) encompassing 6 exons and 2 promoter and 
2 enhancer regions, with promoters 1 and 2 and enhancer 2 (-77kb) located upstream of the transcriptional 
start site (TSS) (red arrow) while enhancer 1 (+9.5kb) is located in an intronic region further downstream. 
The first exon of GATA2 consists of 2 regions: the distal region (IS) is specific to the haematopoietic 
progenitor stem cell fraction and neuron, while the proximal region (IG) is found in tissues where GATA2 
is typically expressed (Pan et al., 2000). The yellow star in exon 5 indicates the location of the germline 
GATA2 mutation (c.1061C>T, p.T354M). The different coloured squares denote the locations of the 
overlapping PCR primers designed and used for variant screening (see methods Chapter 2 - Table 2.1). B. 
Sanger sequencing chromatograms showing promoter 1 and 2 SNPs identified in the symptomatic (IV.10) 
vs. an asymptomatic (III.7) carrier together with variant details obtained from Ensembl and dbSNP 
(Database of Single Nucleotide Polymorphisms). 
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Notably, as promoter 2 SNP [C/A] (rs1806462) resides within the 5’UTR part of the gene, by 
sequencing the cDNA template of our symptomatic patient (IV.10), we were able to 
pinpoint/apportion which allele of the promoter 2 SNP (A) is allelic with the mutant allele (T) of 
the germline GATA2 mutation (p.T354M, c.1061C>T) (Figure 4.6). This allowed us to attribute a 
distinct haplotype to the mutated allele and provided an opportunity to search for allele-specific 
molecular mechanisms governing the observed ASE of GATA2 and a means to test our next 
hypotheses. 
 
 
 
 
 
 
Figure 4.6 Establishing a haplotype on which the mutant allele lies. As promoter 2 is located within the 5’UTR 
of GATA2 where it is transcribed, cDNA sequencing of the symptomatic carrier (IV.10_yr.1) showed that 
promoter 2 SNP allele (A), the one that is expressed, resides on the GATA2 mutant allele (T) (c.1061C>T). 
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4.3.1 GATA2 regulatory SNPs do not induce significant allele-specific differences in GATA2 
promoter activity 
 
The identification of variants within GATA2 promoter regions in the symptomatic patient 
prompted an investigation into the functional impact of these variants and how they contribute 
to ASE. To test whether there are any allele-specific differences in GATA2 promoter activity due 
to the presence of these SNPs, luciferase reporter assay was performed; each allele of GATA2 
promoter 1 [T/C] (1318 bp) and promoter 2 [C/A] (1350bp) SNPs was amplified directly from our 
symptomatic patient (IV.10) (4 plasmid clones) and subcloned separately into a pGL2® luciferase 
reporter vector upstream of the Firefly luciferase gene (Luc) (Promega) (Figure 4.7-A and B). 
These constructs were then transiently co-transfected along with a pRL-CMV® control reporter 
vector containing Renilla luciferase gene (Promega) into HeLa cells. The luciferase activity of each 
promoter allele was next measured 48 hours post HeLa cell transfection, where the intensity of 
the luminescence from the Firefly luciferase was normalised to the luminescence intensity from 
the Renilla luciferase control after the addition of their respective substrates (see methods 
Chapter 2.6 for a brief description of Firefly and Renilla luciferase chemistry).  
 
Overall, while no major differences in luciferase activity were noted between promoter 1 SNP 
alleles [T/C], we observed a reproducible increase in the luciferase activity of the (A) allele 
compared with the (C) allele in promoter 2 SNP [C/A] (Figure 4.7-C). This increased transcriptional 
activity further reinforces the previously established link between the promoter 2 SNP allele (A) 
and the germline GATA2 mutant allele (T) (the one solely expressed in IV.10 monoallelic samples), 
residing on the same haplotype (Figure 4.6). 
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Figure 4.7 Functional validation of GATA2 promoter SNPs. A. Workflow of the experiment procedure showing the 
Firefly luciferase reporter construct used to evaluate GATA2 promoter activity. B. Sanger sequencing 
chromatograms demonstrating promoter 1 [T/C] and 2 [C/A] SNP allele clones that were obtained from IV.10 DNA 
following cloning of a 1318bp and 1350bp region (corresponding to GATA2 promoters 1 and 2 respectively) which 
were then subcloned separately into a Firefly luciferase vector prior to HeLa cell transfection. C. Bar chart depicting 
relative luciferase activity of promoter 1 and promoter 2 alleles, calculated by normalising the intensity of Firefly 
luciferase to the intensity of Renilla luciferase luminescence and a final normalisation to an empty vector control. 
An average of 5 independent experiments is shown, including all samples in triplicates. Statistical significance was 
determined at *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. Error bars represent SEM. 
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The potential role of these promoter SNPs with regards to differential TF binding affinity was 
assessed using PROMO in silico prediction tool (Messeguer et al., 2002). As illustrated in Figure 
4.8, a substitution from C to T in promoter 1 SNP [T/C] can result in the creation of new binding 
sites for TFs XBP1 and YY1 while no allele-specific differences in TF binding occupancy were noted 
in promoter 2 SNP [C/A]. This absence (in silico) of differential TF binding affinity in promoter 2 
SNP and the transient nature of ASE have led us instead to explore the epigenetic control of 
GATA2 allele-specific expression, described in the ensuing sections (4.4 to 4.7). 
 
 
 
 
 
 
 
 
 
Figure 4.8 PROMO-based allele-specific TF binding site prediction for promoter 1 and 2 SNPs. 
Promoter 1 SNP demonstrates allele-specific differences in TF binding sites between alleles T and C, 
whereas it is not the case for promoter 2 SNP alleles C and A. 
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4.3.2 The second promoter CpG-SNP provided a means of distinguishing between alleles 
 
Herein, we utilised the second promoter SNP (rs1806462 [C/A]) as a marker to differentiate 
between mutant and WT alleles in our subsequent experiments (Figure 4.9-A) taking advantage 
of the fact that this second promoter SNP is located within the 5’UTR (and as mentioned earlier), 
we were able to define a haplotype between the SNP allele (A) and the germline mutant GATA2 
allele (T) (Figure 4.9-B). Interestingly, we also noted that this SNP creates/abolishes a CpG 
dinucleotide within the GATA2 promoter region. As shown in Figure 4.9-C, this SNP can remove 
a CpG methylation site within the mutant allele (A) and generate a new CpG methylation site 
within the WT allele (C). In subsequent experiments, and focusing on epigenetic regulation of 
GATA2 second promotor region, we used this CpG-SNP as a vehicle to test whether allele-specific 
differences in DNA methylation and chromatin mark deposition provide an explanation for the 
silencing of the WT GATA2 allele expression observed in the earlier time-points of IV.10 and 
whether this SNP has also a role in modulating (increasing or lowering) methylation at this region. 
Indeed, one would postulate that losing (or gaining) a CpG site due to the presence of these CpG-
SNPs could exert an effect on the expression (or lack thereof) of mutant/WT alleles, such that the 
silencing of the WT allele can be attributed to the presence of extra CpG sites within the promoter 
region, coinciding with increased DNA methylation. Conversely, the expression of the mutant 
allele would be explained by the loss of CpG sites and a reduction in methylation overall. 
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Figure 4.9 Focusing on GATA2 second promoter SNP. A. This promoter SNP (rs1806462 [C/A]) overlaps a CpG 
island and was only present in the symptomatic patient (IV.10). It is situated 5,874 bp away from the p.T354M 
germline mutation site (denoted by a yellow star). B. Given the location of promoter 2 SNP within the 5’UTR, 
a haplotype between the SNP allele (A) and the germline mutant allele (T) was established by cDNA sequencing 
of IV.10_yr.1, providing a key to distinguish between mutant and WT alleles. C. This promoter SNP [C/A] also 
removes a CpG methylation site within the mutant allele (A) and generates an extra CpG methylation site 
within the WT allele (C).  
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4.4 No differences in global DNA methylation were observed between symptomatic and 
asymptomatic family members 
 
Initial experiments focused on comparing GATA2 methylation patterns between symptomatic 
and asymptomatic carriers within the family to establish if there is an increase in global DNA 
methylation of GATA2 promoter 2 region leading to the observed GATA2 transcriptional silencing 
in the symptomatic carrier (IV.10). Methylation-specific PCR (MSP) of bisulphite-modified DNA 
was performed using primers covering GATA2 promoter 2 CpG islands that can specifically 
amplify methylated (M) and/or unmethylated (U) sequences (see section 4.2.1 and methods 
Chapter 2.7 for a summary of bisulphite DNA conversion). Based on the PCR gel in Figure 4.10, 
promoter 2 was shown to be methylated in the symptomatic carrier (IV.10). However, there were 
no major differences in methylation patterns (M and U) when compared with asymptomatic (III.5 
and III.7) and WT (IV.8 and IV.9) family members. 
 
 
Figure 4.10 Global DNA methylation profiles. A representative MSP gel showing PCR products of bisulphite-
modified DNA from select GATA2-mutated family members amplified using GATA2 promoter 2 methylated (M) 
and unmethylated (U) primer set. Positive and negative controls are shown for comparison together with a 
bisulphite DNA conversion control in the second gel lane using conversion-specific primer set from Active Motif 
(see methods Chapter 2.7 and Table 2.1 for a list of primers used). 
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4.5 Allele-specific DNA methylation as a regulatory mechanism of silencing the WT GATA2 
allele expression 
 
It is important to keep in mind that the assay used in the previous section (4.4) assesses global 
DNA methylation and does not specifically distinguish between mutant and WT alleles. We 
therefore utilised the CpG-SNP [C/A] residing within GATA2 promoter 2 to determine whether 
allele-specific differences in DNA methylation is a contributing factor to GATA2 ASE. Bisulphite-
specific PCR (BSP) was performed to amplify a 200-bp region encompassing GATA2 promoter 2 
SNP and overlapping a CpG island (containing ~20 CpG sites) followed by cloning and sequencing, 
to compare DNA methylation patterns between mutant and WT alleles across three time-points 
of IV.10. (yr. 1, 3 and 6) (See methods Chapter 2.7). 
 
As illustrated in Figure 4.11-A-B and Figure 4.12, we observed a significant increase in promoter 
methylation in the WT allele (C) compared to a reduced methylation pattern in the mutant allele 
(A) of IV.10 earlier time-points (yr. 1 and 3). Interestingly, the extra CpG site in the WT allele (C) 
generated by this CpG-SNP [C/A] was frequently methylated, probably favouring the increase in 
DNA methylation and subsequent ASE in these earlier time-points. Conversely, we observed no 
significant allele-specific differences in methylated CpGs in IV.10_yr.6, which offers a potential 
explanation for the restoration of the WT allele expression and an improvement in clinical 
parameters at this later time period.  
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Figure 4.11 Allele-specific DNA methylation profiles. A. Bisulphite cloning and sequencing covering GATA2 second promoter SNP region 
overlapping a CpG island was performed to compare DNA methylation patterns between mutant and WT alleles across 3 time-points of the 
symptomatic patient IV.10 (yr. 1 and 3 with monoallelic GATA2 expression) and (yr.6 with biallelic GATA2 expression). Each row represents a 
separate clone. Each circle represents a CpG site, black circles correspond to methylated CpGs while white circles correspond to unmethylated 
CpGs. B. The proportion of methylated CpGs between mutant and WT alleles across the 3 time-points studied. WT allele is significantly more 
methylated than the mutant allele in monoallelic samples (yr. 1 and 3), whereas no significant allele-specific differences in methylation were 
observed in a biallelic-expressing sample (yr. 6). An average of 3 independent experiments is shown. Statistical significance was determined 
at *p <0.05, **p <0.01, and ***p <0.001 using a t-test with Bonferroni correction. NS: non-significant comparisons. Error bars represent SEM. 
 
GTGGGAGTTTTGAGGGTGATGGGCTTAGGGATAGTATGTTTGGAGGCTGGTGGGG
TTTATAGGGTAGGAGTTGGGGGTAGAGTGTGCTTTGGTTTTGGGTTTTTTTGGTT
CTGGTTTTTTGGTATTTTTTGGTTGTTTTGGCGTTAGTTGTCGATTTTTGTA 
 
A clone 
sequence 
example: 
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Original DNA sequence: 
 
GGCCTCTGAGAGTGAAGGAGTTCCGGCGGGAGCCCCGAGGGCGACGGGCCCAGGGACAGCACGTCCGGAGG
CTGGCGGGGCTTACAGGGTAGGAGCTGGGGGTAGAGTGCGCCTCGGCCTCGGGCCCGCCCGGCTCCGGCCC
CTCGGCATCCTCCGGCCGCCCTGGCGCCAGCTGCCGACTCCTGCACAGACATGAAGCGGGGGCCGCGCACG 
 
Bisulphite-converted DNA sequence:   
 
GGTTTTTGAGAGTGAAGGAGTTTCGGCGGGAGTTTCGAGGGCGACGGGTTTAGGGATAGTACGTTCGGAGG
TTGGCGGGGTTTATAGGGTAGGAGTTGGGGGTAGAGTGCGCTTCGGTTTCGGGTTCGTTCGGTTTCGGTTT
TTCGGTATTTTTCGGTCGTTTTGGCGTTAGTTGTCGATTTTTGTATAGACATGAAGCGGGGGCCGCGCACG 
 
Key:     
    
Total number of CGs = 18   
GGTTTTTGAGAGTGAAGGAGTTTC = forward primer sequence    
CTATACAAAAATCGACAACTAACGC = reverse primer sequence  
CG = Promoter 2 SNP [C/A] removes a CpG site within the mutant allele (A) and creates a CpG site within 
the WT allele (C)                          
TG = unmethylated CpG 
CG = methylated CpG 
 
 
 
Representative examples of mutant and WT allele clones (as shown in Figure 4.11-A): 
 
IV.10_yr.1 clone 1 (wildtype allele CG) TG = 13 CG = 5 
 
TGAGAGTGAAGGAGTTTCGGTGGGAGTTTCGAGGGTGATGGGTTTAGGGATAGTATGTTCGGAGGTTGGTG
GGGTTTATAGGGTAGGAGTTGGGGGTAGAGTGTGTTTTGGTTTTGGGTTTGTTCGGTTTTGGTTTTTTGGT
ATTTTTTGGTTGTTTTGGCGTTAGTTGTCGATTTTTGTATAGA 
 
 
IV.10_yr.1 clone 1 (mutant allele AG) TG = 13 CG = 4  
 
TGAGAGTGAAGGAGTTTCGGCGGGAGTTTAGAGGGTGACGGGTTTAGGGATAGTATGTTTGGAGGTTGGTG
GGGTTTATAGGGTAGGAGTTGGGGGTAGAGTGTGTTTTGGTTTTGGGTTTGTTTGGTTTTGGTTTTTTGGT
ATTTTTTGGTTGTTTTGGCGTTAGTTGTCGATTTTTGTATAGA 
 
 
 
 
 
Figure 4.12 Allele-specific DNA methylation analysis. Two representative examples of mutant (A) and WT (C) 
allele clones obtained from IV.10_yr.1 DNA following bisulphite cloning and sequencing encompassing GATA2 
promoter 2 SNP region (~200bp) and overlapping a CpG island (containing 18 CGs). Sequences highlighted in 
pink represent the primer pair used to amplify this region prior to cloning into pCR2.1® TA-vectors (see 
Chapter 2.7 and Table 2.1). This approach was used to quantitatively measure the proportion of methylated 
(CG) and unmethylated (TG) CpGs across IV.10 different time-points and utilising CG promoter 2 CpG-SNP 
[C/A] as a way of distinguishing between mutant (A) and WT (C) alleles. 
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4.6 Elevated H3K4me3 promoter deposition on the mutant allele  
 
Given the inverse correlation between DNA methylation and gene expression, we next sought to 
establish whether these allele-specific changes in GATA2 methylation and expression are 
accompanied by changes in chromatin deposition at the promoter. We focused specifically on 2 
histone marks, H3K4me3 and H3K27me3. As mentioned in section 4.2.3.1, H3K4me3 (mark of 
gene activation) and H3K27me3 (mark of gene silencing) define poised or closed chromatins, 
respectively, rendering them more or less accessible for TFs, thereby representing potential 
regulators of gene expression.  
 
To assess if these bivalent chromatin marks are differentially enriched between mutant and WT 
alleles of IV.10 samples, allele-specific ChIP was performed which briefly involved protein to DNA 
crosslinking, chromatin sonication and immunoprecipitation using either H3K4me3 or H3K27me3 
antibodies followed by reverse cross-linking and PCR and Sanger sequencing within GATA2 
promoter 2 SNP region (see methods Chapter 2.8). Access to primary material was critical to 
these experiments as it allowed us to test three sequential BM samples from IV.10: two early 
monoallelic samples (yr. 1 and 3) and a later time-point with biallelic GATA2 expression (yr.4), 
using the SNP (rs1806462 [C/A]) genotype as a means of discriminating between mutant and WT 
alleles.  
 
As shown in Figure 4.13-A and B, while there were no apparent allele-specific differences in 
H3K27me3 inhibitory mark deposition across the different time-points of IV.10, we noted a 
significant enrichment in the deposition of H3K4me3 activating mark on the promoter mutant 
allele (A) relative to the WT allele (C) in IV.10 monoallelic samples (yr. 1 and 3). Critically and 
consistent with the pattern observed in DNA methylation, there were no demonstrable allele-
specific differences in H3K4me3 deposition in the IV.10 biallelic sample at the later time point 
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(yr. 4) (both alleles equally enriched for H3K4me3) which coincided with apparent reactivation of 
the WT allele expression and a steady improvement in IV.10 disease symptoms.  
 
PCR quality control assay was performed to confirm that these ChIP Sanger sequencing results 
were not due to bias introduced by PCR. Briefly, this entailed taking promoter 2 SNP [C/A] plasmid 
DNA containing either mutant (A) or WT (C) alleles that were cloned from IV.10 DNA (and were 
generated for the luciferase assay experiments in section 4.3.1) and introducing them together 
into PCR reactions at different ratios (1:1,2:1,3:1,4:1,6:1) of A:C and the reverse 
(1:1,1:2,1:3,1:4,1:6) of A:C. These ratios were measured and confirmed by Sanger sequencing 
trace chromatograms where the proportion of sequence peak height corresponding to each 
allele is compared against the expected ratios of added DNA (Figure 4.14).  
 
Taken together, these findings support the view that monoallelic GATA2 expression is driven in 
part by dynamic epigenetic reprogramming; increased DNA methylation linked with lower 
H3K4me3 promoter deposition on the WT allele and vice versa for the mutant allele, potentially 
underlying the phenotypic variation and disease penetrance of germline GATA2 p.T354M 
mutations. 
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Figure 4.13 Allele-specific enrichment of H3K4me3 and H3K27me3 chromatin marks. A. The first 2 columns from the left (genomic DNA and cDNA) 
represent Sanger sequencing trace chromatograms obtained before ChIP and following PCR for a region spanning GATA2 promoter SNP (rs1806462) 
[C/A] where (A) corresponds to the mutant allele and (C) corresponds to the WT allele. The remaining 3 columns represent Sanger sequencing traces 
obtained after ChIP and showing input DNA control, ChIP for H3K27me3 and H3K4me3, respectively, across three sequential time-points of the 
symptomatic patient (IV.10_yr.1 and yr.3) with monoallelic GATA2 expression and (IV.10_yr.4) with biallelic GATA2 expression. B. Quantification of 
mutant and WT allele ChIP sequence peak heights across the time-points of IV.10 based on Sanger sequencing. H3K4me3 activation mark favoring 
the mutant allele was enriched in monoallelic samples (yr. 1 and yr. 3) compared with the biallelic expressing sample (yr. 4) whereas no significant 
differences in H3K27me3 deposition were noted across the time-points. An average of 3 independent experiments is shown. Statistical significance 
was determined at *p <0.05, **p <0.01, and ***p <0.001 using a t-test with Bonferroni correction. Error bars represent SEM. 
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Figure 4.14 PCR quality control assay. This assay was performed to confirm that Sanger sequencing 
results were not due to bias introduced by PCR. Plasmids containing either mutant (A) or WT (C) 
promoter 2 SNP alleles [C/A] were introduced together in PCR reactions at different ratios 
(1:1,2:1,3:1,4:1,6:1) of A:C and the reverse (1:1,1:2,1:3,1:4,1:6) of A:C which was then confirmed by 
Sanger sequencing chromatograms covering the promoter SNP. Here, the proportions of sequence 
peak heights (measured ratios) are consistent with the expected ratios of added DNA. 
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4.7 Investigating the relationship between DNA methylation and chromatin mark deposition 
in our patient samples  
4.7.1 H3K4me3 promoter deposition appears to be mutually exclusive with DNA methylation 
In light of our previous observations that monoallelic GATA2 expression is associated with allele-
specific DNA methylation and H3K4me3 promotor deposition, we wanted to test whether these 
two events occur simultaneously or indeed if they are mutually exclusive at the GATA2 locus 
within our patient samples. The lines of evidence that the latter scenario may hold true in mice 
and human cells are two-fold:  
1) It has been demonstrated that H3K4me3 occupancy blocks de novo DNA 
methylation by preventing the recruitment of DNA methylation machinery e.g. Dnmt3L 
and Dnmt3a/b tetramers to promoters. These DNMT3 enzymes contain an ADD 
domain that specifically recognises unmethylated H3K4 but cannot bind to H3K4me3.  
2) ZF-CxxC domain proteins such as the Mll1/2 complexes or Cfp1 recruit the Set1a/b 
H3K4-methyltransferase complexes to unmethylated DNA in CpG islands, where they 
function to catalyse H3K4me3 (Rose and Klose, 2014) (Figure 4.15). 
 
 
Figure 4.15 A schematic diagram depicting the associations between H3K4me3 and DNA binding proteins 
at CpG regions. CpG islands associated with actively transcribed genes recruit H3K4-methyltransferases 
(e.g. Set1a/b) through interactions between ZF-CxxC domains (e.g. Cfp1 and MII1/2) and unmethylated 
CpG regions. RNA PolII also associates with H3K4me3 at active gene promoters. H3K4me3 can also block 
DNA methylation by preventing the binding of Dnmt3L/Dnmt3a/b tetrameric complex to CpG islands. 
Figure adapted from (Rose and Klose, 2014). 
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To test this hypothesis in our patient samples, we performed BSP of bisulphite-modified, 
H3K4me3 ChIP-enriched DNA from the previous ChIP experiments followed by cloning and 
sequencing within GATA2 promoter 2 region to assess DNA methylation status. As illustrated in 
Figure 4.16, this revealed little or no DNA methylation at any sampling time-point of IV.10’s 
H3K4me3-enriched cells (yr.3 GATA2 monoallelic and yr.4 GATA2 biallelic expressing samples), 
providing direct experimental evidence that DNA methylation and H3K4me3 promoter 
deposition appear to be mutually exclusive in our IV.10 samples. 
 
 
 
 
 
Figure 4.16 Linking DNA methylation and H3K4me3 promoter deposition. Bisulphite-specific PCR 
followed by cloning and Sanger sequencing covering GATA2 second promoter SNP [C/A] region overlapping 
a CpG island was performed to assess DNA methylation patterns of H3K4me3 ChIP-enriched DNA across 2 
time-points of our symptomatic patient IV.10 (yr.3 with monoallelic GATA2 expression) where H3K4me3 
is only enriched on the mutant allele and (yr.4 with biallelic GATA2 expression) where both alleles are 
equally enriched for H3K4me3. Each row represents a separate clone. Black circles denote methylated 
CpGs while white circles denote unmethylated CpGs. 
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4.7.2 An overlap exists between DNA methylation and H3K27me3 deposition  
 
We also performed the same set of experiments on bisulphite-modified DNA derived from IV.10 
(yr.3 and 4) that has been immunoprecipitated with H3K27me3 repressive chromatin mark. 
Based on the proportion of methylated CpGs shown in Figure 4.17, DNA methylation appears to 
coincide with H3K27me3 promoter deposition in all sampling time-points of IV.10 suggesting that 
the two events are not incompatible. This observation is consistent with the fact that gene 
promoters that are enriched with H3K27me3 are more likely to be methylated during 
differentiation and carcinogenesis and this can be attributed to the recruitment of PRC1 and PRC2 
complexes that methylate H3K27 and silence CpG island associated genes (Statham et al., 2012, 
Rose and Klose, 2014). Although the association between PRC2 and Tet1 could explain why a 
subset of CpG islands that are occupied by PRC2 are not subject to DNA methylation (Neri et al., 
2013). 
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4.8 Discussion  
 
The intra- and inter-individual variations in GATA2 expression profiles seen within and between 
p.T354M GATA2-mutated family members described in Chapter 3 fostered our investigation 
focusing on the molecular mechanisms underlying monoallelic GATA2 expression. We 
hypothesised that these changes in allelic expression could be mediated by a combination of 
regulatory and transient epigenetic mechanisms that include changes in DNA methylation and 
chromatin mark deposition.  
 
The reduction in GATA2 expression due to allele-specific fluctuations in expression implied that 
putative cis-acting regulatory mechanisms might be involved. Indeed, the identification of a 
heterozygous GATA2 promoter 2 SNP residing within the 5’UTR in our symptomatic patient vs. 
asymptomatic carriers constituted a marker to distinguish between mutant and WT alleles and a 
first step in establishing the mechanisms governing the observed ASE. Intriguingly, this SNP can 
also alter (generate/remove) CpG methylation sites within GATA2 promoter region, resembling 
a previous study showing that a CpG-SNP (rs12041331) reinforces PEAR1 enhancer activity in 
platelet formation through allele-specific DNA methylation (Izzi et al., 2016). Here, we also 
showed allele-specific DNA methylation as a regulatory mechanism contributing to the silencing 
of the WT GATA2 allele in our symptomatic patient’s earlier disease time-points. One would 
postulate promoter methylation to have an impact on TF binding affinity; increased promoter 
methylation would lead to lower TF binding affinity thereby inhibiting patterns of gene 
expression and vice versa.  
Figure 4.17 Linking DNA methylation and H3K27me3 promoter deposition. Bisulphite-specific PCR 
followed by cloning and Sanger sequencing covering GATA2 second promoter SNP [C/A] region overlapping 
a CpG island was performed to assess DNA methylation patterns of H3K27me3 ChIP-enriched DNA across 
2 time-points of our symptomatic patient IV.10 (yr.3 with monoallelic GATA2 expression) and (yr.4 with 
biallelic GATA2 expression). Each row represents a separate clone. Black circles denote methylated CpGs 
while white circles denote unmethylated CpGs.  
 
Chapter 4 – Results 2 
 153 
We did not validate allele-specific TF binding occupancy based on the PROMO in silico prediction 
tool in our patient samples. However, our findings are in agreement with a previous study by 
Celton and colleagues who attributed reduced GATA2 expression levels in normal karyotype 
sporadic AMLs (NK-AMLs) to promoter hypermethylation and SNPs acting as loss-of-function 
mutations, highlighting the importance of epigenetic alterations in modulating gene expression 
(Celton et al., 2014). 
 
Another notable observation was made following allele-specific ChIP revealing an enrichment of 
H3K4me3 on the GATA2 promoter mutant allele compared to the WT allele at diagnosis which 
was reversed at later follow-up, correlating with reactivation of the WT allele expression. This 
interpretation is in line with a study by Stern and colleagues who showed mutant TERT promoter 
allele to exhibit H3K4me3 in various cancer cell lines whilst the WT allele retained the H3K27me3 
mark of gene silencing (Stern et al., 2015). We also validated that H3K4me3 blocks de novo DNA 
methylation by showing that DNA methylation and H3K4me3 promoter deposition are mutually 
exclusive in our patient samples. From a translational perspective, this altered GATA2 allelic 
expression can be reversed therapeutically by exposure to specific epigenetic inhibitors and/or 
demethylating agents (e.g. 5-azacytidine). Unfortunately, treating our symptomatic patient cells 
with KDM5 inhibitor, a drug that inhibits the KDM5 family of histone demethylases, stabilising 
H3K4me3 levels and could have the potential therefore of reactivating the expression of the 
silenced WT GATA2 allele, has proven to be challenging due to the short life of our cells in culture 
and the scarcity of material available. 
 
Moreover, with the high frequency of promotor 2 SNP (MAF 39%), there would be a reasonable 
chance that this SNP could be utilised similarly in other GATA2-mutated families. Indeed, we 
should not rule out the possibility that this promoter 2 SNP (rs1806462 [C/A]), by creating an 
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extra CpG methylation site within the WT allele, could play a direct role in its silencing. To test 
the contribution of this SNP, we analysed the haplotype of 12 p.Thr354Met GATA2-mutated 
individuals (10 affected members and 2 asymptomatic carriers) from the three families published 
by Hahn et al. (2011) and we observed two individuals (one symptomatic and one asymptomatic 
carrier) from two different families heterozygous [C/A] for the SNP (rs1806462). In both cases, 
the SNP reference allele [C] was in cis with the GATA2 mutation, the opposite of what we 
detected in our family. Moreover, apart from our symptomatic patient (IV.10), no other family 
members (including the two deceased MDS/AML cousins IV.1 and IV.6) were heterozygous for 
these GATA2 promoter SNPs and given the stable improvement in clinical parameters at IV.10 
later time-points (yr.4 and 6), we reasoned that while this CpG-SNP plays a role in GATA2 
monoallelic expression, there is no evidence to establish a correlation between the haplotype 
rs1806462A-GATA2T354M and the progression of disease/symptomatic status. This SNP was 
therefore used merely as a vehicle to distinguish between mutant and WT alleles in our DNA 
methylation and ChIP experiments.  
 
Collectively, our findings from this chapter propose that allele-specific expression of GATA2 
mutant allele is driven by dynamic epigenetic reprogramming; increased DNA methylation linked 
with lower H3K4me3 promoter deposition on the WT allele and vice versa for the mutant allele 
(Figure 4.18), adding another layer of complexity to the (epi)genetic basis of familial MDS/AML 
and contributing towards the observed reduced penetrance phenotype seen in certain inherited 
GATA2-mutated MDS/AML families.  
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Figure 4.18 Epigenetic dysregulation accounting for the mono-/biallelic GATA2 expression status observed 
across the 4 time-points studied in our symptomatic patient (IV.10) and its correlation with disease 
symptoms, using promoter 2 SNP as a means of distinguishing between mutant and WT alleles.  
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“Cancer begins and ends with people. In the midst of scientific abstraction, 
it is sometimes possible to forget this one basic fact…” 
– June Goodfield  
 
“The greatest need we have today in the human cancer problem, except for a 
universal cure, is a method of detecting the presence of cancer before there are 
any clinical signs of symptoms.”  
– Sidney Farber 
 
5. Final Discussion 
 
5.1 Introduction 
 
 
The first example of familial myeloid malignancies was described in the early 1920’s but it was 
not until the discovery of germline RUNX1 mutations in 6 FPD/AML families in 1999 that our 
understanding of the mutational landscape and genetic complexity of these inherited syndromes 
started to develop immensely (Gunz et al., 1975, Song et al., 1999, Akpan et al., 2018). Now two 
decades later, their recent inclusion as a distinct diagnostic entity in the 2016 WHO classification 
has renewed efforts to improve the recognition, management and care of this group of patients 
and their families (Arber et al., 2016). The clinical and molecular heterogeneity of familial 
MDS/AML, uncovered by harnessing the capabilities of NGS technologies, is reflected in our 
group’s sample collection here at the Barts Cancer Institute in London. Following the discovery 
of germline mutations in CEBPA (Smith et al., 2004), germline mutations have now been 
identified in ~13 additional loci, including GATA2, the subject of this thesis. These studies are not 
merely important for the respective families themselves but also for sporadic MDS/AML patients 
as they offer valuable insights into the aetiology of myeloid malignancies and in this thesis, a 
means to explore the molecular basis of disease penetrance and fluctuations in clinical 
presentation observed in patients with identical predisposing mutations. 
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5.2 Same germline mutations, different clinical manifestations – we GATA ask why 
 
 
We have noted that reduced penetrance is a feature amongst certain GATA2-mutated MDS/AML 
families, especially those carrying germline missense mutations (e.g. p.Thr354Met) and indeed, 
when we examined all our pedigrees, asymptomatic “silent” mutation carriers are detectable 
well into their adult years, suggesting that reduced penetrance (long latency; variable 
expressivity) is an element of these diseases. True estimations of penetrance are however 
hindered by limited genetic and phenotypic screening of extended family members and 
incomplete patient/family medical histories, making the prediction of an individual’s disease risk 
and that of future generations particularly challenging. This is further exacerbated by the scarcity 
of testing tools within diagnostic laboratories worldwide to confirm disease segregation and/or 
germline mutation status, leading to missed opportunities in detecting and managing these 
patients and their families, particularly when it comes to appropriate HSCT timing and donor 
selection. 
 
Herein, we investigated one such family (Bodor et al., 2012) where three generation mutation 
carriers include both symptomatic and asymptomatic family members and most strikingly, one 
particular member (IV.10) presented with recurrent infections and significant monocytopenia 
and neutropenia at the age of 31 years old which fortunately stabilised 3 years after presentation 
as symptoms improved. We had no satisfactory explanation for the reduced penetrance and the 
inter- and intra-individual variability in symptoms observed in this family and indeed in the other 
GATA2-mutated MDS/AML families initially reported by (Hahn et al., 2011) and so this thesis has 
opened up a new research arena not fully addressed in the existing familial leukaemia literature.  
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We believe this has important connotations for the counselling and management of patients and 
their families but also potentially widely in relation to predisposition to sporadic disease, where 
we do not yet have a full grasp of the aetiology and disease initiating events.  
5.3 GATA2 monoallelic expression underlies reduced penetrance in inherited p.T354M-
mutated MDS/AML 
 
The results from this thesis showed a novel mechanism to account for the clinical heterogeneity 
in the setting of germline GATA2 deficiency. Although it is a single family case study, the careful 
longitudinal clinical follow-up and temporal molecular analyses set a paradigm for familial 
leukaemia research and may even have broader implications in MDS/AML as a whole, as it has 
been challenging to rationalise factors governing mutation acquisition and disease risk; this is 
now possible considering the in-depth molecular profiling of AML patients using multi-omic 
approaches such as RNA-seq and the opportunity of detecting monoallelic gene expression. 
Indeed, this is an ongoing area of investigation in the Fitzgibbon laboratory focusing mainly on 
sporadic disease, who are employing these technologies to dissect the genetic and biochemical 
features of poor risk AML (which comprises monosomies, chromosome 3 or 11q abnormalities 
or complex karyotypes) and capture the personality of a disease that has managed to evade 
treatment so effectively. 
 
Furthermore, this study highlights the importance of monitoring and evaluating at-risk 
individuals over time, as access to primary sequential BM or PB material can uncover molecular 
insights responsible for modulating disease phenotype and particularly in our case example 
(IV.10), corresponding to changes in GATA2 expression (total and/or allelic) rather than the more 
conventional markers reflecting acquisition of somatic mutations e.g. ASXL1 (Chapter 3).  
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Interestingly, this finding is akin to the skewed GATA2 ASE observed in sporadic NK-AML patients 
(Celton et al., 2014) however here we report for the first time its involvement in familial disease. 
So, whilst we cannot rule out monosomy 7 and ASXL1 mutations as important secondary events 
in germline GATA2 deficiency, as echoed by previous studies (West et al., 2014b, Pastor et al., 
2017), the work presented in this thesis suggests that the silencing of the WT GATA2 allele is 
perhaps a more critical initiating event and a required step at the very early phases of disease 
and to drive a patient’s initial symptoms. Of note, the mechanisms by which these exact ASXL1 
mutations (p.Gly646TrpfsTer12) and monosomy 7 are selected for in our p.Thr354Met GATA2-
mutated patients remain unclear and it is not just these aberrations as mutations in IDH2, RUNX1, 
SETBP1 and STAG2 have also been reported to co-occur with germline GATA2 mutations in 
paediatric MDS patients (Ding et al., 2017, Fisher et al., 2017, Wang et al., 2015). 
 
We have a lot to learn and we for example think that the precise nature of the germline mutation 
itself (e.g. p.Thr354Met) can also impact on disease penetrance and the notion that these 
missense mutations, by retaining partial protein activity, are insufficient on their own to induce 
overt malignancy and require the involvement of additional co-operating events to facilitate 
clonal expansion and proliferation (Kazenwadel et al., 2012, Katsumura et al., 2018) (Figure 5.1). 
This is exemplified by a study reporting the acquisition of somatic CDC25C, JAK2 and SH2B3 
variants in germline RUNX1-mutated families (Yoshimi et al., 2014, Tawana et al., 2017b). 
Nevertheless, whilst mutant ASE of GATA2 leading to haploinsufficiency is a key initiating event 
in this family, its value as a predictive biomarker may not necessarily hold true in every familial 
case but at least it provides a clue going forward that must be considered when assessing families 
with symptomatic and asymptomatic mutation carriers.  
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Figure 5.1 Hypothetical model showing the properties of germline GATA2 mutations 
(truncating vs. missense vs. WT) and their impact on haematopoietic proliferation and 
disease state. GATA2 truncating (e.g. frameshift) mutations (top panel) diminish protein 
activity, leading to haploinsufficiency, cytopenia and overt disease. In contrast, heterozygous 
missense GATA2 mutation (middle panel) can retain partial or residual protein activity, either 
in relation with DNA binding or interaction with partner proteins, rendering it less disruptive 
to protein function than GATA2 truncating or frameshift mutations and therefore may not be 
enough to drive overt malignancy. The silencing of the WT allele expression, leading to an 
almost complete depletion of GATA2 function, would therefore be needed to induce the 
cytopenia and the acquisition of secondary molecular events (e.g. ASXL1 mutations and 
monosomy 7) is a way of escaping this cytopenia, leading to AML development. The dynamic 
nature of this ASE and its correlation with disease state however means that the biallelic 
GATA2 expression and normal haematopoiesis can be restored as patients’ disease symptoms 
improve (asymptomatic status). Finally, healthy individuals with 2 WT GATA2 alleles (bottom 
panel) have normal haematopoiesis and an uncompromised GATA2 activity. 
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5.4 Epigenetic alterations regulate monoallelic GATA2 expression   
 
The second part of the thesis focused on exploring the molecular mechanisms accounting for the 
allele-specific variations in GATA2 expression; increased promoter methylation at CpG sites on 
the WT allele in the earlier disease time-points of our symptomatic patient was noted, along with 
an allele-specific enrichment of H3K4me3 deposition on the promoter mutant allele, highlighting 
dynamic epigenetic reprogramming that correlated with disease symptoms (Chapter 4). 
Similarly, a recent study showed that monozygotic twins share the same de novo GATA2 mutation 
(c.1192 C>T) but display different phenotypes (the proband was diagnosed with MDS while her 
twin sister has dysmegakaryopoietic features in the BM), possibly due to differences in their 
GATA2 promoter methylation profiles (Kim et al., 2019). Another study on monozygotic twins 
discordant for childhood leukaemia revealed that they too displayed differential BRCA1 promoter 
methylation status (Galetzka et al., 2012), highlighting the role that DNA methylation plays in 
influencing disease penetrance.  
 
Notably, we showed that these two events (DNA methylation and H3K4me3 promoter 
deposition) are mutually exclusive within our patient BM cells however it would be challenging 
to infer how these epigenetic modifications change over time given that the cells were not 
purified or examined at a single cell level. Even considering this caveat and the transient nature 
of epigenetic mechanisms, this study highlights the therapeutic potential of modulating GATA2 
expression, either via the use of demethylating agents (e.g. 5-azacytidine) to restore the 
expression of the silenced allele as described by (Celton et al., 2014) or by maintaining H3K4me3 
levels via KDM5 inhibition which warrants further biological studies. 
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Moreover, we should not underestimate the impact of non-coding regulatory SNPs on the 
penetrance of coding mutations; this is a widespread genetic phenomenon as evidenced by the 
wealth of GWAS, with studies demonstrating that high expressing SNP alleles in cis can act in 
concert with the coding mutation to modify disease risk (Lappalainen et al., 2011, Castel et al., 
2018). Despite these assertions, here we used a promoter CpG-SNP located within the 
transcribed 5’UTR region of GATA2 and overlapping a CpG island as a means of discriminating 
between mutant and WT alleles, which enabled us to define a haplotype between the promoter 
SNP allele (A) and p.T354M and provided an impetus for further exploration to explain 
monoallelic GATA2 expression. However, it is important to state that we cannot exclude the 
possibility that other SNPs distributed throughout the GATA2 locus are equally regulating the 
gene in question.  
5.5 Summary 
 
 
Overall, while we do not know the exact trigger causing GATA2 ASE in the earlier disease time-
points of our symptomatic patient, these findings allowed us to propose a model whereby a pre-
MDS stage follows a non-linear trajectory and is likely governed by a complex network of factors 
regulating gene expression and the acquisition of cytogenetic and/or molecular genetic 
anomalies over a protracted period of time, predetermined by inherited/host genetic factors 
(McReynolds et al., 2019). Validating the order of these molecular events experimentally 
however requires the use of colony forming unit (CFU) assay on CD34+ enriched cells which was 
unattainable in our patient samples due to the low number of blasts. Nevertheless, it is hoped 
that elucidating these genotype-phenotype associations would improve our understanding of 
leukaemogeneisis and ultimately provide important insights with which to counsel at-risk 
mutation carriers and their families. 
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In summary, it is worth considering that germline mutations are not inherited equally and that 
variations in expression of these mutated alleles may explain differences in disease outcomes 
and with this, highlight new opportunities for therapeutic intervention. Altogether, the results 
presented in this thesis provide a step forward in understanding the molecular mechanisms 
underpinning reduced penetrance of germline GATA2 mutations in familial MDS/AML, identifying 
non-coding regulatory variations and deregulated chromatin signatures alongside additional co-
operating somatic mutations and mutant allele-specific expression. 
5.6 Potential clinical implications 
 
From a clinical perspective, this study reinforces the importance of careful clinical evaluation of 
these families and recognition of symptomatic and asymptomatic mutation carriers for close 
monitoring, genetic counselling, screening and exclusion as potential related HSC transplant 
donors, since several reports on donor-derived AML act as an important reminder of the 
potential consequences when these germline mutations are not tested at first hand (Berger et 
al., 2017, Galera et al., 2018). This study should also urge the haematology community to pause 
when considering the timing and use of prophylactic allogeneic HSCT in individuals with germline 
mutations at risk of developing full-blown malignancy, as in the case of IV.10 who has significant 
leukopenia or in III.5 and III.7 asymptomatic carriers who remain unaffected with no evidence of 
haematological abnormality (Cuellar-Rodriguez et al., 2011, Akpan et al., 2018). Given the wide 
spectrum of clinical presentations associated with GATA2 deficiency syndromes (Hirabayashi et 
al., 2017), it is pertinent to identify patients early in their disease course when HSCT might be of 
clinical benefit. Therefore, prognostic biomarkers which can help detect early signs of disease 
symptoms (e.g. by performing serial gene expression analyses of BM biopsies at presentation) 
might prove particularly useful and if sufficiently robust, could be translated feasibly into clinical 
practice. 
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5.7 Future research directions 
 
 
"Daring ideas are like chessmen moved forward: they may be beaten, 
but they may start a winning game."  
– Johann Wolfgang von Goethe 
 
 
There is certainly scope to develop and expand on the information arising from this thesis. In 
familial disease particularly, there is still a limited understanding of the secondary genetic events 
that are promoting the occurrence of overt disease and so there is a need to better delineate and 
decipher the clonal evolutionary dynamics, patterns of mutational co-occurrence and the precise 
order of genetic monstrosities, whereby potentially a shift in ASE might inform the nature of 
these events. Consolidating these findings necessitates their replication in additional families and 
larger patient cohorts. Also, the identification of novel germline predisposing variants with 
functional and/or translational impact using NGS technologies represents another research 
avenue that is currently being explored in our laboratory, which relies on sample availability from 
multiple affected family members with well-annotated clinical information and unknown genetic 
aetiology (Rio-Machin et al., 2018a). Indeed, while the prevalence of familial MDS/AML at 
present amounts to ~5% of adults and 4-13% of pediatric patients (Akpan et al., 2018), these 
percentages are likely to increase as more familial cases and susceptibility genes are being 
discovered.   
 
Moving forward, we believe that studying familial and sporadic disease in unison represents an 
important next step in the field as a whole. This is particularly pertinent given the development 
of mutational risk scores for AML and MDS such as (Gerstung et al., 2017, Nazha et al., 2017) that 
do not factor in the possibility of familial disease. Nevertheless, considering the increasing 
vigilance on behalf of the wider haematology community to recognise inherited forms of these 
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blood cancers, it seems sensible that targeted myeloid resequencing panels in the future include 
tumour and germline/remission testing for both sporadic and familial disease simultaneously and 
should be offered in routine diagnostics to all MDS/AML patients, irrespective of their family 
history. Indeed, we are beginning to learn that familial studies can highlight novel lesions unique 
to inherited MDS/AML (e.g. DDX41), shedding light on new disease biology (Polprasert et al., 
2015).  
 
The rarity of these familial cases however means that new gene discovery is likely to require the 
collaborative effort of an international clinical and research consortia, to power and validate 
these studies. Ongoing work includes functional analyses of candidate genes using in vitro and/or 
in vivo disease model systems (e.g. zebrafish) and gene knockdown techniques (e.g. CRISPR-Cas9) 
to assess the functional impact of these novel lesions in the pathophysiology of MDS/AML. The 
possibility exists that germline mutations within the non-coding genome may also be an 
important component in the aetiology of these diseases, as demonstrated by mutations in the 
intronic GATA2 enhancer element (Hsu et al., 2013). Likewise, and based on the findings from 
this thesis, epigenetic alterations of non-coding regions need to be explored further, with the 
possibility that gene silencing by means of promoter hypermethylation, as described in CEBPA 
(Fasan et al., 2013a), GATA2 (Celton et al., 2014) and RUNX1 (Webber et al., 2013), may be more 
widely implicated in familial and sporadic MDS/AML. 
 
 
*** 
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While the majority of myelodysplasia and acute myeloid
leukemia (MDS/AML) cases are sporadic, rare familial
predisposition syndromes have been delineated and now
represent a separate disease entity in the revised World
Health Organization (WHO) classification of myeloid neo-
plasms [1]. Germline mutations in ~14 disease genes have
been uncovered thus far, with GATA2 representing one of
the key transcriptional regulators commonly mutated in
inherited MDS/AML [2]. Increasing evidence suggests that
aberrations in GATA2 impair its transcription and promoter
activation, leading to a loss-of-function, supporting a
mechanism of GATA2 haploinsufficiency [3–5]. Reduced
penetrance, the observation that family members carry an
identical germline mutation yet display variable clinical
manifestations, is common and poses a clinical challenge in
the diagnosis and management of familial leukemia's, par-
ticularly when identifying “silent” mutation carriers for
genetic screening and exclusion as potential stem cell
transplant donors [6, 7]. Indeed, we have noted that reduced
penetrance is a feature among certain GATA2-mutated
MDS/AML families [8], especially those harboring mis-
sense germline mutations such as c.1061C>T (p.
Thr354Met) (Table S1) although the precise molecular
explanation of such occurrence has not been investigated.
Analysis of five MDS/AML families harboring p.
Thr354Met GATA2 mutations displayed significant intra-
and interfamilial variations in disease latency, phenotype,
and penetrance (Figure S1). These observations suggest that
individuals require additional co-operating events for the
development of overt malignancy within the context of a
shared germline mutation. To investigate this hypothesis
further, we examined an extensive five-generation pedigree
[9] (Fig. 1a) where two first-degree cousins (IV.1 and IV.6)
developed high-risk MDS/AML with monosomy 7, while a
third cousin (IV.10) presented with recurrent minor infec-
tions and significant monocytopenia [0.1 × 109/L] and
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neutropenia [0.8 × 109/L] in year (yr.) 1–3 which subse-
quently stabilized (monocyte count, neutrophils [>1 × 109/
L]) 3 years after presentation (Fig. 1b). This contrasted with
the parental generation (III.1, III.5, and III.7) where muta-
tion carriers remain symptom-free with no evidence of
hematopoietic abnormality over 60 years of age.
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We therefore started with targeted deep sequencing of 33
genes frequently mutated in MDS/AML to define the
landscape of secondary genetic mutations across mutation
carriers. Notably, while no acquired mutations were detec-
ted in asymptomatic family members, all affected cousins
analyzed shared an identical somatic ASXL1 mutation (p.
Gly646TrpfsTer12) (Fig. 1c). The variant allele frequency
(VAF), however, was lower (12%) in IV.10 and remained
stable (range 12–6%) over a 6-year monitoring period.
While the co-occurrence of ASXL1 and GATA2 mutations
has been proposed as one mechanism for driving the onset
and severity of disease symptoms [9–11], the low VAF of
ASXL1 mutation and stable improvement in hematopoiesis
at IV.10 later follow-up suggested that a combination of
GATA2–ASXL1 mutation alone is insufficient to promote
clonal expansion and leukemic transformation, as this sec-
ondary somatic hit may not represent disease progression or
identify when treatment is indicated. Intriguingly, apart
from the ASXL1 mutation, no other acquired mutations were
detected in the 33-myeloid genes assessed in the affected
individuals. Moreover, on the basis of our observations and
in agreement with previous studies [12, 13], it seems that
monosomy 7 in IV.1 and IV.6 is acquired following
acquisition of ASXL1 mutations, hence contributing to the
malignancy but not initiating symptoms.
We next considered whether disease symptoms are
modulated by endogenous levels of GATA2. Quantitative
real-time PCR (qRT-PCR) of bone marrow material
demonstrated total GATA2 expression to be significantly
lower in the symptomatic (IV.10-yr.1) compared with an
asymptomatic carrier (III.7) (Fig. 1d). Significantly, Sanger
sequencing of the cDNA template revealed striking allele-
specific expression (ASE), favoring the mutant (T) allele
with the absence of the wild-type (WT) (C) allele expres-
sion in the symptomatic patient (IV.10), contrasting with
biallelic expression in asymptomatic members (III.5 and
III.7) (Fig. 1e). This observation was validated by cDNA
cloning of III.7 and IV.10 bone marrow samples and sub-
sequent Sanger sequencing of individual clones (Figure S2).
As this suggested that an allelic imbalance in WT:mutant
GATA2 expression ratio may account for the variable dis-
ease penetrance in this pedigree, we assessed GATA2
expression in IV.10 over a 6-year disease period at four
time-points (yr. 1, 3, 4, and 6), demonstrating increased
GATA2 expression at later time-points (yr. 4 and 6)
(Fig. 1d) coinciding with reactivation of the WT (C) allele
expression (Fig. 1f) and an improvement in hematological
parameters, in the absence of any clinical intervention
(Fig. 1b).
To test whether monoallelic GATA2 expression has an
impact on the transcriptome driving the onset of disease
symptoms, we performed RNA-seq with a view of exam-
ining downstream biological features distinctive of GATA2
monoallelic (IV.10-yr.1 and 3) vs. biallelic (IV.10-yr.4 and
III.7) groups. Unsupervised analysis revealed a clear
separation between GATA2 monoallelic and biallelic sam-
ples (Fig. 1g, S3 and Table S2). It was noteworthy that
certain canonical pathways and gene sets related to tumor-
igenesis (e.g., DNA replication and cell cycle) were enri-
ched in GATA2 monoallelic vs. biallelic groups (Figure S4),
potentially reflecting the clinical and phenotypic switch
Fig. 1 Investigating the molecular mechanisms underlying the reduced
penetrance of germline p.Thr354Met mutations observed in a GATA2-
mutated MDS/AML family. a Genogram of the GATA2-mutated
pedigree. Squares denote males and circles denote females. This five-
generation MDS/AML family presented to Barts Health hospital in
London with identical germline GATA2 mutations (p.Thr354Met;
c.1061C>T) and variable clinical manifestations. Two first-degree
cousins (IV.1 and IV.6) presented at 23 and 18 years of age, respec-
tively, with high-grade MDS transforming to AML and monosomy 7.
Both cousins died post allogeneic hematopoietic stem cell transplant
(HSCT) due to transplant-related complications (IV.1 from graft vs.
host disease (GvHD) and IV.6 from relapsed MDS/AML). Ten years
later, their first cousin (IV.10) developed symptoms at 31 years,
including recurrent minor infections and significant leukopenia
(monocytopenia [0.1 × 109/L] and neutropenia [0.8 × 109/L]) with mild
macrocytosis and normal hemoglobin and platelet counts. She remains
under close surveillance where her blood counts are routinely mon-
itored. All four of her children have inherited her WT GATA2 allele.
Similarly, members (IV.7, IV.8, and IV.9) were screened for the
mutation and all have a WT GATA2 configuration. The paternal
grandmother (II.2) of IV.10 as well as her paternal great-uncle (II.3)
and great-grandmother (I.2) all were reported to have died of AML
(ages of disease onset were 53, 24, and 53-years old, respectively). Not
only did GATA2 mutations correlate with early age of disease onset in
the fourth generation (IV.1/23 yr., IV.6/18 yr., and IV.10/31 yr.), but
the parental third-generation carriers (III.1, III.5, and III.7) remain
hematologically normal and symptom-free into their mid–late 60s. No
material was available from other family members. b A clinical
timeline of IV.10 showing the change in clinical parameters over the
course of disease presentation. Photographs of peripheral blood smears
from IV.10 (yr. 1, 3, 4, and 6) stained with May-Grünwald Giemsa
staining. Magnification: ×20. c Secondary ASXL1 mutations: variant
allele frequencies of GATA2 germline mutation and ASXL1 acquired
mutation. Samples from three individuals were sequenced: one
asymptomatic parent (III.7), one deceased MDS/AML cousin (IV.6),
and across three time-points (yr. 1, 4, and 6) from the symptomatic
patient (IV.10) reflecting disease evolution. d GATA2 global expres-
sion measured by qRT-PCR of bone marrow samples and normalized
to healthy bone marrow control: downregulation in IV.10_yr.1 com-
pared with III.7 and downregulation in IV.10_yr.1–3 GATA2 expres-
sion compared with IV.10_yr.4–6. The average of five independent
experiments is shown. Statistical significance was determined at *p <
0.05, **p < 0.01, and ***p < 0.001 using a t-test with Bonferroni
correction. Error bars represent standard error of the mean (SEM). e
GATA2 monoallelic expression of the mutant allele in symptomatic
(IV.10) vs. asymptomatic carriers (III.5 and III.7), as measured by
cDNA sequencing of bone marrow samples. f Correlation of mono-
allelic GATA2 expression with disease symptoms across the time-
points studied in IV.10 with reactivation of the WT allele “C”
expression noted 3 years after presentation, concurrent with
improvements in hematological parameters. g RNA-seq analysis:
principal component analysis (PCA) plot showing a good separation
between GATA2 biallelic (green) and monoallelic (blue) groups based
on all transcriptomes
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Fig. 2 Elucidating the molecular mechanisms driving allele-specific
changes in GATA2 expression. a(i) A noncoding SNP (rs1806462 [C/
A]) located within the second GATA2 promoter region overlapping a
CpG island was detected in the symptomatic (IV.10) but not in
asymptomatic members (III.7). a(ii) Given the location of promoter 2
SNP within the 5’UTR, a haplotype between the SNP allele “A” and
the germline mutant allele “T” was established, providing a means of
distinguishing between mutant and WT alleles in subsequent experi-
ments. a(iii) This promoter SNP [C/A] removes a CpG methylation
site in the mutant allele “A” and generates a CpG methylation site in
the WT allele “C”. b The proportion of methylated CpGs between
mutant and WT alleles across the three time-points of IV.10. WT allele
is significantly more methylated than the mutant allele in monoallelic
samples (yr. 1 and yr. 3), whereas no significant allele-specific dif-
ferences in methylation were observed in a biallelic-expressing sample
(yr. 6). The average of three independent experiments is shown. c
Quantification of mutant and WT allele ChIP sequence peak heights
across the time-points of IV.10 based on Sanger sequencing.
H3K4me3 activation mark favoring the mutant allele was enriched in
monoallelic samples (yr. 1 and yr. 3) compared with the biallelic
sample (yr. 4). The average of three independent experiments is
shown. Statistical significance was determined at *p < 0.05, **p <
0.01, and ***p < 0.001 using a t-test with Bonferroni correction. NS
corresponds to nonsignificant comparisons. Error bars represent SEM
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between these two groups. We also noted a significant
overexpression of genes with GATA2 cofactor PU.1 motifs
in their regulatory regions (p value NES= 2.06) in GATA2
biallelic vs. monoallelic samples, in support of a recent
finding [14] that p.Thr354Met mutants bind and interact
with PU.1 more tightly than WT, thus leading to seques-
tration of PU.1 from its normal cellular functions. Conse-
quently, the transcriptional activation triggered by PU.1 will
be diminished in our GATA2 monoallelic samples.
The differences observed in these gene-expression pro-
files prompted us to explore the molecular mechanisms
underlying monoallelic GATA2 expression. We hypothe-
sized that these allele-specific changes in GATA2 expression
are driven by transient epigenetic mechanisms that include
changes in DNA methylation and chromatin mark deposi-
tion. A CpG single-nucleotide polymorphism (CpG-SNP)
(rs1806462) [C/A] located within the promoter and 5′UTR
of GATA2 overlapping a CpG island offered a marker to
distinguish between mutant and WT alleles where this SNP
creates/abolishes a CpG dinucleotide within the GATA2
promoter region (Fig. 2a). More specifically, cDNA
sequencing of 5′UTR allowed us to define haplotypes,
where the promoter SNP allele (A) resides on the germline
mutant GATA2 allele (T) (Fig. 2a(ii)). Apart from IV.10, no
other family members and only 2/12 individuals from
pedigrees presented in Figure S1 were heterozygous for this
SNP (one of whom is an asymptomatic carrier). Therefore,
we do not infer that this haplotype would contribute to the
progression of symptoms. Instead, we used this SNP to
determine whether allele-specific differences in DNA
methylation could explain the silencing of WT GATA2
allele expression observed in earlier time-points of IV.10.
As illustrated in Fig. 2b and S5, bisulfite sequencing of a
200-bp region encompassing rs1806462 demonstrated a
significant increase in promoter methylation in the WT
allele of IV.10 in yr. 1 and yr. 3 following diagnosis, in
contrast with the absence of allele-specific differences in
methylation at a later time-point.
We next sought to establish whether these allele-specific
changes in GATA2 methylation and expression are accom-
panied by changes in chromatin structure at the promoter.
H3K4me3 and H3K27me3 define poised or closed chro-
matin, respectively, rendering them more or less accessible
for transcription factors, thereby regulating gene expression
[15]. The deposition of these bivalent marks was assessed in
IV.10 by allele-specific chromatin immunoprecipitation
(ChIP) followed by Sanger sequencing within GATA2
promoter region encompassing the SNP rs1806462 [C/A].
While there were no apparent allele-specific differences in
H3K27me3 deposition across the different time-points of
IV.10, an enrichment in the deposition of H3K4me3 on the
promoter of the mutant allele (A) relative to the WT allele
(C) was noted in IV.10 monoallelic samples (yr. 1 and 3)
(Fig. 2c, S6 and S7). In contrast, and consistent with the
pattern observed with DNA methylation, there was no
demonstrable difference in H3K4me3 deposition in the
IV.10 biallelic sample (yr. 4), coinciding with reactivation
of the WT allele expression and an overall improvement in
clinical parameters. We believe that these observations are
in keeping with the notion that H3K4me3 occupancy inhi-
bits de novo DNA methylation [16] which was borne out by
subsequent bisulfite sequencing of H3K4me3-enriched
DNA from our ChIP experiments, demonstrating that
DNA methylation and H3K4me3 deposition are mutually
exclusive in our IV.10 samples (Figure S8).
Collectively, our findings provide a step forward in
understanding the molecular mechanisms underlying
reduced penetrance in GATA2-mutated MDS/AML pedi-
grees, which may be governed by the acquisition of addi-
tional co-operating mutations (e.g., ASXL1) combined with
dynamic epigenetic reprogramming and subsequent allele-
specific expression of GATA2 mutant allele, adding another
level of complexity to the (epi)genetic basis of familial
MDS/AML.
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Sample	 Gene	 Variant	 Chr.	 Coordinate	 Amino	Acid	Change	 Transcript	Change	 VAF%	 Variant	Classification	
	
	
IV.10_yr.1	
GATA2	 G>G/A	 3	 128200744	 p.Thr354Met	 c.1061C>T	 49	 Pathogenic	
TET2	 A>A/G	 4	 106196951	 p.Ile1762Val	 c.5284A>G	 51	 High	freq	SNP	
TP53	 G>C/C	 17	 7579472	 p.Pro72Arg	 c.215C>G	 99	 High	freq	SNP	
ASXL1	 A>A/AG	 20	 31022441	 p.Gly646TrpfsTer12	 c.1926_1927insG	 12	 Presumed	Pathogenic	
ASXL1	 T>C/C	 20	 31022959	 p.Leu815Pro	 c.2444T>C	 100	 High	freq	SNP	
	
	
IV.10_yr.4	
GATA2	 G>G/A	 3	 128200744	 p.Thr354Met	 c.1061C>T	 51	 Pathogenic	
TET2	 A>A/G	 4	 106196951	 p.Ile1762Val	 c.5284A>G	 52	 High	freq	SNP	
TP53	 G>C/C	 17	 7579472	 p.Pro72Arg	 c.215C>G	 100	 High	freq	SNP	
ASXL1	 A>A/AG	 20	 31022441	 p.Gly646TrpfsTer12	 c.1926_1927insG	 6	 Presumed	Pathogenic	
ASXL1	 T>C/C	 20	 31022959	 p.Leu815Pro	 c.2444T>C	 100	 High	freq	SNP	
	
	
IV.10_yr.6	
GATA2	 G>G/A	 3	 128200744	 p.Thr354Met	 c.1061C>T	 46	 Pathogenic	
TET2	 A>A/G	 4	 106196951	 p.Ile1762Val	 c.5284A>G	 51	 High	freq	SNP	
TP53	 G>C/C	 17	 7579472	 p.Pro72Arg	 c.215C>G	 100	 High	freq	SNP	
ASXL1	 A>A/AG	 20	 31022441	 p.Gly646TrpfsTer12	 c.1926_1927insG	 7	 Presumed	Pathogenic	
ASXL1	 T>C/C	 20	 31022959	 p.Leu815Pro	 c.2444T>C	 100	 High	freq	SNP	
	
	
III.7_Asym	
	
	
	
	
	
GATA2	 G>G/A	 3	 128200744	 p.Thr354Met	 c.1061C>T	 47	 Pathogenic	
TET2	 C>C/T	 4	 106156187	 p.Pro363Leu	 c.1088C>T	 50	 Unknown	Significance	
TET2	 T>T/G	 4	 106196829	 p.Leu1721Trp	 c.5162T>G	 47	 Unknown	Significance	
TP53	 G>C/C	 17	 7579472	 p.Pro72Arg	 c.215C>G	 99	 High	freq	SNP	
ASXL1	 T>C/C	 20	 31022959	 p.Leu815Pro	 c.2444T>C	 100	 High	freq	SNP	
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IV.6_MDS/AML	
GATA2	 G>G/A	 3	 128200744	 p.Thr354Met	 c.1061C>T	 47	 Pathogenic	
TET2	 A>G/G	 4	 106196951	 p.Ile1762Val	 c.5284A>G	 100	 High	freq	SNP	
EZH2	 C>C/G	 7	 148525904	 p.Asp185His	 c.553G>C	 15	 High	freq	SNP	
TP53	 G>G/C	 17	 7579472	 p.Pro72Arg	 c.215C>G	 49	 High	freq	SNP	
ASXL1	 A>A/AG	 20	 31022441	 p.Gly646TrpfsTer12	 c.1926_1927insG	 33	 Presumed	Pathogenic	
ASXL1	 T>C/C	 20	 31022959	 p.Leu815Pro	 c.2444T>C	 100	 High	freq	SNP	
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Appendix	3.	Table	2		
	
Select	differentially	expressed	(DE)	genes	between	GATA2	biallelic	and	monoallelic	group	
	
(Top	30	upregulated	and	top	30	downregulated	genes)	
Table S2. List of 2,432 differentially expressed (DE) genes between GATA2 biallelic (green) and monoallelic (blue) groups
ID Name Description log2FC (Bi_ vs Mono_allelic) logCPM LR PValue FDR IV.10_yr.1 IV.10_yr.3 IV.10_yr.4 III.7_asym BM_control
ENSG00000112077 RHAG Rh-associated glycoprotein [Source:HGNC 
Symbol;Acc:10006]
-7.065450382 5.860144216 250.1161537 2.45E-56 4.30E-52 6.93698598 7.148898694 -0.82139248 -1.572251189 4.628306871
ENSG00000107562 CXCL12 chemokine (C-X-C motif) ligand 12 
[Source:HGNC Symbol;Acc:10672]
-8.330878237 6.904575843 221.365128 4.56E-50 4.00E-46 8.463534146 7.896112965 -2.073364206 -0.956081001 2.751827722
ENSG00000169877 AHSP alpha hemoglobin stabilizing protein 
[Source:HGNC Symbol;Acc:18075]
-7.680771874 6.64991784 218.0163748 2.45E-49 1.43E-45 7.868211149 7.83620084 0.505333341 -1.854339469 5.243726669
ENSG00000163554 SPTA1 spectrin, alpha, erythrocytic 1 (elliptocytosis 
2) [Source:HGNC Symbol;Acc:11272]
-6.718271315 6.277401811 211.6474111 6.00E-48 2.64E-44 6.962770807 7.687236572 -0.589913612 0.154058352 5.777640584
ENSG00000223609 HBD hemoglobin, delta [Source:HGNC 
Symbol;Acc:4829]
-6.948481557 7.476636825 209.3272706 1.93E-47 6.76E-44 8.65012583 8.713064225 1.855590689 0.984547783 5.982087099
ENSG00000196415 PRTN3 proteinase 3 [Source:HGNC 
Symbol;Acc:9495]
-6.967317693 6.019308576 198.8586812 3.71E-45 1.08E-41 6.122897312 6.891813193 -2.073364206 -1.133744865 7.075716419
ENSG00000197993 KEL Kell blood group, metallo-endopeptidase 
[Source:HGNC Symbol;Acc:6308]
-6.10505537 5.103502598 194.5611546 3.21E-44 8.06E-41 6.075729559 6.416350763 -0.907612816 -0.874832399 4.138027348
ENSG00000143627 PKLR pyruvate kinase, liver and RBC [Source:HGNC 
Symbol;Acc:9020]
-7.880567753 4.966265406 188.39622 7.12E-43 1.56E-39 6.184539705 6.111783523 -2.845623393 -7.002070102 3.799873749
ENSG00000170180 GYPA glycophorin A (MNS blood group) 
[Source:HGNC Symbol;Acc:4702]
-7.67602921 5.312758052 187.8619216 9.31E-43 1.82E-39 6.067486521 6.812344661 -3.766908349 -2.97427061 4.224973246
ENSG00000197561 ELANE elastase, neutrophil expressed 
[Source:HGNC Symbol;Acc:3309]
-6.023520652 5.626150861 183.3194363 9.13E-42 1.60E-38 5.682950487 6.155375067 -1.57307192 -0.406691783 6.942114908
ENSG00000055118 KCNH2
potassium voltage-gated channel, subfamily 
H (eag-related), member 2 [Source:HGNC 
Symbol;Acc:6251]
-5.924295794 6.923850092 181.6691407 2.09E-41 3.34E-38 8.16572184 8.025555626 2.330744516 1.508271876 5.67656232
ENSG00000131747 TOP2A topoisomerase (DNA) II alpha 170kDa 
[Source:HGNC Symbol;Acc:11989]
-5.305849613 6.626103217 178.9653596 8.15E-41 1.19E-37 7.516881607 7.660910295 2.1289755 1.926103707 6.641917567
ENSG00000100448 CTSG cathepsin G [Source:HGNC 
Symbol;Acc:2532]
-6.007947553 4.87429023 164.0906188 1.45E-37 1.95E-34 5.426778226 5.465512461 -2.845623393 -0.874832399 5.870464764
ENSG00000166947 EPB42 erythrocyte membrane protein band 4.2 
[Source:HGNC Symbol;Acc:3381]
-5.874982473 5.431230207 160.912567 7.15E-37 8.96E-34 6.346024108 6.732915862 0.832340008 -1.449512048 4.673975502
ENSG00000211951 IGHV2-26 immunoglobulin heavy variable 2-26 
[Source:HGNC Symbol;Acc:5575]
-5.975286828 4.456068793 156.1900471 7.69E-36 9.00E-33 5.80861299 5.379702666 -0.740035668 -1.449512048 3.430160334
ENSG00000211950 IGHV1-24 immunoglobulin heavy variable 1-24 
[Source:HGNC Symbol;Acc:5551]
-6.106323229 5.519851109 154.179973 2.12E-35 2.32E-32 7.02191272 6.079121061 0.401591237 -0.589083246 4.886100463
ENSG00000126787 DLGAP5 discs, large (Drosophila) homolog-associated 
protein 5 [Source:HGNC Symbol;Acc:16864]
-5.030396722 4.916172395 151.7018599 7.36E-35 7.60E-32 6.028383742 5.949930118 0.365283811 0.114810932 4.405023371
ENSG00000039068 CDH1 cadherin 1, type 1, E-cadherin (epithelial) 
[Source:HGNC Symbol;Acc:1748]
-5.211476345 5.007048086 151.170497 9.62E-35 9.38E-32 6.306294485 6.123695506 0.036330944 0.642123966 3.168221511
ENSG00000243290 IGKV1-12 immunoglobulin kappa variable 1-12 
[Source:HGNC Symbol;Acc:5730]
-6.1006739 5.961036193 149.0565118 2.79E-34 2.58E-31 7.514104155 6.586960424 1.098750223 -0.099242291 4.866565467
ENSG00000105610 KLF1 Kruppel-like factor 1 (erythroid) 
[Source:HGNC Symbol;Acc:6345]
-5.893335408 5.483139827 148.7154177 3.31E-34 2.90E-31 6.696714221 6.563538635 -0.66302287 0.940331404 4.488333455
ENSG00000168754 FAM178B family with sequence similarity 178, member 
B [Source:HGNC Symbol;Acc:28036]
-5.635000879 4.527501921 146.0502752 1.27E-33 1.06E-30 5.687439991 5.669431044 -0.99931534 -1.854339469 3.557451401
ENSG00000088325 TPX2 TPX2, microtubule-associated [Source:HGNC 
Symbol;Acc:1249]
-4.530458654 5.615112454 144.8830773 2.28E-33 1.82E-30 6.672460965 6.601088773 1.89432737 1.820287937 5.263777731
ENSG00000231007 CDC20P1 cell division cycle 20 pseudogene 1 
[Source:HGNC Symbol;Acc:29487]
-4.914837736 4.76963257 143.8082952 3.91E-33 2.99E-30 5.992551784 5.715811808 0.663204908 0.466186565 4.077008772
ENSG00000100336 APOL4 apolipoprotein L, 4 [Source:HGNC 
Symbol;Acc:14867]
-5.404204325 4.551292878 141.9318706 1.01E-32 7.36E-30 5.907365734 5.659645999 -0.059127673 -0.956081001 2.276968566
ENSG00000196188 CTSE cathepsin E [Source:HGNC Symbol;Acc:2530] -7.240018267 4.396196948 141.7465507 1.10E-32 7.76E-30 5.275162165 5.882824592 -4.621297774 -3.360122781 2.814341322
ENSG00000206177 HBM hemoglobin, mu [Source:HGNC 
Symbol;Acc:4826]
-6.018993929 4.307945359 139.7225011 3.06E-32 2.07E-29 5.402953745 5.522410173 -1.886652327 -3.360122781 3.32911422
ENSG00000075340 ADD2 adducin 2 (beta) [Source:HGNC 
Symbol;Acc:244]
-4.937267494 6.496103826 138.9965122 4.41E-32 2.87E-29 7.586318744 7.695839822 3.149202463 2.116960417 5.257541658
ENSG00000152078 TMEM56 transmembrane protein 56 [Source:HGNC 
Symbol;Acc:26477]
-5.101636196 4.71092014 138.7745449 4.93E-32 3.09E-29 5.604410474 5.996020807 -0.907612816 0.192266291 4.039700715
ENSG00000117724 CENPF centromere protein F, 350/400kDa 
[Source:HGNC Symbol;Acc:1857]
-4.399528673 5.736076703 137.1273625 1.13E-31 6.85E-29 6.447442448 6.927587689 2.439516168 1.65228493 5.60272092
ENSG00000211937 IGHV2-5 immunoglobulin heavy variable 2-5 
[Source:HGNC Symbol;Acc:5576]
-5.788759437 5.939255855 134.1804102 4.99E-31 2.92E-28 7.429800935 6.439885712 1.32354911 -0.053815412 5.453583221
GATA2 Monoallelic  group GATA2  Biallelic group
ENSG00000272916 RP11-574K11.31
Bifunctional heparan sulfate N-
deacetylase/N-sulfotransferase 2  
[Source:UniProtKB/TrEMBL;Acc:S4R438]
1.895169426 -0.080107053 7.425683559 0.006429939 0.045903858 -1.921450438 0.376157587 0.28980717 0.229488395 -1.083770229
ENSG00000102362 SYTL4 synaptotagmin-like 4 [Source:HGNC 
Symbol;Acc:15588]
-1.508716051 2.529138462 7.42029063 0.00644924 0.046008476 3.279606408 3.624712133 -0.271377577 1.926103707 0.872340852
ENSG00000166682 TMPRSS5 transmembrane protease, serine 5 
[Source:HGNC Symbol;Acc:14908]
1.453346791 0.026648253 7.420124482 0.006449835 0.046008476 -0.306880589 0.207316148 -0.059127673 0.154058352 -0.376928291
ENSG00000198682 PAPSS2 3'-phosphoadenosine 5'-phosphosulfate 
synthase 2 [Source:HGNC Symbol;Acc:8604]
1.187849402 2.942744312 7.418345016 0.006456217 0.046016603 2.093195522 2.865836059 3.186096972 3.462952422 2.693890668
ENSG00000095015 MAP3K1
mitogen-activated protein kinase kinase 
kinase 1, E3 ubiquitin protein ligase 
[Source:HGNC Symbol;Acc:6848]
1.006237645 7.413284549 7.416767579 0.00646188 0.046019279 6.645948858 7.029244774 7.678502925 8.132325486 7.085254968
ENSG00000180871 CXCR2 chemokine (C-X-C motif) receptor 2 
[Source:HGNC Symbol;Acc:6027]
1.153748193 4.447115437 7.417026106 0.006460952 0.046019279 3.774188075 3.594215211 3.963622948 5.031513688 5.118566908
ENSG00000165731 RET ret proto-oncogene [Source:HGNC 
Symbol;Acc:9967]
1.429635349 0.540780314 7.416050236 0.006464457 0.046019279 0.254194054 0.583576386 0.036330944 0.798919003 0.615745481
ENSG00000156042 TTC18 tetratricopeptide repeat domain 18 
[Source:HGNC Symbol;Acc:30726]
1.303891817 1.387166748 7.404556889 0.006505887 0.046276678 1.063037713 1.202433699 2.06249931 1.538247531 0.415212929
ENSG00000027001 MIPEP mitochondrial intermediate peptidase 
[Source:HGNC Symbol;Acc:7104]
-1.20366588 2.461408994 7.402380781 0.006513761 0.046313924 3.265262705 3.100920657 1.907011864 1.006157955 1.71760268
ENSG00000254275 RP11-89M16.1 1.824245891 0.64189445 7.397948715 0.00652983 0.046409376 -0.094677427 0.637745977 2.171650019 -0.956081001 -4.610216385
ENSG00000101986 ABCD1 ATP-binding cassette, sub-family D (ALD), 
member 1 [Source:HGNC Symbol;Acc:61]
1.007791581 5.118248111 7.392562491 0.006549412 0.046529713 4.323547566 4.848976944 5.034357156 5.666843359 5.356557658
ENSG00000088280 ASAP3
ArfGAP with SH3 domain, ankyrin repeat 
and PH domain 3 [Source:HGNC 
Symbol;Acc:14987]
1.362288127 0.764587205 7.390456507 0.006557084 0.046565379 0.627538984 0.637745977 0.959559782 1.069111613 0.095393329
ENSG00000168939 SPRY3 sprouty homolog 3 (Drosophila) 
[Source:HGNC Symbol;Acc:11271]
1.327178976 1.509170667 7.383842246 0.006581242 0.046718037 1.148882041 0.789025519 1.842443831 1.55300499 1.81594051
ENSG00000115271 GCA grancalcin, EF-hand calcium binding protein 
[Source:HGNC Symbol;Acc:15990]
1.056674214 6.854864594 7.381563071 0.006589587 0.04675837 5.762549857 6.144892317 6.431546497 7.293451993 7.716050489
ENSG00000224177 LINC00570 long intergenic non-protein coding RNA 570 
[Source:HGNC Symbol;Acc:43717]
-2.195408906 -0.221097885 7.380303926 0.006594203 0.046772212 0.597320328 0.836121102 -2.845623393 -7.002070102 -0.894110176
ENSG00000224997 AL049840.1 Uncharacterized protein; cDNA FLJ53535  
[Source:UniProtKB/TrEMBL;Acc:B4DK98]
1.791161532 0.079465802 7.379475133 0.006597242 0.046774873 -0.196880952 -0.713501401 -0.99931534 0.984547783 0.04992943
ENSG00000269430 LRRC3DN LRRC3 downstream neighbor (non-protein 
coding) [Source:HGNC Symbol;Acc:1270]
1.530725369 -0.012518843 7.373415318 0.00661951 0.046913803 -0.856736938 -0.112176905 -0.010608983 0.192266291 0.095393329
ENSG00000120278 PLEKHG1
pleckstrin homology domain containing, 
family G (with RhoGef domain) member 1 
[Source:HGNC Symbol;Acc:20884]
-1.045837648 3.990736015 7.371890885 0.006625123 0.046934641 4.659599832 4.343766522 3.159840379 3.47074529 3.765128041
ENSG00000152213 ARL11 ADP-ribosylation factor-like 11 
[Source:HGNC Symbol;Acc:24046]
1.178833221 4.211010055 7.365252226 0.006649627 0.047088648 3.270059802 3.408048696 3.599523466 4.81596796 4.990560977
ENSG00000273066 RP11-216L13.19 1.337198964 1.199656576 7.364549306 0.006652227 0.047088648 0.848890306 0.925936776 1.432844522 1.679439471 0.676839958
ENSG00000164509 IL31RA interleukin 31 receptor A [Source:HGNC 
Symbol;Acc:18969]
1.637830248 1.177203543 7.362174388 0.006661019 0.047131879 0.796654307 0.689955027 0.210162819 2.106994346 1.134350211
ENSG00000179397 C1orf101 chromosome 1 open reading frame 101 
[Source:HGNC Symbol;Acc:28491]
1.422560513 0.185249923 7.359130146 0.006672306 0.047192723 -0.046168491 0.056395802 0.28980717 0.114810932 0.139468177
ENSG00000132470 ITGB4 integrin, beta 4 [Source:HGNC 
Symbol;Acc:6158]
-1.434396202 1.345867818 7.355262591 0.006686674 0.047256267 2.304339895 2.068117593 -0.161352853 -1.231517591 0.973207307
ENSG00000175061 FAM211A-AS1 FAM211A antisense RNA 1 [Source:HGNC 
Symbol;Acc:28619]
-1.163828968 8.186586087 7.355523034 0.006685706 0.047256267 8.824219999 8.564105195 8.014408596 7.232878216 7.75287062
ENSG00000257702 LBX2-AS1 LBX2 antisense RNA 1 [Source:HGNC 
Symbol;Acc:25136]
1.358330496 1.919436653 7.35042267 0.006704699 0.047364585 1.531025871 1.050973916 1.89432737 2.491046607 2.120832889
ENSG00000261996 CTC-281F24.1 1.495877221 0.41714269 7.347814364 0.006714434 0.047395208 -0.489407866 0.498306264 1.120696904 0.722650538 -1.18885156
ENSG00000143061 IGSF3 immunoglobulin superfamily, member 3 
[Source:HGNC Symbol;Acc:5950]
-1.401462209 1.004725071 7.344976241 0.006725042 0.04745101 1.883815937 1.997369264 -0.99931534 -0.406691783 -0.376928291
ENSG00000204632 HLA-G major histocompatibility complex, class I, G 
[Source:HGNC Symbol;Acc:4964]
1.051900528 4.502240137 7.328995724 0.006785095 0.047836285 3.998873122 3.783314832 4.305306726 5.190971206 4.754122018
ENSG00000105948 TTC26 tetratricopeptide repeat domain 26 
[Source:HGNC Symbol;Acc:21882]
-1.330606475 1.839178966 7.32651943 0.00679445 0.047883007 2.798442909 2.369639072 0.6928072 0.265774258 1.410986673
ENSG00000117425 PTCH2 patched 2 [Source:HGNC Symbol;Acc:9586] 1.383549148 0.448712955 7.302763092 0.006884865 0.048500727 0.254194054 0.468724906 0.6928072 0.434658742 0.002986071
ENSG00000169258 GPRIN1
G protein regulated inducer of neurite 
outgrowth 1 [Source:HGNC 
Symbol;Acc:24835]
1.400363076 0.551438443 7.301219368 0.006890783 0.048522943 0.090278201 0.498306264 0.505333341 0.669468625 0.646616095
ENSG00000177096 FAM109B family with sequence similarity 109, member 
B [Source:HGNC Symbol;Acc:27161]
-1.124077846 3.066512988 7.297885336 0.006903581 0.048592364 3.701474281 3.541909135 1.956663165 2.404187718 2.956635145
ENSG00000157657 ZNF618 zinc finger protein 618 [Source:HGNC 
Symbol;Acc:29416]
-1.094603082 3.373908118 7.297209782 0.006906178 0.048592364 3.878388807 3.847931966 2.213098418 2.756300061 3.465217709
